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ABSTRACT 
Multidrug resistance (MDR), a clinical outcome characterized by subtherapeutic 
intracellular drug concentration, is one of the predominant factors limiting effective cancer 
chemotherapy. Several possible mechanisms and molecular alterations have been implicated in 
the development of MDR, including activation of efflux transporters and metabolizing enzymes 
in response to therapeutic agents. Therefore, the primary objective of my dissertation project is to 
develop strategies for overcoming drug resistance in cancer chemotherapy. Human 
adenocarcinoma cells (LS-180) were treated for 72 hours with vinblastine alone and in the 
presence of ritonavir. The expression of efflux transporters (MDR1 and MRP2), metabolizing 
enzyme (CYP3A4) and nuclear hormone receptor (PXR) was induced in response to vinblastine. 
This overexpression was completely neutralized when cells were cotreated with ritonavir. Uptake 
of [
3
H] lopinavir and Vivid™ assay further confirmed the functional activity of transcribed genes 
upon cotreatment. Reduced cell proliferation, migration and increased apoptosis of cancer cells 
were further indicative of enhanced activity of chemotherapeutics (doxorubicin, paclitaxel, 
tamoxifen and vinblastine) in the presence of ritonavir. Combination therapy of anticancer drug 
with ritonavir may overcome drug resistance by neutralizing overexpression of efflux 
transporters and metabolizing enzymes.  
Hypoxia leading to neovascularization has also been implicated in the development of 
MDR and ocular neovascular diseases. Despite introduction of novel therapeutics, treatment of 
iv 
 
retinal disorders remains challenging, possibly due to complex nature of hypoxia signaling. This 
study demonstrates for the first time that hypoxic conditions may alter expression of efflux and 
influx transporters in retinal pigment epithelial (RPE) cells. These findings suggest that hypoxia 
may further alter disposition of ophthalmic drugs. Inhibiting this signaling mechanism with an 
already approved therapeutic molecule may have promising antiangiogenic role with fewer side 
effects. Our studies (quantitative PCR, immunoblot analysis, ELISA and angiogenic assay) have 
demonstrated that ritonavir inhibits the expression of hypoxia-inducible factor-1α (HIF-1α) 
mediated vascular endothelial growth factor (VEGF) expression in RPE cells probably via 
inhibition of PI3K/AKT pathway. This inhibition may reduce retinal neovascularization. These 
findings shed new light on the possibility of incorporating ritonavir in the treatment regimen of 
ocular angiogenic diseases. Although many inhibitors of HIF-1α are in clinical trials, additional 
benefit of using ritonavir is that it has been given to HIV patients with relatively low toxicity. 
The process of traditional drug development could be fast tracked since ritonavir is clinically 
approved for human use. However, further preclinical and clinical experiments are necessary to 
determine the repositioning of ritonavir in the treatment of ocular neovascular diseases.  
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CHAPTER 1 
MECHANISMS OF DRUG RESISTANCE IN CANCER CHEMOTHERAPY: 
COORDINATED ROLE AND REGULATION OF EFFLUX TRANSPORTERS AND 
METABOLIZING ENZYMES 
Introduction 
Cancer remains a major health problem accounting for one in every four deaths in the 
United States. In 2013, a total of 1.6 million new cases and 0.6 million cancer deaths are 
predicted to occur [1]. Chemotherapy is one of the major therapeutic interventions in the field of 
oncology. Chemotherapy can either be administered alone or as an adjuvant therapy depending 
on the stage of cancer progression. Despite numerous advances and intensive research, a large 
number of patients acquire multidrug resistance (MDR) and no longer respond to chemotherapy. 
MDR is a phenomenon where resistance develops to functionally and structurally unrelated 
drugs. This represents a major obstacle to successful chemotherapy. Resistance, either acquired 
or inherent, can be developed via multiple pathways. These mechanisms may function 
independently or synergistically, leading to treatment failure and rise in cancer deaths [2]. 
Therefore, the focus of this chapter is to discuss the integrated role of efflux transporters (P-
glycoprotein, multidrug resistant proteins and breast cancer resistance protein), metabolizing 
enzymes (cytochrome P450) and nuclear receptors (pregnane X receptor) in development of 
MDR.  
Mechanisms of Cancer Drug Resistance 
 Several mechanisms of MDR have been suggested, which can be categorized into 
pharmacokinetic and pharmacodynamic resistance pathways [3]. These mechanisms include i) 
decreased influx, ii) increased efflux, iii) activation of detoxifying systems, iv) drug 
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sequestration, v) alteration of specific drug targets, vi) activation of DNA repair and vii) 
modulation of cellular death pathways and viii) impact of microenvironment (Figure 1). The 
first four mechanisms leading to reduced intratumor drug levels account for pharmacokinetic 
resistance while changes in microenvironment or biology of the cancer cells (the last four 
mechanisms) lead to pharmacodynamic resistance.  
Decreased Influx 
 MDR can be mediated by a decrease in drug uptake into target cells. Many drug 
molecules find their way into the cell by means of passive diffusion, endocytosis or facilitated 
transport [4, 5]. Notably, the solute carrier family (SLC) comprising of 43 families and 298 
transporters is involved in the uptake of several anticancer drugs [6]. Therefore, a decrease in the 
expression or mutation of these transporters results in drug resistance. For example, methotrexate 
(antifolate chemotherapeutic) utilizes reduced folate carrier (RFC/SLC19A1) for cellular 
accumulation. Downregulation and/or mutation of this carrier develops antifolate resistance [7]. 
Similarly, mutations in human equilibrative nucleoside transporter 1 (ENT1/SLC29A1) and 
organic cation/carnitine transporter 1 (OCTN1/ SLC22A4) confer sensitivity to gemcitabine and 
doxorubicin, respectively by reducing cellular uptake [8, 9].  
Increased Efflux 
 A family of ATP-binding cassette (ABC) efflux transporters expels drug molecules out of 
the cell thereby lowering intracellular drug concentration. This is considered to be one of the 
most predominant mechanisms for development of MDR. The human genome encodes 48 ABC 
transporters, organized into seven distinct subfamilies (ABCA-ABCG) based on phylogenetic 
analysis [10]. The structure, biology and mechanism of action of ABC transporters are 
thoroughly described in the later sections of this chapter.  
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Figure 1. Mechanisms of cancer drug resistance. 
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Activation of Detoxification 
 Drug detoxification is considered as the second line for development of drug resistance. 
Metabolism involves two distinctive pathways - phase I and phase II. Phase I reactions include 
oxidation, reduction or hydrolysis reactions. These functionalization reactions either introduce a 
new polar functional group or modify an existing functional group [11, 12]. The key players 
involved in phase I metabolism are cytochrome P450 enzymes (CYP450). Since CYP450 plays 
an important role in mediating MDR, more details are described in subsequent sections. Phase II 
reactions are termed as conjugation reactions and include acetylation, glucuronidation, 
glutathionylation, methylation and sulfonation reactions [13-15]. These reactions transform the 
parent drug or phase I metabolite into hydrophilic conjugate and favors excretion. Also, phase II 
conjugates are actively effluxed via ABCC transporters [16]. One such example includes 7-ethyl-
10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan. The glucuronide conjugate 
of SN-38 is actively effluxed by ABC transporters, enhancing drug clearance in liver [17]. Thus, 
the synergistic interplay between phase II enzymes and efflux transporters can dramatically 
decrease chemotherapeutic efficacy [18].   
Drug Sequestration 
 Recent investigations have demonstrated that altered intracellular distribution of 
chemotherapeutic agents is another important factor involved in MDR. Intracellular drug 
sequestration as a result of defects in lysosomal and protein trafficking leads to subtherapeutic 
concentration in the target compartment, leading to treatment failure [19]. Cisplatin is commonly 
employed in treatment of many malignant tumors. However, development of resistance 
represents a major obstacle in its therapeutic utility. Cisplatin is extensively sequestered in the 
vesicular structures of lysosome, golgi and secretory compartments and then effluxed from the 
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cell [20-23]. Recent investigations have analyzed the expression of an ABC efflux transporter, 
ABCA3, on limiting membranes of lysosomes and other vesicular bodies. The expression of this 
transport protein correlated with poor survival rate in patients with acute myeloid leukemia. 
Intracellular drug sequestration mediated by ABCA3 transporter was reported to develop 
resistance to chemotherapeutics such as daunorubicin, etoposide, imatinib, mitoxantrone and 
vincristine [24-27].  
Alteration of Drug Targets 
 Resistance can also be associated with changes in expression of target protein. A classic 
example of this mechanism is the decrease of DNA topoisomerase (Top) activity [28].  Top I and 
II play a key role in DNA replication, facilitating relaxation (untangling) and subsequent 
relegation of intertwined DNA strands. Top I induces single strand breaks while Top II cleaves 
both strands. Chemotherapeutics stabilize Top-DNA complex interaction, prevent religation, and 
promote cellular death. Camptothecins act on Top I while anthracyclines and 
epipodophyllotoxins act on Top II. Use of such drug molecules is limited due to acquisition of 
resistance via reduced expression of the enzyme or mutation thus preventing drug binding [29, 
30]. Similarly, resistance to methotrexate acquires via elevated expression or mutation of 
intracellular target, dihydrofolate reductase (DHFR). L22R mutation of DHFR reduced the 
binding of methotrexate by approximately 270 fold, enabling acquisition of drug resistance [3, 
31, 32].   
Activation of DNA Repair 
 Exposure to radiation or use of classical anticancer drugs (including alkylating agents, 
anthracyclines and platinum based compounds) causes extensive DNA damage leading to cell 
death. However, activation of DNA repair significantly reduces therapeutic efficacy. These 
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repair pathways include i) direct reversal, (ii) mismatch repair (MMR), (iii) nucleotide excision 
repair (NER), (iv) base excision repair (BER), (v) homologous recombination (HR) and (vi) 
nonhomologous end joining (NHEJ) pathways [33-35]. DNA repair mechanism depends on the 
type of DNA-drug adduct, tissue location and the participating proteins. The important rate 
limiting protein of NER pathway is ERCC1. Various in vitro studies have demonstrated elevated 
expression levels of ERCC1 in drug-resistant cell lines [36]. Also, the survival rate of patients 
receiving cisplatin-based chemotherapy is reported to be higher in ERCC1-negative non-small 
cell lung tumors compared to ERCC1-positive tumors [37]. Similarly, resistance to alkylating 
agents was reported to occur by ubiquitously expressed, O
6
-methylguanine DNA 
methyltransferase (MGMT) repair protein. The expression levels of this protein were correlated 
with resistance to carmustine and temozolamide in glioblastoma. Patients with higher expression 
of MGMT exhibited treatment failure and increased death rate compared to patients with lower 
expression levels [38, 39].  
Modulation of Cellular Death Pathways 
 Disruption of cellular death pathways is an important hallmark of cancer. Hence, the 
principal pharmacological purpose of chemotherapy is to trigger cell cycle arrest or cell death. 
Any alterations in these pathways appear to have critical impact in mediating drug resistance. 
Cellular death is mediated by both apoptotic and non-apoptotic mechanisms (autophagy, mitotic 
catastrophe, necrosis and senescence) [40, 41]. The programmed cell death, apoptosis, is 
characterized by morphological changes including chromatin condensation, nuclear 
fragmentation and DNA laddering in the nucleus; formation of apoptotic bodies in the cytoplasm 
and blebbing of cell membrane. Apoptosis occurs via two pathways - extrinsic (involving 
activation of tumor necrosis factor receptor family) and intrinsic (involving mitochondria) [42, 
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43]. A balance between pro- and antiapoptotic proteins governs chemotherapy induced 
resistance. A relation between Bcl-2 (antiapoptotic protein) expression and response to 
chemotherapy has been investigated in breast cancer treatment. The study revealed that a 
complete pathological response was noted in Bcl-2 lacking tumors while tumors with stable 
levels of Bcl-2 exhibited no response to chemotherapy [44]. Similar chemotherapeutic resistance 
in acute myeloid leukemia, non-Hodgkins lymphoma and advanced breast cancer was positively 
correlated with expression levels of Bcl-2 [45, 46].  
Impact of Microenvironment 
Tumors are characterized by impaired blood supply, abnormal vasculature and decreased 
lymphatic clearance. Consequently, the availability of nutrients and oxygen is reduced and the 
clearance of metabolic byproducts is impaired. This leads to formation of hypoxic and acidic 
regions in tumors [47, 48]. Such heterogeneous tumor microenvironment can trigger a cascade or 
reactions that influence treatment outcome [49, 50]. 
Acidic pH: Tumor cells meet their energy requirements through glycolytic pathway 
rather than oxidative phosphorylation pathway due to lack of oxygen. Lactic acid produced 
during glycolysis is not cleared due to high interstitial pressure, leading to intracellular 
acidification. In a process to maintain pH homeostasis, the expression of proton pumps is 
increased, rendering the extracellular milieu acidic. This extracellular pH influences 
chemotherapy. Weakly basic chemotherapeutics such as doxorubicin, mitoxantrone, vinblastine 
and vincristine are ionized at acidic pH, hindering passive cellular uptake [51]. Also, the active 
uptake of methotrexate is lowered at acidic extracellular conditions [52]. Conversely, the cellular 
uptake of weakly acidic drugs such as camptothecins, chlorambucil and cyclophosphamide is 
enhanced at acidic extracellular pH [51, 53]. 
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Hypoxia: Hypoxia, reduced tissue oxygen levels, represents a major hallmark of tumor 
microenvironment. Apart from efflux transporters and metabolizing enzymes, hypoxia is the 
other major factor contributing not only to developing MDR but also to intensifying or 
amplifying resistance acquisition. Tissue response to hypoxia is orchestrated by the transcription 
factor, hypoxia-inducible factor 1 (HIF-1), which regulates the expression of more than hundred 
target genes [54, 55]. The target genes play a key role in regulating angiogenesis, cell survival, 
chemotherapy, genetic instability, immortalization, immune evasion, invasion, metabolism, 
metastasis, proliferation, radiation resistance and stem cell maintenance [56-63]. For instance, 
hypoxia induces the expression of Bcl-2 genes rendering resistance to many chemotherapeutic 
agents. Furthermore, the expression of nucleophiles such as glutathione and metallothionein is 
upregulated in hypoxic cells. This significantly reduces the treatment outcome of alkylating 
agents and platinum based compounds [64, 65]. HIF-1 transcription factor also regulates the 
basal expression of important ABC efflux transporters [66, 67]. Taken together, independent of 
the mechanism involved, hypoxia is associated with increased patient mortality in many different 
cancers including bladder, brain, breast, colon, endometrium, head and neck, liver, lung, ovary, 
pancreas and skin [68-71]. 
In a nut shell, it appears that several resistance pathways pose a significant barrier to 
chemotherapy. Although these pathways can act independently, they are more often 
interconnected. Of the various mechanisms involved, upregulation of efflux transporters and 
metabolizing enzymes constitute a major resistance phenotype.  
ABC Efflux Transporters 
Overview 
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Significant research from the past 30 years has demonstrated the importance of ABC 
transporters in development of resistance [72, 73]. Efflux transporters are ubiquitous and 
identified in both prokaryotes and eukaryotes. Phylogenetic analysis categorized ABC proteins 
into seven subfamilies, ABCA-ABCG, and fifteen of these members have been associated with 
MDR [74]. ABC efflux transporters provide body’s first line of defense against xenobiotics and 
endogenous metabolites. They constitute a large family of membrane proteins involved in 
translocation of diverse compounds including amino acids, bile salts, drug molecules, metal ions, 
metabolites, nucleotides, peptides, sterols and sugars. ABC transporters utilize the energy 
harnessed from ATP hydrolysis and thus considered an active transport process [75].  
A typical ABC transporter consists of two membrane spanning domains (MSDs) and two 
nucleotide binding domains (NBDs). The structural requirement is met by single polypeptide 
chain or dimerization of two polypeptide chains. MSDs and NBDs form the backbone of ABC 
transporter and are required for transporter activity. MSDs exhibit glycosylation sites at specific 
extracellular domains. Mutagenic studies revealed that these sites are not required for transporter 
function. However, they are needed for proper expression and membrane insertion [76-78]. The 
sequence of MSDs is not conserved across different members, the length and framework of each 
MSD determines ligand binding and substrate specificity. Unlike MSD, the sequence of NBD is 
conserved [79]. Each NBD contains i) Walker A motif (or P-loop) ii) Walker B motif iii) 
signature C motif iv) Q-loop v) D-loop vi) A-loop and vii) H-loop. The highly conserved Walker 
A motif binds ATP and the Walker B motif initiates nucleophilic attack and ATP hydrolysis. 
Signature C motif (LSGGQ motif) is considered as the hallmark of ABC transporters and helps 
in communicating MSDs. Q-loop mediates interactions between MSD and NBD while D-loop 
communicates the two NBDs. A-loop and H-loop contribute to the ATP binding and catalytic 
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cycle [80-83]. The structure of efflux transporters is depicted in Figure 2 and important genomic 
characteristics are summarized in Table 1. Efflux transporters expel drug molecules out of the 
cell thereby reducing intracellular drug concentration leading to acquisition of drug resistance. A 
partial list of chemotherapeutics effluxed by ABC transporters is given in Table 2. 
P-Glycoprotein (P-gp/MDR1/ABCB1) 
Structure: P-gp was the first member of ABC superfamily to be studied. This surface 
glycoprotein was initially identified in chinese hamster ovary cells and found to modulate drug 
permeability of a wide range of amphiphilic drugs [84]. P-gp shares high sequence identity 
(78%) with another isoform of ABCB family (MDR2/3/ABCB4) involved in exporting 
phosphatidylcholine into bile. Structurally, P-gp comprises two MSDs and two NBDs. Each 
MSD comprises six hydrophobic transmembrane domains (TMDs). P-gp is a single polypeptide 
chain with two 2 homologous halves (each of 610 amino acids) linked by 60 amino acid region. 
Tissue localization: P-gp is expressed in almost all the tissues. However, abundant 
expression is found at apical surface of small intestine, pancreatic ducts, bile ducts, kidney 
proximal tubules, and adrenal glands. Moderate expression is found in hepatocytes, spleen and 
lung while low expression is observed in prostate, ovary and skin. This localization suggests that 
P-gp plays a physiological role in protection of many tissues. Further, the protective role is also 
evident from its expression at blood-brain, blood-testis and blood-mammary tissue barriers [85-
87]. Overexpression of P-gp leading to drug resistance has been reported in many tumor cells 
including breast, colon, gastric, kidney, leukemic, liver and pancreatic cells [88].  
Structure-activity relationship (SAR): P-gp interacts with structurally diverse substrates. 
Although majority of them are amphipathic and relatively hydrophobic, few of them are water 
soluble. Extensive research has been conducted to predict SAR for P-gp substrates or inhibitors. 
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Figure 2. Structure of ABC transporters. Reproduced with permission from reference [73]. 
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Table 1. Summary of genomic properties and tissue localization of ABC efflux transporters. 
 
 
)Iembt>r Cbromosomal TranSCIipt Amino )101. Wl'igbt (Da) b ons Timle localization 
location 1. lIglil (bp) acids 
P-gpl 7q2Ll2 4872 1280 141 ,463 28 Admlal, blood-bralll barrier, Illt~Stin~, 
lIDRII kidn~y, tiv~r, placenta 
ABCBI _ipical 
llRPli 16pl312 5927 153 1 171,561 31 Ubiqmtolls 
ABeCl Basolotera! 
lIRPli cllOATI IOq24.2 4930 1545 174,191 32 Colon, gall bladder, intestin~, kidn~y, 
_-IIlCC2 liv~, ltulg, placenta 
Apical 
lIRP311IOAT-DI 17q2 113 5176 1527 169,343 31 Adrenal ~3lld, gall bbddec, 8111, mtes-
ABee3 tine, kidn~y, livt'l', panmas, placl'Ilta, 
prostat~ 
Baso!atera! 
lIRP41110AT-B/ llq321 5871 1325 149,541 31 Adrenal glands, limg, inlestine, ovary, 
_-IIlCC4 panCfl"3S, prostat~, testis 
Apica! and baso/oterol 
l1RP51110AT-CI 3q27.1 5851 1437 160,6&1 30 Ubiquitous 
_-IIlCC5 Apical and basoloterol 
l1RP61110AT-EI 16p1 312 5UI 1503 164,901 31 Kidney, liver, tracheal 
ABCC6 l'pitheliulll 
Basolotera! 
lIRP7I _-IIlCC I0 6p2Ll 5U8 1464 161 ,629 22 Low in aU tissu~s 
Baso!otera! 
lIRP81_-IIlCC II 16q121 4576 ll82 154,301 29 Low in aU tiss\le's 
Apica! and baso/otero! 
llRP9I_-IIlCC Il 16q121 5168 1359 152,244 29 Low in all tiss\le's 
? 
BCRPI 4q22 4445 655 72,314 16 Br~ast, intestine, liver, placenta 
llXRl Apical 
ABCG2 
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Table 2. Chemotherapeutic substrates of ABC efflux transporters. 
 
 
 
 
 
 
ErnUl b'all'porter Chemotherapeutic sub,trates 
lIDRl Blsantreu" daunombicll, doc,t",~ doxorublClll, "I'irubiclll, ,toposide, idambiclll, m.thotrexat" nutoxantroll1, partit",l, 
tffiiposide, vrnblastm" vmmstrn. 
llRPl DalUlorubicin, doxorublCll, 'prrubicin, ,toposide, llrutirub, melphalan, m,thotrexate, nutnxantrone, partitaxel, vrnblastm" vmetis-
tin, 
llRPl C"platin, doxorublCin, ,tOPOSllie, rnnnt"an, melhntrexate, SN-38, vmblastin" VllCristin, 
lIRP3 CarlJoplatin, '"platin, ,tOPOSlde, m,llintrexat" tffiipoSld, 
lIRP4 M,thotrexat" topot,,'" 
lIRP5 5-l1uorouracil, m,thotrexate 
lIRP6 Crsplatin, 'toposide, teruposide 
llRPJ lJoc,t,,'~ pactita,,~ vinblastine, \;,mstin, 
lIRP8 1-l1uorouracil 
BCRP Blsantreue, dalUlorublClll, doxorubicin, "I'rrublClll, etopoSide, gefitirub, lIl"tirub, II1I1Ot1<an, m,thotrexate, untox'"trone, SN-38, 
terupoSlde, topot"," 
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Seelig reported a general pattern for substrate recognition by P-gp by comparing more than 
hundred known substrates. Two types of recognition elements have been described. Type I group 
exhibits two electron donor groups with a spatial separation of 2.5 ± 0.3 Ǻ while type II group 
exhibits two or three electron donor groups with a spatial separation of 4.6 ± 0.6 Ǻ. Based on the 
type and number of groups, various molecules can be predicted as strong substrate, weak 
substrate or non-substrate [89]. A more recent pharmacophore hypothesis for P-gp substrate 
recognition was proposed by studying 129 diverse compounds. This approach suggested that the 
interaction of substrate with one or more binding sites plays a key role in transport. According to 
this three dimensional model, the minimal recognition elements for transport by P-gp are 
dimensions of the molecule, two hydrophobic groups 16.5 Ǻ apart and two hydrogen bond 
acceptor groups 11.5 Ǻ apart [90]. Another pharmacophore model proposes a pattern consisting 
of two hydrophobic units, three hydrogen bond acceptor units and one hydrogen bond donor 
[91]. These SAR methods can be a promising approach to study P-gp substrates and modulators 
[92].  
Transport cycle: P-gp is considered as the archetype of ABC efflux transporters; hence 
the mechanism of substrate translocation has been highly investigated. The transport mechanism 
involves two interconnected cycles i) catalytic cycle involving ATP hydrolysis and ii) transport 
cycle involving translocation of the substrate. However, the molecular details still remain 
enigmatic [93, 94]. Two alternative models have been proposed describing the transport cycle of 
P-gp. The key difference in both these models is the nature of energy that expels the substrate. 
The first model proposed by Higgins and Linton (ATP switch model) hypothesizes ATP binding 
as the power stroke for translocation [95]. This model postulates the following steps. The 
transport cycle begins with binding of substrate to high-affinity site on TMD. This binding 
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increases affinity for ATP, reduces activation energy and results in dimerization of two NBDs. 
Subsequent conformational changes releases the bound substrate. Two sequential ATP 
hydrolysis events reset P-gp to the ground state. The second model described by Sauna and 
Ambudkar proposes ATP hydrolysis as the key step for translocation [96]. The second model 
proposes the flowing steps. The transport cycle begins with binding of both substrate and ATP 
simultaneously to the transporter. The ATP molecule is hydrolyzed resulting in conformational 
change of the transporter and release of bound substrate. A second ATP hydrolysis then resets 
the ground state of the molecule. The essential steps of two models are illustrated in Figure 3.  
Multidrug Resistant Proteins (MRPs/ABCC) 
 Structure: ABCC represents the largest branch of ABC transporters. This family includes 
nine efflux transporters (MRP1-6/ABCC1-6 and MRP7-9/ABCC10-13), one gated chloride 
channel (cystic fibrosis transmembrane conductance regulator/CFTR/ABCC7) and two 
potassium channel regulators (sulfonylurea receptor1-2/SUR1-2/ABCC8-9) [97-100]. The 
founding member of this family, MRP1, was cloned by Cole et al., in doxorubicin-resistant lung 
cancer cells [101]. MRP2 was isolated from cisplatin resistant head and neck cancer cells [102]. 
Subsequent studies have identified additional members of this family. Although the molecular 
and functional mechanisms may vary, all members are structurally similar and ATP-dependent. 
Computational analyses, hydropathy profiles and sequence alignments have predicted the 
structure of MRPs.  MRPs 4, 5, 8 and 9 are described as short MRPs with typical ABC structure 
comprising two MSDs and two NBDs. MRPs 1, 2, 3, 6 and 7 are described as long MRPs with 
an additional hydrophobic amino terminal domain (MSD0) of approximately 200 amino acids  
[103, 104]. In contrast to the intracellular amino terminus in P-gp and short MRPs; the long 
MRPs exhibit extracellular amino terminus [105, 106].  
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Figure 3. The transport cycle of P-glycoprotein. (A) ATP switch model proposed by Higgins and 
Linton (B) Alternate model proposed by Sauna and Ambudkar. Reproduced with permission 
from reference [94]. 
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Tissue localization: MRP1 is ubiquitously found in a number of human cells. Higher 
expression is noticed in lung, testis, kidney and macrophages. MRP1 plays a protective role and 
is localized in the basolateral membrane of blood-testis barrier, blood-cerebrospinal fluid barrier 
and bronchial epithelium [107-109]. MRP2 is predominantly present in apical membrane of 
polarized cells including colon, gall bladder, intestine, kidney, liver, lung and placenta [110-
114]. MRP1 and MRP2 are the most studied ABCC transporters believed to mediate MDR in 
cancer. Upregulation of MRP1 is correlated with poor patient outcome in retinoblastoma and 
neuroblastoma [115, 116]. Elevated levels of MRP1 have also been reported in breast, lung, and 
acute myeloid leukemic and prostate tumor cells [117, 118]. Similarly, overexpression of MRP2 
is observed in breast, colorectal, hepatic, leukemic, lung and ovarian cancers [119-123].  
Breast Cancer Resistant Protein (BCRP/MXR/ABCP/ABCG2) 
Structure: The ABCG family includes six half-transporters and the second member of this 
family (ABCG2) is involved in mediating MDR [10]. Nakagawa et al., identified a distinct 
pathway mediating resistance in mitoxantrone resistant (MXR) human breast cancer cells [124]. 
However, the protein was first cloned in drug resistant human breast cancer cells, hence referred 
as BCRP [125]. Shortly after this cloning, a new human ABC transporter highly expressed in the 
placenta (termed as ABCP) was reported [126]. All these designations mapped the same 
transporter. BCRP is organized into two structural units comprising one NBD and one MSD. 
Since a functional ABC transporter requires a minimum of two NBDs and two MSDs, BCRP 
homodimerizes in a reverse orientation for transport activity [127, 128]. The dimerization of 
BCRP has been proposed to occur via disulfide bridge formed by cysteine moieties (Cys603) 
located in the extracellular loop between TMDs 5 and 6 [129].  
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Tissue localization: BCRP is highly expressed on apical membranes of biliary canaliculi, 
brain capillary endothelial cells, colon, placenta, prostate, small intestine, testis and uterus [130, 
131]. The pharmacological importance of BCRP in mediating MDR is evident by its expression 
in melanoma and tumors of digestive tract, endometrium, esophageal and lung cancers [132-
134].  
CYP450 Metabolizing Enzymes 
Overview 
Among the various enzyme systems involved in drug metabolism, CYP450 includes the 
most important constitutive and inducible superfamily (Figure 4). CYPs are heme containing 
monooxygenases and the number 450 indicates absorption maximum of the enzyme in reduced 
carbon monoxide bound form. To date, more than 57 active human P450 genes belonging to 17 
distinct families have been described [135]. Each member consists of atleast two protein 
components (heme-protein and flavoprotein) and a lipid component (phophatidylcholine). The 
catalytic cycle of CYP450 utilizes molecular oxygen to oxidize a substrate with the release of a 
water molecule and utilizing electrons from NADPH. The cycle includes the following steps i) 
substrate binds to the resting ferric state of the enzyme, ii) an electron is transferred from 
NADPH-CYP reductase to the ferric enzyme resulting in formation of ferrous enzyme-substrate 
complex, iii) oxygen binding leads to an oxy-P450 complex, iv) a second electron is added 
resulting in formation of iron peroxo species, v) oxygen-oxygen bond is cleaved to form an iron 
oxo intermediate with release of water and finally vi) oxygen from iron oxo intermediate is 
transferred to the bound substrate, with release of product and regeneration of ground state of 
CYP [136, 137]. While the CYP450s are mainly localized in the liver, extrahepatic localization 
is also noted in brain, colon, esophagus, kidneys, lungs, nasal, respiratory and olfactory mucosa, 
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small intestine, stomach, and trachea [138-141]. P450s can be categorized into i) drug 
metabolizing enzymes (DMEs) mostly involving CYP families 1-4 (Table 3) and ii) enzymes 
involved in metabolism and synthesis of endogenous substrates (fatty acids, prostaglandins, 
steroids, vitamins) involving CYP11, 17 and 19 families [142-144].  
CYP3A4 
Among the different xenobiotic metabolizing enzymes, CYP3A 4 (family 3, subfamily A, 
member 4) accounts for metabolism of more than 50% of the marketed drugs [145]. Although 
CYP3A4 plays an important role in detoxification of many chemotherapeutic agents, certain 
prodrugs require bioactivation by this enzyme for therapeutic activity [146]. CYP3A4 is 
expressed in many tumors including breast, colon, esophagus, lung, ovarian and soft tissue 
sarcomas [143]. A higher CYP3A4 activity would generally result in increased detoxification of 
the drug and subsequent development of MDR. For example, patients with lower expression of 
CYP3A4 showed a higher response rate to docetaxel in treatment of breast tumors [147]. 
Similarly, higher expression of CYP3A4 is associated with metastasis and poor prognosis in 
osteosarcoma patients [148].  
Combined Action and Regulation of Efflux and Metabolism 
Efflux transporters and phase I DMEs orchestrate a defensive system against various 
chemotherapeutics. Synergistic action leading to MDR could possibly arise due to two different 
factors - overlapping substrate specificity and coordinated regulation of their expression. 
Oncolytic drugs such as docetaxel, doxorubicin, etoposide, imatinib, paclitaxel, teniposide, 
vinblastine and vincristine are substrates for both P-gp and CYP3A4. This close overlap of 
substrates and tissue distribution may lead to development of MDR [149, 150]. Also, their 
inducible expression is governed by molecular mechanisms involving nuclear receptors (NRs). 
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Figure 4. Contribution of enzyme systems and individual P450s in metabolism of marketed 
drugs. Reproduced with permission from reference [11]. 
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Table 3. Chemotherapeutic substrates of CYP450 enzymes. 
 
 
 
 
 
 
 
CYP450 fnZ)'me Chemotheraptutic substrates 
1.'11 Docelaxel, edotinib, tamorifeo 
1.'11 Erlotinib, etoposide, flutainide, mMtinib, tamorifeo 
lB6 Cydophosphanude, ifosfanude, lamo~fen 
lC9 Cyclophosphanude, ifosfanude, mMtinib, lamoxifeo 
lCl9 Cydophosphanude, ifosfanUde, llMtinib, lamoxife~ teniposide 
lD6 Inmtinib, lamoxifen, vllorelbine 
lEI C~platin, etoposide, tamorifen, vinorelbine 
3A4/5 C~platin, cyclophosphanude, c~arabllll, dexamethasolll, docetaxel, doxorubiCin, erlotinib, etoposide, exemestane, flutanude, fuI-
vestrant, gefitinib, ifosfanude, inutinib, 1IUlotecan, letrozole, medroX)~rogresterone acelate, nutoxantrone, paclitaxe( lamoxifen, 
taJWetin, teniposide, topotecan, vmblastine, vmcri~me 
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Certain chemotherapeutics can activate NRs, leading to increased expression of both 
efflux transporters and metabolizing enzymes [18, 151]. This untoward activation can lead to 
decreased oral uptake in the intestine, increased excretion in the liver and decreased 
concentrations at the tumor site Figure 5. These factors substantially increase the severity of 
drug resistance. NRs include a superfamily of transcription factors with more than 70 distinct 
members [152]. The characteristic structural features are shared in most of the NRs, exhibiting a 
highly conserved central DNA binding domain (DBD) and a ligand binding domain (LBD) at the 
C-terminal. Two transactivating domains, activation function 1 and 2 (AF-1 and 2) are located at 
the N- and C- terminus, respectively [153]. These domains help in recruiting various 
transcriptional coactivators. While AF-1 allows ligand-independent regulation, AF-2 acts in a 
ligand-dependent manner [153]. NRs are categorized into two different subclasses, ligand-
dependent and orphan NRs, depending on their ligand-binding requirement. The regulatory 
ligands have not been identified for orphan NRs. Pregnane X receptor (PXR) and constitutive 
androstane/activated receptor (CAR) are the master orphan NRs involved in xenobiotic 
metabolism and elimination [154, 155]. The pharmacological action of PXR and its potential role 
in mediating MDR to cancer chemotherapy has been extensively investigated.  
Pregnane X Receptor (PXR) 
PXR (the gene product of NR1I2) was cloned in 1998 by three independent groups [156-
158]. This NR was initially found to be activated by endogenous pregnanes, which gave rise to 
its name. PXR is considered as a ‘molecular sentinel’ localized to both cytoplasm and nucleus. In 
cytoplasm, PXR is sequestered by heat shock protein 90 (Hsp90) or cytoplasmic CAR retention 
protein (CCRP) [159]. Following ligand binding, PXR dissociates and translocates to nucleus via 
nuclear localization signal (NLS) located with residues 66 to 92 of DBD [160]. 
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Figure 5. Role of nuclear receptors in mediating drug resistance via upregulation of efflux 
transporters and metabolizing enzymes. Reproduced with permission from reference [18]. 
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In nucleus, it forms a heterodimeric complex with 9-cis retinoic acid receptor/retinoid X 
receptor (RXR) [159]. Various transcriptional coactivators including steroid receptor coactivator 
1 (SRC1), glucocorticoid receptor interacting protein 1 (GRIP1), activator for thyroid hormone 
and retinoid receptors (ACTR), and peroxisome proliferator activated receptor coactivator 1-
alpha (PGC1α) are recruited [161-163]. Subsequently, PXR promotes the transcription of various 
target genes by binding to (A/G)G(T/G)TCA in a sequence-specific manner [164]. The target 
genes include Phase I DMEs (CYPs, carboxylesterases, aldehyde and alcohol dehydrogenases), 
Phase II DMEs (glucoronosyltransferases, glutathione-S-transferases and sulfotransferases) and 
ABC  efflux transporters (MDR1, MRPs and BCRP) [165-169] (Figure 6).  
Tissue localization: PXR is highly expressed in liver, intestine and kidney. Other tissues 
including adrenal gland, blood-brain barrier, breast, bone marrow, colon, heart, osteoclasts, 
ovary, placenta, peripheral blood monocytes, stomach and uterus also express PXR [158, 170-
174]. The expression of PXR has also been detected in breast, colon, endometrial, osteosarcoma, 
ovarian, and prostate cancers [175-180].  
MDR Modulators: Potential Strategy for Overcoming MDR  
A potential approach to overcome MDR is to administer compounds that would inhibit 
ABC transporters at the substrate binding sites. These compounds are referred as MDR 
inhibitors/modulators/reversal agents or chemosensitizers. They may modulate the activity of 
more than one ABC transporter. The modulators are categorized into first, second and third 
generations. First generation modulators include verapamil, cyclosporine A and erythromycin. 
These modulators exhibited low affinity towards ABC transporters, thus necessitating the use of 
high dose which often lead to undesirable side effects and toxicity. The second generation 
modulators such as dexverapamil and valspodar were developed and found to be potent.  
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Figure 6. Mechanism of action of pregnane X receptor (PXR). 
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However, the inhibition of CYP450-mediated drug metabolism resulted in unpredictable 
pharmacokinetics of coadministered drugs, often raising their systemic toxicity. Third generation 
modulators such as tariquidar and zosuquidar are designed with the aid of combinatorial 
chemistry to overcome the limitations of the other generation MDR modulators. Clinical trials 
demonstrated no encouraging results so far [181, 182].  
The small molecule tyrosine kinase inhibitor - cabozantinib, has entered into a phase III 
clinical trial for the treatment of hepatocellular carcinoma. Xiang Q et al., assessed the effect of 
this molecule on inhibiting MDR. Results demonstrated that cabozantinib increased the 
inhibitory effect of doxorubicin in xenograft nude mice model via inhibition of P-gp [183]. A 
similar study was performed by Liu KJ and colleagues using saracatinib (AZD0530), a highly 
potent dual kinase inhibitor, currently under investigation for the treatment of ovarian cancer. 
Their studies have concluded that this molecule reverses P-gp mediated drug resistance in cancer 
and enhances the chemotherapeutic efficacy of paclitaxel in mice xenografts [184]. All these 
studies suggest that efflux transporter inhibition may serve as a viable therapeutic approach for 
overcoming MDR in cancer. 
Also, many anticancer drugs currently used in clinical setting can activate PXR. The 
concept of downregulating PXR to sensitize cancer cells to anticancer agents has been 
thoroughly investigated. In a study by Chen et al., expression of PXR in normal and cancerous 
prostate cancer (PC-3) cells has been examined [185]. PC-3 cells treated with PXR agonist 
SR12813 elevated MDR1 expression, enabling PC-3 cells resistant to paclitaxel and vinblastine. 
Knock-down of PXR with short hairpin RNA (shRNA) augmented sensitivity of PC-3 cells to 
anticancer drugs. Results from this investigation suggest that blockade of PXR activity enhances 
the effectiveness of anticancer drugs, particularly in PXR-positive cancers.  
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In a similar study, downregulation of PXR by small interfering RNA (siRNA) in HEC-1, 
an endometrial cancer cell line, reduced MDR1 expression and sensitized cells to anticancer 
agents such as paclitaxel and cisplatin [186]. Similarly, activation of PXR reduced the 
effectiveness of etoposide in treatment of osteosarcoma [179]. All these observations suggest 
that downregulation of PXR could be a novel therapeutic intervention to augment sensitivity of 
anticancer drugs and/or overcome resistance. PXR mediated chemoresistance may be surpassed 
with the use of appropriate antagonists (Figure 7) [154].  
Ecteinascidin-743 (ET-743), a novel antineoplastic agent inhibits the proliferation of 
various cancer cells and human xenografts with half-maximal inhibitory (IC50) concentrations 
ranging from 1 to 100 nM. This compound was one of the first PXR antagonists to be reported. 
Dose-dependent inhibition studies on transient transfected cells with SXR revealed that ET-743 
inhibited PXR at nanomolar concentrations, with IC50 of approximately 3 nM [187]. Takeshita et 
al., reported inhibition of steroid-induced PXR mediated transcription of CYP3A4 by 
ketoconazole [188]. The exact mechanism of this inhibition was subsequently demonstrated by 
Huang et al [189]. Ketoconazole disrupted the interaction of PXR with coactivator SRC1, 
resulting in decreased activation of this NR and delayed metabolism of tribromoethanol in mice. 
A-792611, a novel HIV protease inhibitor exhibited downregulation of constitutive CYP3A4 
expression. Also, this compound attenuated activation of PXR and resulted in decreased 
expression of PXR target genes in human hepatocytes. Cell based transactivation studies 
demonstrated that A-792611 inhibits activity of human PXR but not other NRs (such as CAR, 
farnesoid X receptor, vitamin D receptor, and peroxisome proliferator-activated receptor alpha) 
that regulate CYP3A4. Such unique property suggests that this compound may be used to 
prevent PXR mediated drug resistance [190]. 
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Figure 7. Structure of PXR antagonists. 
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Sulforaphane (SFN), a biologically active phytochemical, is an inhibitor of histone 
deacetylases and an inducer of phase II DMEs such as glutathione S-transferases. SFN 
significantly downregulates CYP3A4 expression in human primary hepatocytes. Cell based 
assays demonstrated that SFN is a PXR antagonist and inhibits PXR mediated augmentation of 
drug clearance. SFN can bind directly to PXR, inhibit coactivator recruitment, and efficiently 
prevent PXR activity [191]. PXR activation reduced the chemosensitivity of colorectal cancer 
cells to irinotecan. However, SFN reversed this effect by increasing the chemosensitivity of 
anticancer drug [192]. Camptothecin, a Top I inhibitor, inhibits PXR mediated transcriptional 
activation of CYP3A4. This compound acts by disrupting PXR interaction with SRC1 and do not 
compete with the agonist for binding to PXR. However, the effect of camptothecin is not 
particularly specific for PXR, since this compound also inhibits CAR mediated transactivation 
[193].  
Fucoxanthin, a major non-provitamin A carotenoid, is a putative chemopreventive agent. 
Recently Lu et al. examined if fucoxanthin could overcome drug resistance through 
downregulation of PXR mediated pathways in hepatoma (HepG2) and colon adenocarcinoma 
(LS174T) cells. Fucoxanthin significantly decreased rifampin induced CYP3A4, MDR1 mRNA 
and CYP3A4 protein expression levels. PXR mediated CYP3A4 promoter activity was strongly 
attenuated with this compound in HepG2 cells. Also, CAR and rPXR mediated CYP3A4 
promoter activity was attenuated in the same cell line. Mammalian two-hybrid assay revealed 
that this compound inhibited the interaction between PXR and SRC1. These interesting results 
could lead to development of new therapeutic and dietary approaches to lessen the incidence of 
adverse drug reactions [194]. 
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Several attempts have been made to identify chemical scaffolds essential for PXR 
antagonist activity. The impact of functional groups on azole scaffold for PXR antagonist 
activity was studied. Fifteen analogs of ketoconazole were designed and SAR was predicted by 
studying dose-dependent inhibition of PXR mediated transcription in transfected cells. This 
study has identified that the two aromatic rings on ketoconazole and the five membered ring 
joining them are essential. The analogs lacking these functional groups did not exhibit any PXR 
antagonistic activity. SAR study facilitated identification of a new analog of ketoconazole, FLB-
12, with lower IC50 value for PXR antagonism. FLB-12 was significantly less toxic than 
ketoconazole in all cell lines tested [195]. Also, FLB-12 antagonized PXR mediated SN-38 drug 
resistance in colon cancer cells [196]. These studies demonstrated the potential for developing 
PXR antagonists in overcoming MDR. A second scaffold for PXR antagonism was identified by 
screening several analogs of SPB-3255. The promising lead was SPB-3255 itself with an IC50 
value of 850 nM compared to its analogs which exhibited PXR antagonism in the range of 1.5-16 
µM. Two adjacent aromatic rings along with a second aromatic group connected by a two-atom 
linker were considered to be critical for PXR antagonistic activity [197, 198]. High throughput 
studies identified coumestrol, a phytoestrogen as a PXR antagonist with an IC50 value of 11 μM. 
These studies suggested that hydrogen bond donors are an important pharmacophore in PXR 
antagonist activity. Analogs devoid of hydroxyl group at the compound’s termini were found to 
be inactive [199]. It is clearly evident that SAR studies may enable accelerated discovery of PXR 
antagonists with implications in attenuating drug resistance in cancer cells.  
Conclusions and Future Perspectives 
Drug resistance entails several mechanisms and different targets, thus impeding the 
possibility of overcoming drug resistance by targeting one protein. Efflux transporters and 
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metabolizing enzymes play a predominant role in drug disposition and acquisition of resistance. 
The use of MDR modulators demonstrated limited success due to toxicity issues. With increasing 
reports, it is clearly evident that the expression of efflux transporters and metabolizing enzymes 
is regulated by PXR, an orphan xenobiotic receptor. This striking evidence enabled discovery of 
PXR antagonists which can prevent drug mediated overexpression of efflux transporters and 
metabolizing enzymes. PXR inhibitors or antagonists currently under investigation possess 
activities other than inhibiting PXR. Future studies are warranted to identify specific PXR 
antagonists that do not interfere with the basal levels of PXR and may cause minimal/no side 
effects. It may be difficult for pharmaceutical scientists to design novel PXR antagonists owing 
to the ligand promiscuity, complexity of biology and lack of proper understanding. Better 
understanding of antagonist or allosteric sites on PXR that could modulate activity and 
application of computational approaches could lead to development of new molecules that could 
selectively fit into these sites. SAR studies amalgamated with high throughput screening studies 
will provide an effective and successful approach to identify and develop novel non-toxic, 
specific and potent PXR antagonists. Successful development of PXR antagonists may 
selectively target neoplastic cells or disrupt undesirable PXR mediated upregulation of drug 
metabolism. Such specific PXR antagonists may have wide applications in overcoming drug 
resistance including treatment of several cancers. 
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CHAPTER 2 
DIFFERENTIAL EFFECT OF MDR1 AND MRP2 ON CELLULAR TRANSLOCATION OF 
GEMIFLOXACIN 
Rationale 
Fluoroquinolones are broad spectrum antibiotics widely indicated in both human and 
animal diseases. These compounds demonstrate excellent bactericidal activity and concentration-
dependent killing effect [200-203]. Nalidixic acid and oxolinic acid were the earliest quinolone 
antibacterial drugs to be introduced. Emergence of resistance coupled with undesirable side 
effects has driven researchers to develop newer analogs, leading to the discovery of second, third 
and fourth generation fluoroquinolones. These agents have been widely indicated in the 
treatment of bacterial diseases including systemic infections [204-207]. The newer 
fluoroquinolone, gemifloxacin was approved by the United States Food and Drug Administration 
(US FDA) in 2003. It is recommended for the treatment of mild to moderate community acquired 
pneumonia (CAP), acute bacterial exacerbations of chronic bronchitis (ABECB) and urinary 
tract infections [208, 209].  
The structure of gemifloxacin is depicted in Figure 8. It is a fluoronaphthyridine 
molecule having a side chain with cyclopropanyl group at position-1 and 3-aminomethyl-4-syn-
methoxyimino-1-pyrrolidinyl substituent at C-7 position. Substitution of the carbon at C-8 
position with nitrogen enhanced antimicrobial activity. Gemifloxacin acts by forming a ternary 
complex with both DNA gyrase and topoisomerase IV. Formation of this complex is responsible 
for the blockade of DNA replication and transcription, resulting in chromosomal disruption and 
bacterial cell death [205, 208]. Most fluoroquinolones acquire resistance due to two 
chromosomal mutations in the quinolone resistance determining regions (QRDR). 
33 
 
 
Figure 8. Structure of gemifloxacin mesylate. 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
Gemifloxacin has often shown retained activity despite two-step mutations in the QRDR 
[210, 211]. Unlike ciprofloxacin and levofloxacin, reduced photosensitivity and phototoxicity 
was observed with gemifloxacin [212-215]. Gemifloxacin exhibits a broad spectrum of activity 
against gram-positive and gram-negative bacteria [216-219]. The compound showed excellent 
antimicrobial activity with low minimum inhibitory concentrations (MIC90) of 0.03, 0.06 and 
0.008 µg/mL against Streptococcus pneumoniae, S. pyrogenes and Haemophilus influenzae, 
respectively [220-224]. Potent antibacterial activity against clinical isolates and reference strains 
was observed with gemifloxacin in both in vitro as well as in vivo infectious animal models [209, 
217, 225, 226]. Upon oral administration, gemifloxacin is rapidly absorbed with peak 
concentration reaching within 0.5-2 hours. The absolute bioavailability (71%) was found to be 
lower than that of gatifloxacin (96%) and levofloxacin (99%) [201, 227]. This limitation could 
be due to efflux of fluoroquinolones by ATP-binding cassette (ABC) transporters [204].  
ABC transporters i.e. P-glycoprotein (P-gp/MDR1), multidrug resistance protein 2 
(MRP2) and breast cancer resistant protein (BCRP) are responsible for the efflux of several 
drugs, altering their absorption, distribution and excretion [228-232]. These efflux transporters 
are one of the leading membrane bound protein families in both prokaryotes and eukaryotes. 
MDR1, a 170 kDa transmembrane protein, is expressed on the apical membrane of many 
epithelial and endothelial cells. It acts as a biological barrier by extruding toxins and xenobiotics 
into extracellular environment [233]. MRP family consists of 190 kDa proteins responsible for 
the transport of drugs across lipid membranes. These proteins are similar to MDR1 with regard 
to function and localization, but may differ in substrate specificity. These efflux pumps derive 
their energy from ATP hydrolysis and expel antimicrobial drugs out of cell, thus reducing 
intracellular drug accumulation. This process may eventually lead to suboptimal eradication of 
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microorganisms. Interaction of gemifloxacin with efflux transporters in short term could possibly 
reduce bioavailability and consequently drug efficacy, which may also augment the risk of 
resistance development. Better understanding of these mechanistic interactions may aid in the 
development of newer strategies to achieve adequate therapeutic levels and higher 
bioavailability. Therefore, the primary objective of this study was to assess the short term affinity 
of gemifloxacin towards efflux transporters using polarized canine MDCKII-MDR1, MDCKII-
MRP2 cells. 
Materials and Methods 
Materials 
Gemifloxacin mesylate was obtained from Bosche Scientific LLC (New Brunswick, NJ). 
Madin-Darby Canine Kidney (MDCK) type II cells over expressing human MDR1 and MRP2 
proteins (MDCKII-MDR1, MDCKII-MRP2) were a generous gift from Drs. A. Schinkel and P. 
Borst (The Netherlands Cancer Institute, Amsterdam). [
14
C] Erythromycin (specific activity: 
51.3 mCi/mMol) was procured from Moravek Biochemicals (Brea, CA). Dulbecco’s modified 
eagle’s medium (DMEM), trypsin replacement (TrypLE™ Express), non-essential amino acids, 
TRIzol® and ATP determination kit were obtained from Invitrogen (Carlsbad, CA). Fetal bovine 
serum (FBS) was purchased from Atlanta Biologicals (Lawrenceville, GA). Culture flasks (75 
cm
2
 and 25 cm
2 
growth area), 12-well plates (3.8 cm
2
 growth area per well), polyester transwells 
(pore size of 0.4 µm) and 96-well plates (0.32 cm
2
 growth area per well) were procured from 
Corning Costar Corp. (Cambridge, MA). CellTiter 96® aqueous non-radioactive cell 
proliferation assay was obtained from Promega Corporation (Madison, WI). All other chemicals 
were purchased from Sigma Chemicals (St. Louis, MO) and used without further purification.  
Cell Culture 
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MDCK cells are the most studied epithelial cells with respect to genetics, lipid and 
protein composition [234]. MDCK type-II cells transfected with human MDR1 and MRP2 genes 
have been considered the best models to study various substrates for their efflux mechanisms 
[235, 236]. MDCKII-MDR1, MDCKII-MRP2 cells of passage numbers 5-10, 5-15 respectively 
were used for the studies. These cells were maintained with DMEM medium supplemented with 
10% FBS (heat inactivated), 1% non-essential amino acids, 29 mM sodium bicarbonate, 100 
µg/mL of penicillin and streptomycin each at 37
°
C. Cells were grown in T-75 flasks, passaged 
using TrypLE
™
 Express and plated at a density of 250,000 cells/well for uptake and transport 
studies. Medium was changed every alternate day and studies were conducted 5-7 days post 
seeding, unless specified. 
Uptake Studies 
Uptake studies were performed on cells grown on 12-well plates. [
14
C] erythromycin 
(0.25 µCi/mL) was employed to study MDR1 and MRP2 mediated efflux on MDCKII-MDR1 
and MDCKII-MRP2 cells [237, 238]. Cellular accumulation of [
14
C] erythromycin was 
determined alone, and in the presence of gemifloxacin as well as quinidine and MK-571, specific 
inhibitors for MDR1 and MRP2 respectively. After reaching confluency, the medium was 
removed and cells were washed thrice with 1 mL of Dulbecco’s phosphate buffered saline 
(DPBS) (130 mM NaCl, 0.03 mM KCl, 7.5 mM Na2HPO4, 1.5 mM KH2PO4, 1 mM CaCl2, 0.5 
mM MgSO4, 20 mM HEPES and 5 mM glucose). Later 500 µL of the test solution was added. 
Cells were then incubated for 30 min at 37
°
C. Later, uptake was arrested with ice cold PBS and 1 
mL of lysis solution (0.1% (v/v) Triton-X in 0.3 N NaOH) was added. Cells were lysed 
overnight and the cell lysate was then quantified for radioactivity with scintillation cocktail 
(Fisher Scientific, Fair Lawn, NJ) in scintillation counter (BeckmanCounter, Fullerton, CA). The 
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protein concentration in each well was estimated by Bio-Rad protein estimation kit (Bio-Rad, 
Hercules, CA) and used to normalize the radioactivity. Following a similar procedure, dose-
dependent inhibition studies were performed. [
14
C] erythromycin was spiked with various 
concentrations of gemifloxacin ranging from 1 µM to 1000 µM. Studies were performed in a 
similar way and the data was fitted to calculate the half maximal inhibitory concentration (IC50) 
according to a published method [239].  
Cellular Accumulation of Calcein-AM 
Calcein-AM is an acetoxymethyl ester derivative of calcein, a cell impermeable 
compound. This ester derivative is cell permeable and upon translocation is metabolized by 
intracellular esterases into calcein. Calcein-AM is a substrate of MDR1 and calcein is a substrate 
of MRP2 [240, 241]. Inhibition of these efflux proteins causes an increase in intracellular 
accumulation of calcein, which produces fluorescence. This assay was performed on cells 
cultured in 96-well plates at a density of 10,000 cells/well. After washing, cells were exposed to 
100 µL of calcein-AM (0.05 µM) alone, in the presence of specific inhibitor and gemifloxacin 
for 15 min. The test solution was immediately removed and replaced with 100 µL of DPBS. 
Fluorescence associated with the cells was quantified with a 96-well micro titer plate reader 
(SpectraFluor Plus, Maennedorf, Switzerland) at an excitation and emission wavelengths of 495 
and 515 nm respectively.  
Permeability Studies 
Transport studies were performed on cells grown on transwells. The donor chamber 
contained test solution where as the receiver chamber contained DPBS. Apparent permeability of 
[
14
C] erythromycin was determined from apical to basolateral (AP-BL) and basolateral to apical 
(BL-AP) directions across MDCKII-MDR1 and MDCKII-MRP2 cells. At predetermined 
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intervals (0, 15, 30, 45, 60, 90, 120, 150 min); samples were withdrawn from the receiver 
chamber and replaced with same amount of DPBS to maintain sink conditions. The samples 
were then quantified for [
14
C] erythromycin as described previously. Cumulative amount 
transported was plotted with time to determine apparent permeability. 
ATP Assay 
The efflux proteins require ATP to extrude xenobiotics out of the cell [242]. Any change 
in the intrinsic levels of ATP may alter the functional activity of efflux proteins. Hence ATP 
activity assay was performed to examine if gemifloxacin alters ATP activity in cells. MDCKII-
MDR1 and MRP2 cells grown in 96-well plates were treated with 100 µL of various 
concentrations of gemifloxacin for 150 min. Later 100 µL of lysis solution was added and cell 
lysate was used for the quantification of ATP with a kit (Invitrogen, Carlsbad, CA) following 
manufacturer’s protocol.  
Cell Proliferative Assay 
MTS assay is used to determine if concentrations of gemifloxacin used are toxic to the 
cells. Cells were exposed to various concentrations of gemifloxacin for 150 min. The solutions 
were aspirated and 100 µL of serum free media was added. Twenty microliters of MTS and PMS 
(CellTiter 96® aqueous non-radioactive cell proliferation assay) reagent were then added to 
wells. After incubating for 4 hours, the quantity of formazan formed from MTS, is measured at 
490 nm with a plate reader. The amount of formazan is directly proportional to the number of 
viable cells.  
Data Analysis 
Cellular accumulation of [
14
C] erythromycin was determined with Eq. 1. 
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      - Eq. 1 
Disintegrations per minute (DPM) of sample and donor are represented as DPMsample and 
DPMdonor respectively. The concentration of donor used is represented Cdonor and Csample 
represents the concentration of sample thus obtained.  
The half maximal inhibitory concentration (IC50) of [
14
C] erythromycin by gemifloxacin was 
calculated with Eq. 2. 
    - Eq. 2            
Y is the cellular accumulation of [
14
C] erythromycin and X represents the logarithm of the 
gemifloxacin concentration used. Data was fitted to Eq. 2 with a transformed nonlinear 
regression curve analysis program (GraphPad Prism Version 4.0; GraphPad Software, San 
Diego, CA) to calculate IC50. 
The amount of [
14
C] erythromycin transported across the cell monolayers over a specific interval 
(dM/dt) divided by the cross-sectional area of the transwell (A) generates the flux (J). Flux is 
thus estimated by Eq. 3. 
    - Eq. 3 
Apparent permeability (P) was then obtained by normalizing flux to donor concentration, as 
described in Eq. 4. 
    - Eq. 4 
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The efflux ratio was then obtained by dividing the BL-AP permeability by AP-BL permeability 
as described in Eq.5. 
     - Eq. 5 
Statistical Analysis 
All experiments were performed atleast in quadruplicate (n=4). The results were 
represented as mean ± standard deviation (SD). One way analysis of variance (ANOVA) or 
student’s t test (GraphPad InStat Version 4.0) was performed to determine statistical difference 
from the control. A P-value of <0.05 is considered to be statistically significant.  
Results 
Uptake Studies 
Accumulation of [
14
C] erythromycin on MDCKII-MDR1 cells was significantly 
enhanced (1.7 fold) in the presence of quinidine (100 µM), suggesting the inhibition of MDR1 
efflux protein. A similar increase was also observed in the presence of gemifloxacin (250 µM) 
(Figure 9). Cellular accumulation of [
14
C] erythromycin was also performed on MDCKII-MRP2 
cells. Uptake of [
14
C] erythromycin was elevated by almost 1.8 fold in the presence of MK-571 
(100 µM). A similar rise was also observed in presence of gemifloxacin (250 µM) (Figure 10). 
Dose-dependent inhibition of [
14
C] erythromycin excretion was performed on MDCKII-MDR1 
cells with varying concentrations of gemifloxacin (1 µM to 1000 µM). IC50 value of 
gemifloxacin from the dose-response curve was calculated to be 123 ± 2 µM (Figure 11). 
Similar inhibition studies were also performed on MDCKII-MRP2 cells to delineate the 
inhibitory potential of gemifloxacin on [
14
C] erythromycin uptake. IC50 value of gemifloxacin 
from the dose-response curve was calculated to be 16 ± 2 µM (Figure 12).  
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Figure 9. Cellular accumulation of [
14
C] erythromycin alone, in presence of gemifloxacin (250 
µM) and quinidine (100 µM) in MDCKII-MDR1 cells. Values represent mean ± SD. * 
represents statistical significance from control at P-value of <0.05. 
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Figure 10. Cellular accumulation of [
14
C] erythromycin alone, in presence of gemifloxacin (250 
µM) and MK-571 (100 µM) in MDCKII-MRP2 cells. Values represent mean ± SD. * represents 
statistical significance from control at P-value of <0.05. 
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Figure 11. Dose-dependent inhibition of [
14
C] erythromycin uptake in MDCKII-MDR1 cells in 
presence of varying concentrations of gemifloxacin (1 µM to1000 µM). Values represent mean ± 
SD. Inset shows the Lineweaver-Burk transformation of the data; ♦ represents gemifloxacin and 
■ represents erythromycin. 
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Figure 12. Dose-dependent inhibition of [
14
C] erythromycin uptake in MDCKII-MRP2 cells in 
presence of varying concentrations of gemifloxacin (1 µM to1000 µM). Values represent mean ± 
SD. Inset shows the Lineweaver-Burk transformation of the data; ♦ represents gemifloxacin and 
■ represents erythromycin. 
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Cellular Calcein Fluorescence 
Intracellular fluorescence in MDCKII-MDR1 cells is doubled in the presence of 
quinidine (100 µM), suggesting increased accumulation of calcein-AM through inhibition of 
MDR1. Similar increase in fluorescence was also observed in the presence of gemifloxacin (250 
µM) (Figure 13). This study was also performed on MDCKII-MRP2 cells to delineate calcein 
efflux by MRP2. Intracellular calcein fluorescence did significantly rise (2.5 fold) in presence of 
MK-571 (100 µM), probably through reduction in calcein efflux by MRP2. Accumulation of 
calcein was also significantly higher in the presence of gemifloxacin (250 µM) and was also 
confirmed by fluorescent microscopic images (Figure 14). 
Permeability Studies 
Transport of [
14
C] erythromycin across MDCKII-MDR1 cells was assessed in both AP-
BL and BL-AP directions. Since these efflux transporters are polarized on the apical side, 
permeability of [
14
C] erythromycin in AP-BL is lower than BL-AP direction. Apparent 
permeability of [
14
C] erythromycin from AP-BL direction was observed to be 2.96 ± 0.37 × 10
-6
 
cm/sec. This permeability significantly ascended to 6.37 ± 0.74 × 10
-6
 cm/sec in the presence of 
quinidine (100 µM), probably due to inhibition of MDR1. A similar rise in the permeability of 
[
14
C] erythromycin to 5.24 ± 0.52 × 10
-6
 cm/sec was also observed in the presence of 
gemifloxacin (250 µM). Permeability of [
14
C] erythromycin was obtained as 10.56 ± 0.86 × 10
-6
 
cm/sec from BL-AP direction. Such BL-AP permeability was reduced in the presence of 
quinidine (100 µM) and gemifloxacin (250 µM) to 8.56 ± 0.43 and 7.38 ± 0.72 × 10
-6
 cm/sec, 
respectively (Figure 15). Efflux ratio of [
14
C] erythromycin on MDCKII-MDR1 cells as 
calculated by ratio of permeability in BL-AP to AP-BL direction was found to significantly 
diminish in the presence of quinidine (100 µM) and gemifloxacin (250 µM).  
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Figure 13. Cellular accumulation of calcein-AM alone, in presence of gemifloxacin (250 µM) 
and quinidine (100 µM) in MDCKII-MDR1 cells. Values represent mean ± SD. * represents 
statistical significance from control at P-value of <0.05. 
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Figure 14. (A) Cellular accumulation of calcein-AM alone, in presence of gemifloxacin (250 
µM) and MK-571 (100 µM) in MDCKII-MRP2 cells as measured by intrinsic calcein 
fluorescence. Values represent mean ± SD. * represents statistical significance from control at P-
value of <0.05. (B) Cellular images of two independent experiments. 
 
 
48 
 
 
Figure 15: Transepithelial transport of [
14
C] erythromycin alone, in presence of gemifloxacin 
(250 µM) and quinidine (100 µM) in MDCKII-MDR1 cells from AP-BL and BL-AP directions. 
Values represent mean ± SD.  
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Transport of [
14
C] erythromycin across MDCKII-MRP2 cells was similarly assessed in 
both AP-BL and BL-AP directions. Apparent permeability of [
14
C] erythromycin in AP-BL 
direction was found to be 3.76 ± 1.37 × 10
-6
 cm/sec. This permeability significantly rises in the 
presence of MK-571 (100 µM) to 10.61 ± 2.20 × 10
-6
 cm/sec, probably indicating the inhibition 
of MRP2 efflux pump. In a similar manner, permeability was also enhanced in the presence of 
gemifloxacin (250 µM) to 8.80 ± 0.68 × 10
-6
 cm/sec. In a similar manner, permeability of [
14
C] 
erythromycin decreased from BL-AP in the presence of MK-571 and gemifloxacin to 10.38 ± 
1.34 and 11.05 ± 0.93 × 10
-6
 cm/sec respectively, relative to control with 18.53 ± 1.94 × 10
-6
 
cm/sec (Figure 16).  
ATP Activity Assay 
ATP activity assay was performed post treatment with gemifloxacin for 150 min on 
MDCKII-MDR1 and MRP2 cells. All concentrations of gemifloxacin used (1 µM to 1000 µM) 
except 1000 µM, did not significantly alter ATP levels compared to control. Gemifloxacin (1000 
µM) increased ATP level by almost 15% and 10% in MDCKII-MDR1 and MRP2 cells, 
respectively (Figure 17).  
Cell Proliferation Assay 
MTS assay was performed to examine the cytotoxicity of various concentrations of 
gemifloxacin (1 µM to 1000 µM) post treatment over 150 min. All concentrations of 
gemifloxacin used (1 µM to 1000 µM) except 1000 µM, did not significantly alter cell viability 
compared to control. Gemifloxacin (1000 µM) decreased cell viability by almost 25% and 20% 
on both MDCKII-MDR1 and MRP2 cells. All the other concentrations used were found to be 
non-cytotoxic (Figure 18). 
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Figure 16: Transepithelial transport of [
14
C] erythromycin alone, in presence of gemifloxacin 
(250 µM) and MK-571 (100 µM) in MDCKII-MRP2 cells from AP-BL and BL-AP directions. 
Values represent mean ± SD. 
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Figure 17. ATP assay in the presence of varying concentrations of gemifloxacin (1 µM to1000 
µM) in MDCKII-MDR1 and MDCKII-MRP2 cells for 150 min. Values represent mean ± SD. * 
represents statistical significance from control at P-value of <0.05. 
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Figure 18. Cytotoxicity assay in the presence of varying concentrations of gemifloxacin (1 µM 
to1000 µM) in MDCKII-MDR1 and MDCKII-MRP2 cells for 150 min. Values represent mean ± 
SD. * represents statistical significance from control at P-value of <0.05. 
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Discussion 
Gemifloxacin is a new fluoroquinolone antibiotic approved by US FDA for treatment of 
both gram positive and negative bacterial infections. It has broad spectrum of activity and 
inhibits both bacterial DNA gyrase and topoisomerase IV. Most fluoroquinolones, being 
substrates of efflux transporters, are generally extruded out from cellular matrix, significantly 
reducing intracellular accumulation and thereby altering drug bioavailability [204]. The primary 
objective of this study was to evaluate the effect of efflux transporters on the cellular 
translocation of gemifloxacin.  
Cellular accumulation of [
14
C] erythromycin in the presence of quinidine (a known 
substrate and/or inhibitor) appears to be significantly higher than the control, confirming the 
presence of MDR1 in MDCKII-MDR1 cells [229, 231]. A significantly elevated cellular 
accumulation of [
14
C] erythromycin in the presence of gemifloxacin is also observed. This result 
indicates that this fluoroquinolone interacts with MDR1, suggesting gemifloxacin may be a 
substrate. Similarly, cellular accumulation of [
14
C] erythromycin in the presence of MK-571 (a 
known inhibitor of MRPs) [229, 243] was found to be significantly higher than the control, 
confirming the presence of MRP2 in MDCKII-MRP2 cells. A significantly elevated cellular 
accumulation of [
14
C] erythromycin in the presence of gemifloxacin suggests that this 
fluoroquinolone may also be a substrate of MRP2. A significant rise in [
14
C] erythromycin 
uptake in the presence of quinidine and MK571 is consistent with our earlier results that both 
MDR1 and MRP2 are functionally active in MDCKII-MDR1 and MDCKII-MRP2 cells, 
respectively [229, 244].  
Dose-dependent inhibition studies suggest high affinity of gemifloxacin towards both 
MDR1 and MRP2. Gemifloxacin inhibited both MDR1 and MRP2 mediated efflux of [
14
C] 
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erythromycin in a dose-dependent manner with an IC50 value of 123 ± 2 µM and 16 ± 2 µM, 
respectively. A comparison of IC50 values indicates that gemifloxacin probably has a much 
higher affinity towards MRP2 relative to MDR1. IC50 value of gemifloxacin was also found to be 
significantly lower than another fourth generation fluoroquinolone, gatifloxacin previously 
reported from our laboratory [228]. These lower IC50 values represent that gemifloxacin is a 
better substrate of efflux transporters as compared to gatifloxacin. This further explains the 
difference in their bioavailability values (gatifloxacin - 97% as compared to gemifloxacin - 
71%). Lineweaver-Burk transformation of the above data revealed that the inhibitory mode of 
gemifloxacin for MDR1 and MRP2 mediated excretion of [
14
C] erythromycin was a competitive 
type. This analysis suggests that gemifloxacin and erythromycin may share a common binding 
site in both the efflux transporters. Further evidence of functional activity of MDR1 and MRP2 
on the cellular translocation of gemifloxacin has been studied with calcein-AM. Calcein-AM is a 
substrate of MDR1 and calcein is a substrate of MRP2 [240, 241, 245]. A rise in intracellular 
calcein fluorescence in presence of quinidine and MK-571 confirms inhibition of both MDR1 
and MRP2 functional activities. A similar elevation in calcein fluorescence in presence of 
gemifloxacin in MDCKII-MDR1 and MRP2 cells demonstrates its substrate specificity for both 
MDR1 and MRP2. Such increase in calcein accumulation in MDCKII-MRP2 cells is further 
confirmed by fluorescent microscopic images.  
The efflux ratio (ratio of basolateral to apical versus apical to basolateral permeability) is 
considered as one of the indicators for identifying MDR1 and MRP2 substrates [246]. Since 
these efflux transporters (MDR1 and MRP2) are localized on the apical direction, [
14
C] 
erythromycin alone exhibited much higher transport in the BL-AP direction relative to AP-BL 
direction. When this ratio of apparent permeability approaches 1.0 transport equals in both the 
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directions. Efflux ratios of [
14
C] erythromycin were found to be 3.56 and 4.93 in MDCKII-
MDR1 and MRP2 cells, respectively. A significant reduction in efflux ratio to 1 (complete 
inhibition) was evident in the presence of quinidine and MK-571 confirming inhibition of MDR1 
and MRP2 functional activities. Furthermore, the presence of gemifloxacin also affected bi-
directional permeability of [
14
C] erythromycin. The efflux ratio is lowered to 1.63 and 1.26 in 
MDCKII-MDR1 and MRP2 cells. This significant reduction further confirms the substrate 
specificity of gemifloxacin towards MDR1 and MRP2. 
Since the efflux pumps require ATP for their activation, it is postulated that any change 
in the amount or activity of ATP may signify sensitivity of the substrate for the transporter. ATP 
determination assay was performed in MDCKII-MDR1 and MRP2 cells to examine ATP 
involvement in cellular translocation of gemifloxacin. No significant change in the ATP activity 
was observed at various gemifloxacin concentrations. This result suggests that MDR1 and MRP2 
mediated efflux by gemifloxacin is not affected by ATP activity. Though not to a large extent, a 
minor increase in ATP levels was observed in the presence of 1000 µM concentration of 
gemifloxacin. This aberration may be due to stress response generated with the usage of a very 
high concentration. A cell proliferation assay is carried out to determine if the concentrations 
used are cytotoxic. Results obtained from this assay indicated that gemifloxacin tested at various 
concentrations do not elicit any cytotoxic effects in MDCKII-MDR1 and MRP2 cells. However, 
the highest concentration (1000 µM) tested was found to reduce the number of viable cells. This 
high concentration leads to cytotoxicity which may be one of the factors responsible for elevated 
ATP levels [229, 247].  
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Conclusions 
In conclusion, this report provides direct evidence that gemifloxacin is effluxed by both 
MDR1 and MRP2. This report provides an insight onto the mechanism of gemifloxacin 
interaction with efflux transporters. It also offers strategy for the development of new therapeutic 
delivery systems. This study also indicates that simultaneous administration of macrolides and 
fluoroquinolones may be more effective against various strains of Streptococci [231]. Expression 
of efflux transporters is regulated by the ligand activated transcription factor, pregnane X 
receptor (PXR, NR1I2) [168, 169, 248, 249]. PXR is considered to play an important role in 
regulating response to various drugs, thereby regulating their physiological disposition. 
Prolonged administration of fluoroquinolones may induce the expression of MDR1 and MRP2, 
which may contribute to the development of drug resistance. This induction in the expression of 
efflux transporters may affect intracellular drug accumulation, limiting oral bioavailability. 
However, further studies are required to confirm this hypothesis. 
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CHAPTER 3 
PXR MEDIATED INDUCTION OF EFFLUX TRANSPORTERS BY 
FLUOROQUINOLONES: A POSSIBLE MECHANISM FOR DEVELOPMENT OF 
MULTIDRUG RESISTANCE 
Rationale 
Fluoroquinolones represent an important class in the armamentarium of antimicrobial 
agents. Because of their broad spectrum activity, they are widely indicated in the treatment of 
human and veterinary diseases [250]. Structural modifications of the basic 4-quinolone skeleton 
resulted in the development of newer analogs i.e., second, third and fourth generation 
fluoroquinolones [251]. These molecules have been widely indicated for the treatment of 
systemic bacterial infections. Fluoroquinolones such as ofloxacin, levofloxacin, gatifloxacin and 
gemifloxacin were reported to be substrates of efflux transporters when investigated during 
short-term interaction studies [252-255]. Such substrate specificity of fluoroquinolones towards 
efflux transporters may be one of the major factors accounting for their alterations in oral 
bioavailability. A vast amount of literature is documented on the pharmacokinetic properties of 
fluoroquinolones [256]. However, little information is available on the molecular determinants 
(nuclear receptors) of their cellular absorption and viable potential for acquisition of multidrug 
resistance (MDR).  
Development of MDR is a complex cellular signaling process and reduces efficacy of 
therapeutic drug molecules. Development of MDR can occur at various levels including drug 
delivery, drug detoxification and cellular microenvironment. Significant research from the last 
two decades has demonstrated that acquisition of MDR is predominantly due to the elevated 
expression and activity of ATP-binding cassette (ABC) proteins [257]. ABC transporters 
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represent a super family of membrane bound proteins found in both prokaryotes and eukaryotes. 
These integral proteins translocate a wide variety of exogenous and endogenous substances 
across concentration gradient utilizing the energy derived from ATP hydrolysis. To date, forty-
eight efflux transporters have been identified and fifteen of them are associated with the 
development of drug resistance. Of these ABC proteins, P-glycoprotein (P-gp/MDR1) and 
multidrug resistance protein 2 (MRP2) plays a predominant role in efflux of several drugs 
altering their absorption, distribution and excretion [258].  
MDR1 is a 170 kDa transmembrane protein expressed on the apical membrane of many 
epithelial and endothelial cells. This protein exhibits twelve transmembrane domains (TMDs) 
and two ATP binding sites. MRP family is the largest branch of the ABC transporters consisting 
of thirteen different proteins (MRP 1-10, CFTR SUR1 and SUR2), primarily responsible for 
drug transport across lipid membranes. Similar to P-gp, MRP proteins also possess twelve TMDs 
and two ATP binding regions. However, few MRP transporters (MRP 1, 2, 3, 6 and 7) possess an 
additional hydrophobic region composed of five TMDs at the NH2-terminal end totaling 17 
TMDs [73, 259]. Expression of these efflux transporters is not static. Rather, it is controlled 
dynamically via transcriptional regulators by certain nuclear receptors or xenosensors. The 
ligand activated transcription factor, pregnane X receptor (PXR; NR1I2), is considered a master 
regulator of "homeland" defense and plays vital role in modulating response to various 
xenobiotics, thereby regulating drug disposition kinetics [249]. Upon transcriptional activation, 
PXR present in the cytoplasm translocates to the nucleus and forms a heterodimer with retinoid 
X receptor (RXR; NR2B1). This heterodimeric complex binds to the promoter region of target 
genes, thereby increasing transcription. The target genes include phase I drug metabolizing 
enzymes (DMEs) including a number of cytochrome P450 enzymes (CYPs), carboxylesterases, 
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aldehyde and alcohol dehydrogenases, phase II DMEs such as UGTs, GSTs, and SULTs and 
phase III ABC drug efflux transporters [165, 260].   
The clinical effectiveness of fluoroquinolones may depend on the activation of nuclear 
receptors and development of MDR. Therefore, the objective of this study was to examine the 
interaction of fluoroquinolones with nuclear receptor and efflux transporters upon long term 
treatment. Such information on functional and molecular aspects may assist in the development 
of alternative and newer strategies to overcome/prevent drug-drug interactions, adjust dose, 
achieve adequate therapeutic levels and most importantly reduce drug resistance.  
Materials and Methods 
Materials 
Gemifloxacin and gatifloxacin were procured from Bosche Scientific LLC (New 
Brunswick, NJ). Levofloxacin and ofloxacin were obtained from TCI America (Portland, OR). 
LS-180 cells were obtained from American Type Culture Collection (Manassas, VA). 
Dulbecco’s modified eagle’s medium (DMEM), TrypLE™ Express (stable trypsin replacement), 
non-essential amino acids, TRIzol®, Lipofectamine™, Opti-MEM® and NuPAGE® Novex 4-
12% bis-tris gels were procured from Invitrogen (Carlsbad, CA). Fetal bovine serum (FBS) was 
purchased from Atlanta Biologicals (Lawrenceville, GA). Culture flasks (75 cm
2
 and 25 cm
2
 
growth area); 12-well plates (3.8 cm
2
 growth area per well), and 96-well plates (0.32 cm
2
 growth 
area per well) were procured from Corning Costar Corp. (Cambridge, MA). The chemicals and 
buffers for cDNA synthesis (oligodT, MgCl2, dNTP, M-MLV reverse transcriptase), Dual-Glo® 
luciferase assay system and CellTiter 96® aqueous non-radioactive cell proliferation assay kit 
were obtained from Promega (Madison, WI). Light Cycler 480® SYBR I green master mix was 
purchased from Roche Applied Science (Indianapolis, IN). [
3
H] Digoxin (specific activity: 0.1 
60 
 
Ci/mMol) and [
14
C] erythromycin (specific activity: 51.3 mCi/mMol) were procured from 
Moravek Biochemicals (Brea, CA). All other chemicals were obtained from Sigma Chemicals 
(St. Louis, MO) and used without further purification.  
Plasmids 
The pCDG-hPXR expression vector was generously provided by Dr. Ronald M. Evans 
(Salk Institute for Biological Studies, La Jolla, CA). The pGL3-MDR1 and pGL3-MRP2 
luciferase reporter constructs were generously donated by Dr. Ahmad R. Safa (Indiana 
University Simon Cancer Center, Indianapolis, IN) and Dr. Ishtiaq Qadri (NUST Center of 
Virology & Immunology, Rawalpindi, Pakistan). The renilla luciferase control plasmid pRL-TK 
was obtained from Promega. All these plasmids were checked by enzyme restriction, followed 
by agarose gel electrophoresis. 
Cell Culture 
LS-180 cells of passage numbers 65-70 were selected for the studies. Cells were 
maintained using DMEM medium supplemented with 10% FBS (heat inactivated), 1% non-
essential amino acids, 29 mM sodium bicarbonate, 100 µg/mL of penicillin and streptomycin 
each at 37
°
C. Cells were grown in T-75 flasks, passaged using TrypLE™ Express and plated at a 
density of one million cells in T-25 flasks, 250,000 cells/well in 12-well plates and 10,000 
cells/well in 96-well plates for further studies. After reaching 70-80% confluency, the growth 
medium was replaced with medium containing fluoroquinolones at three different concentrations 
(2.5, 5 and 7.5 µM). The concentrations of fluoroquinolones were determined from clinically 
relevant plasma concentrations in human volunteers [261-263]. Four different fluoroquinolones 
(gemifloxacin, gatifloxacin, levofloxacin, ofloxacin) were selected for our studies. Rifampin (7.5 
µM), a well-known inducer of PXR and efflux transporters, was included as a positive control in 
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all the experiments [264]. Stocks of respective drugs were prepared either in sterile water or 
dimethyl sulfoxide (DMSO). Stocks were diluted appropriately with medium to achieve the 
desired concentration. DMSO concentration did not exceed 0.5% in all the drug solutions. Cells 
were treated for 72 hours and processed for respective experiments accordingly. 
Quantitative Gene Expression Analysis 
LS-180 cells were lysed in TRIzol®, phase separated using chloroform and the aqueous 
layer containing RNA was precipitated using isopropanol. The obtained RNA was washed twice 
with 75% ethanol and dissolved in DNase⁄RNase-free water. Concentration was determined by 
measuring the absorbance at 260 nm using Nanodrop (Thermo Fisher Scientific, Wilmington, 
DE). RNA was reverse transcribed into complementary DNA (cDNA) with oligodT as a 
template and M-MLV reverse transcriptase. The conditions for reverse transcription were initial 
denaturation at 70
°
C for 5 min, reverse transcription at 42
°
C for 1 hour and final extension at 
72
°
C for 5 min. For quantitative gene expression analysis, 80 µg of cDNA was amplified using 
10 µM of forward and reverse primers and SYBR I green master mix on ABI Prism 5700 
Sequence Detection System (Applied Biosystems, CA). Primer-Blast tool (PubMed) was used 
for designing the primers and sequences are summarized in Table 4. All the primers were 
designed such that 100-150 bp long amplicons will be generated to increase the efficiency of 
amplification. The reactions were carried out with initial denaturation at 70
°
C for 5 min, 
followed by 45 cycles of denaturation at 95
°
C for 10 sec, annealing at 55
°
C for 10 sec and 
extension at 72
°
C for 10 sec. The specificity of polymerase chain reaction (PCR) products was 
confirmed by melting curve analysis. To normalize the amount of cDNA in all the samples, 
GAPDH (glyceraldehyde 3-phosphate dehydrogenase) was used as an internal standard.  
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Table 4. Primers used in quantitative gene expression analysis. Sequence is given from 5'->3'. 
Gene Forward primer Reverse primer 
GAPDH ATCCCTCCAAAATCAAGTGG GTTGTCATGGATGACCTTGG 
PXR GCAGGTGGCTTCCAGCAACT GGGCGGTCTGGGGAGAAGAG 
MDR1 CTTATGCTCTGGCCTTCTGG TGCTTCAATGCTTGGAGATG 
MRP2 AAATATTTTGCCTGGGAACC TGTGACCACAGATACCAGGA 
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Reporter Activity Assays 
MDR1 and MRP2 reporter activity assays were performed as described in previous 
published protocols [265, 266]. Briefly, LS-180 cells plated in 96-well plates were transfected 
with 75 ng/well of nuclear receptor expression vector (pCDG-hPXR), 200 ng/well of respective 
gene firefly luciferase reporter construct (pGL3-MDR1 or pGL3-MRP2) and 15ng/well of 
control renilla luciferase expression vector (pRL-TK), using Lipofectamine™ 2000 for 24 hours 
in reduced media. Later, the transfection media was aspirated and cells were washed with sterile 
phosphate buffered saline (PBS - 3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl and 135 mM 
NaCl). Following drug exposure for 72 hours, the firefly and renilla luciferase activities were 
measured using Dual-Glo® luciferase assay system following manufacturer’s protocol. The ratio 
of firefly luminescence to renilla luminescence is used to normalize the transfection efficiency in 
all the samples.  
Immunoblot Assay 
Cells were washed with PBS and lysed in PBS containing 1% Triton X-100 and protease 
inhibitor cocktail.  The lysate was collected following centrifugation at 12,000 rpm for 15 min 
and quantified using Bio-Rad protein estimation kit (Bio-Rad, Hercules, CA) and bovine serum 
albumin (BSA) as an internal standard. Proteins were denatured and separated using poly 
acrylamide gel electrophoresis (PAGE). Later, the protein was transferred onto polyvinylidene 
difluoride (PVDF) membrane and blocked overnight at 4
°
C with 2% non-fat dry milk and 0.25% 
BSA in 0.05 M tris buffered saline (TBS). The blot was exposed to primary antibody at 25
°
C for 
4 hours. After subsequent washes (3×10 min), the blot was exposed to the secondary antibody at 
25
°
C for 1.5 hours. Finally the blot was visualized for the protein using chemiluminescent 
substrate with chemiImager 8900 (Alpha Innotech, San Leandro, CA). 
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Uptake Study 
The effect of long term exposure of fluoroquinolones on the intracellular accumulation of 
[
3
H] digoxin and [
14
C] erythromycin was studied on LS-180 cells. Digoxin and erythromycin 
were used as model substrates to study MDR1 and MRP2 mediated efflux, respectively. 
Following treatment with fluoroquinolones, the medium was aspirated and cells were washed 
with 1 mL of PBS (3×10 min). Later, 500 µL of respective substrate was added and cells were 
incubated for 30 min at 37
°
C. Uptake was terminated with ice cold PBS and 1 mL of lysis 
solution (0.3 N NaOH containing 0.1% (v/v) Triton-X) was added. Followed by overnight lysis, 
the cell lysate was analyzed for radioactivity using a scintillation cocktail (3 mL) (MP 
Biomedicals, Santa Ana, CA) in scintillation counter (BeckmanCounter, Fullerton, CA). Protein 
concentration was used to normalize the uptake values. 
Cell Viability Assay 
Cytotoxicity assay was carried out with a Cell Titer 96® aqueous non-radioactive cell 
proliferation assay kit. This assay was performed to determine if the highest concentrations of 
each drug used was toxic to the cells. Following drug treatment in a 96-well plate, solutions were 
aspirated and 100 µL of reduced serum media was added. Twenty microliters of MTS and PMS 
reagent were then added to the wells and incubated for 4 hours at 37
°
C. The amount of formazan 
formed from MTS is measured at 490 nm using a plate spectrophotometer (SpectraFluor Plus, 
Maennedorf, Switzerland). As the amount of formazan formed is directly proportional to the 
number of viable cells, the toxicity of treatment can be estimated. 
Statistical Analysis 
For experiments performed as biological duplicate and experimental quadruplicates, 
results were expressed as mean ± standard error (SE). For experiments performed as 
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experimental quadruplicates, results were expressed as mean ± standard deviation (SD). One way 
analysis of variance (ANOVA) or student’s t test (Graph Pad InStat Version 4.0) was performed 
to confirm statistical significance of the experimental values. A P-value of less than 0.05 was 
considered to be statistically significant.  
Results 
Quantitative Gene Expression Analysis 
All concentrations (2, 5 and 7.5 µM) of gemifloxacin significantly induced PXR by 
almost 18 fold. Gatifloxacin showed a gradual increase in induction of PXR by 6-14 fold. 
Levofloxacin and ofloxacin exhibited 10-15 fold increase in PXR levels, with no significant 
difference observed between 5 and 7.5 µM concentrations. Rifampin induced PXR by almost 15 
fold (Figure 19). Upon treatment with fluoroquinolones, the direct transcriptional downstream 
targets of PXR, such as MDR1 and MRP2, were also measured. All three concentrations of 
gemifloxacin (2, 5 and 7.5 µM) induced MDR1 by 5-7 fold.  The other three fluoroquinolones 
demonstrated a concentration-dependent induction of MDR1 mRNA levels from 3-7 fold. 
Rifampin induced MDR1 by 9 fold (Figure 20). Similar changes in mRNA levels of MRP2 were 
also noticed in LS-180 cells treated with all the fluoroquinolones tested in the study. 
Surprisingly, all fluoroquinolones and rifampin induced MRP2 to a similar extent (~ 5-6 fold) at 
various concentrations tested (Figure 21). 
Reporter Activity Assays 
Post treatment with fluoroquinolones at three different concentrations, the cell lysate was 
quantified for simultaneous detection of both firefly and renilla luciferase luminescence signals. 
All the fluoroquinolones studied demonstrated a concentration-dependent increase in the relative 
luminescence values (RLVs) when transfected with MDR1 reporter construct (Figure 22).  
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Figure 19. Relative fold induction of PXR mRNA in LS-180 cells treated with gemifloxacin, 
gatifloxacin, levofloxacin, ofloxacin (2.5, 5 and 7.5 µM) and rifampin (7.5 µM) for 72 hours. 
Values represent mean ± SE. * represents statistical significance from control at P-value of 
<0.05. 
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Figure 20. Relative fold induction of MDR1 mRNA in LS-180 cells treated with gemifloxacin, 
gatifloxacin, levofloxacin, ofloxacin (2.5, 5 and 7.5 µM) and rifampin (7.5 µM) for 72 hours. 
Values represent mean ± SE. * represents statistical significance from control at P-value of 
<0.05. 
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Figure 21. Relative fold induction of MRP2 mRNA in LS-180 cells treated with gemifloxacin, 
gatifloxacin, levofloxacin, ofloxacin (2.5, 5 and 7.5 µM) and rifampin (7.5 µM) for 72 hours. 
Values represent mean ± SE. * represents statistical significance from control at P-value of 
<0.05. 
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Figure 22. Relative fold expression of MDR1 reporter activity values in LS-180 cells treated 
with gemifloxacin, gatifloxacin, levofloxacin, ofloxacin (2.5, 5 and 7.5 µM) and rifampin (7.5 
µM) for 72 hours. Values represent mean ± SE. * represents statistical significance from control 
at P-value of <0.05. 
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With the MRP2 reporter construct, gemifloxacin and gatifloxacin showed a linear 
increase in reporter activity while the other two drugs (levofloxacin and ofloxacin) had a similar 
rise (~ 6 fold) with all the concentrations (Figure 23). Rifampin exhibited a 10 fold rise in RLVs 
with both the reporter constructs.  
Relative Fold Expression of MDR1 and MRP2 Protein Levels 
LS-180 cells were treated with the highest concentration (7.5 µM) of each 
fluoroquinolone and rifampin (7.5 µM). Post treatment, cell lysate was extracted and the relative 
levels of MDR1 and MRP2 proteins were monitored. Protein expression was quantified by spot 
densitometry using AlphaEase software (AlphaInnotech, San Leandro, CA). All the 
fluoroquinolones significantly induced the protein expression of MDR1. Gemifloxacin and 
gatifloxacin showed a marked increase in MDR1 protein expression by 2 fold. Levofloxacin and 
ofloxacin showed 1.9 and 1.6 fold rise in MDR1 protein expression levels (Figure 24). A similar 
increase in MRP2 protein levels was also evident when treated with these drug molecules. 
Gemifloxacin and gatifloxacin induced MRP2 protein level (~ 2.3 fold) as that of the positive 
control rifampin. Levofloxacin and ofloxacin also showed 2 fold induction in the protein 
expression of MRP2 (Figure 25). 
Cellular Accumulation of MDR1 and MRP2 Substrates 
Uptake of [
3
H] digoxin and [
14
C] erythromycin was assessed to examine if the induction 
in MDR1 and MRP2 mRNA and protein levels further translates to functional activity. A 
significant decrease in the uptake of [
3
H] digoxin was evident in treated cells relative to control 
cells. Gemifloxacin and gatifloxacin diminished digoxin uptake by almost 30% and 25% 
respectively, while the other two fluoroquinolones and rifampin lowered the uptake by 20% 
(Figure 26). 
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Figure 23. Relative fold expression of MRP2 reporter activity values in LS-180 cells treated with 
gemifloxacin, gatifloxacin, levofloxacin, ofloxacin (2.5, 5 and 7.5 µM) and rifampin (7.5 µM) 
for 72 hours. Values represent mean ± SE. * represents statistical significance from control at P-
value of <0.05. 
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Figure 24. Relative fold induction of MDR1 protein levels in LS-180 cells treated with 7.5 µM 
of gemifloxacin, gatifloxacin, levofloxacin, ofloxacin and rifampin for 72 hours. Values 
represent mean ± SE. * represents statistical significance from control at P-value of <0.05. 
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Figure 25. Relative fold induction of MRP2 protein levels in LS-180 cells treated with 7.5 µM of 
gemifloxacin, gatifloxacin, levofloxacin, ofloxacin and rifampin for 72 hours. Values represent 
mean ± SE. * represents statistical significance from control at P-value of <0.05. 
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Figure 26. Cellular accumulation of [
3
H] digoxin in LS-180 cells treated with 7.5 µM of 
gemifloxacin, gatifloxacin, levofloxacin, ofloxacin and rifampin for 72 hours. Values represent 
mean ± SD. * represents statistical significance from control at P-value of <0.05. 
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Similarly, the uptake of [
14
C] erythromycin was also assessed post treatment on LS-180 
cells. All the fluoroquinolones and rifampin reduced the uptake of this substrate by ~20% 
compared to control/untreated cells (Figure 27).  
Cell Viability Assay 
A cell viability assay was performed to evaluate the cytotoxicity of the highest 
concentration (7.5 µM) of each fluoroquinolone and rifampin post treatment for 72 hours on LS-
180 cells. The highest concentration tested was found to be non-cytotoxic to the cells as evident 
by the number of viable cells (Figure 28). This assay indicated that the highest concentration of 
all fluoroquinolones did not elicit any cytotoxic effects or cause any toxic stress to LS-180 cells 
when treated for 72 hours. 
Discussion 
Fluoroquinolones (fluorinated 6-quinolones) represent a class of antibacterial agents 
widely indicated in the treatment of various bacterial infections including ocular, lower 
respiratory, urinary tract, biliary-tract, bone and joint infections. However, their clinical utility 
has been impended due to their widespread misuse and overuse, leading to the development of 
resistance [267]. A major determinant for development of resistance is the induction of ABC 
efflux transporters regulated by the nuclear receptor PXR. Hence, the primary objective of this 
study was to assess the differential expression pattern and functional activity of nuclear receptor 
(PXR) and efflux transporters (MDR1 and MRP2) upon long term treatment with 
fluoroquinolones. LS-180 cells were selected for our studies since they are considered as high 
throughput cell culture models to study PXR mediated induction of efflux transporters [268, 
269].  
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Figure 27. Cellular accumulation of [
14
C] erythromycin in LS-180 cells treated with 7.5 µM of 
gemifloxacin, gatifloxacin, levofloxacin, ofloxacin and rifampin for 72 hours. Values represent 
mean ± SD. * represents statistical significance from control at P-value of <0.05. 
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Figure 28. Cell viability assay  on LS-180 cells treated with 7.5 µM of gemifloxacin, 
gatifloxacin, levofloxacin, ofloxacin and rifampin for 72 hours. Values represent mean ± SD.  
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All four fluoroquinolones tested in the study demonstrated a significant induction in the 
RNA levels of PXR. This study confirms the promiscuous nature of PXR and the ability of 
different molecules to activate PXR. Upon transcriptional activation, PXR heterodimerizes with 
RXR and promotes the transcription of various target genes by binding to a specific region 
(A/G)G(T/G)TCA in the promoter sequence [164]. Hence, the RNA levels of downstream target 
genes of PXR such as MDR1 and MRP2 were also examined. All the fluoroquinolones 
demonstrated a variable rise in MDR1 mRNA levels, with gemifloxacin showing the highest 
induction. Surprisingly, mRNA levels of MRP2 were induced to a similar extent with all the 
concentrations of fluoroquinolones studied. This variable degree of activation possibly arises 
from crosstalk between different nuclear receptors and various signaling mechanisms [270].  
In order to confirm PXR mediated activation of efflux transporters by fluoroquinolones, 
cell based reporter assays have been performed as an alternative to study animal based in vivo 
PXR activation. The relative luminescence values (RLVs) showed a concentration-dependent 
increase when transfected with the pGL3-MDR1 vector. Both the gene expression analysis and 
reporter studies demonstrate that fluoroquinolones exhibit a concentration-dependent activation 
of MDR1 via PXR, with gemifloxacin demonstrating the highest level of induction. Similarly, 
LS-180 cells co-transfected with the pGL3-MRP2 vector demonstrated that only gemifloxacin 
and gatifloxacin produced a concentration-dependent activation of MRP2. Levofloxacin and 
ofloxacin showed similar rise in reporter activity values with all the three different 
concentrations studied. This study has further confirmed PXR mediated activation of MRP2 by 
all the fluoroquinolones.  
Results from immunoblot analysis suggest that elevated RNA levels of MDR1 and MRP2 
efflux transporters are being translated to protein expression. Though the mRNA expression 
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levels were induced to a greater extent, the protein expression levels were not comparably 
higher. Several possible biological reasons can account for such poor correlation in expression 
levels between mRNA and protein. These include post transcriptional and translational 
modifications, along with the half-lives of respective proteins [271]. Further, research has shown 
that only 20-40% of corresponding mRNA levels translate to protein concentration [272].  
Uptake studies were performed to assess if increased protein expression levels translate into 
increased functional activity. Reduced cellular accumulation of [
3
H] digoxin and [
14
C] 
erythromycin was the result of elevated functional activity of both the efflux proteins post long 
term treatment with fluoroquinolones. Results from this study are consistent with Vallet et. al 
who studied the cellular accumulation of rhodamine-123 in J774 macrophage wild-type cells and 
moxifloxacin treated cells. Cellular accumulation of rhodamine-123 was significantly lower in 
moxifloxacin treated macrophage cells compared to wild-type cells. This study also suggested 
overexpression of efflux transporters upon prolonged treatment with moxifloxacin [273].   
Conclusions 
In summary, this study provides an evidence-based scientific explanation that all the 
fluoroquinolones tested induce the expression of efflux proteins (MDR1 and MRP2) via 
activation of nuclear factor (PXR). The activated ‘master xenosensor’ affects the cellular uptake, 
pharmacokinetics, toxicity and drug-drug interactions of many xenobiotics. Induction of efflux 
transporters alters drug disposition and consequently affects the plasma drug concentrations. This 
study provides an insight onto the mechanism of development of MDR with long term usage of 
these drugs and warrants their misuse. 
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CHAPTER 4 
RITONAVIR: A NOVEL THERAPEUTIC FOR OVERCOMING DRUG RESISTANCE IN 
CANCER CHEMOTHERAPY 
Rationale 
Chemotherapy represents the most common treatment modalities for cancer. However, a 
major impediment to successful chemotherapy is the development of multidrug resistance 
(MDR). MDR is described as a phenomenon where resistance to one drug often confers 
resistance to several structurally and functionally unrelated drugs. Resistance to chemotherapy 
can either be intrinsic (resistance exists before the drug treatment is initiated) or acquired 
(resistance develops during treatment) [2]. Several possible mechanisms and molecular 
alterations have been implicated in the development of MDR, including activation of efflux 
transporters and metabolizing enzymes, mutation of drug targets, tumor microenvironment 
conditions (hypoxic conditions leading to vascularization) and altered cellular repair mechanisms 
(activation of DNA repair, mutant p53 and impaired apoptosis) [3].   
Induction of ATP-binding cassette (ABC) efflux transporters and drug metabolizing 
enzymes was found to be the major cause of MDR development in response to chemotherapy 
[18, 88]. Among the different ABC transporters, P-glycoprotein (P-gp/MDR1), multidrug 
resistance protein 2 (MRP2) and breast cancer resistant protein (BCRP/MXR) play a 
predominant role in acquisition of drug resistance. P-gp for example exports several anticancer 
agents (doxorubicin, paclitaxel, dasatinib, erlotinib, gefitinib, vinblastine and vincristine) and its 
overexpression is correlated with drug resistance and treatment failure. Similarly, overproduction 
of MRP2 is responsible for reducing effect of several chemotherapeutics including etoposide, 
mitoxantrone and valsartan; while BCRP overexpression has been attributed to resistance for 
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topoisomerase I inhibitors, anthracyclines and mitoxantrone [73]. Also, metabolizing enzymes 
such as cytochrome P450 (CYP450) are induced in response to many anticancer drugs causing 
rapid biotransformation of active molecule, resulting in treatment failure [147, 148]. Also, many 
drug molecules require enzymatic biotransformation to exert their cytotoxic effect. For example, 
cytarabine, a nucleoside drug extensively administered for leukemia, requires phosphorylation by 
deoxycytidine kinase to active form cytarabine triphosphate. Cancer cells acquire resistance via 
downregulation/mutation of involved metabolic enzyme [274]. Two recent review articles have 
discussed mechanisms and insights of drug resistance in cancer [257, 275]. 
Drug resistance in HIV patients is also well known. Application of highly active 
antiretroviral therapy (HAART) played an instrumental role in reducing AIDS related mortality 
and morbidity. A prototypical HAART combination includes two nucleoside reverse 
transcriptase inhibitors (NRTIs) and a boosted protease inhibitor (PI). Ritonavir, a first 
generation PI is considered as a powerful boosting drug. Inhibition of CYP3A4 and efflux 
transporters by ritonavir forms the basis for enhancing the concentration of concomitantly 
administered drugs. Pharmacokinetic ‘boosting’ by ritonavir enables higher sustained levels of 
the coadministered drug. Such boosted regimens have been utilized to overcome resistance, 
allowing simplified dosage regimen and potentially improving patient adherence. This 
combination is clinically proven beneficial for individuals with HIV infection [276]. Therefore, a 
hypothesis has been tested to overcome drug resistance in cancer employing ritonavir and 
anticancer drug combination. This hypothesis has been examined in vitro using model intestinal 
cells (LS-180). These cells have been selected to study expression levels of efflux transporters 
(MDR1, MRP2) and metabolizing enzyme (CYP3A4). Various efficacy studies including cell 
proliferation, migration and apoptosis have also been performed on human breast 
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adenocarcinoma cells (T47D) and prostate cancer cells (PC-3) due to their aggressive phenotypic 
nature.  
Materials and Methods 
Materials 
Doxorubicin, paclitaxel, tamoxifen, vinblastine and ritonavir were obtained from Sigma 
Chemicals (St. Louis, MO). LS-180, T47D and PC-3 cells were procured from American Type 
Culture Collection (Manassas, VA). [
3
H] Lopinavir (specific activity: 0.5 Ci/mMol) was 
purchased from Moravek Biochemicals (Brea, CA). Dulbecco’s modified eagle medium 
(DMEM), RPMI 1640, stable trypsin replacement (TrypLE™ Express), non-essential amino 
acids and Vivid™ CYP450 screening kit were obtained from Invitrogen (Carlsbad, CA). Fetal 
bovine serum (FBS) was purchased from Atlanta Biologicals (Lawrenceville, GA). Culture 
flasks (75 cm
2
 and 25 cm
2 
growth area), 12-well plates (3.8 cm
2
 growth area per well) and 96-
well plates (0.32 cm
2
 growth area per well) were purchased from Corning Costar Corp. 
(Cambridge, MA). The buffers for cDNA synthesis (oligodT, dNTP, MgCl2, M-MLV reverse 
transcriptase), CellTiter 96® aqueous non-radioactive cell proliferation assay and ApoONE® 
homogeneous caspase-3/7 assay kit were obtained from Promega Corporation (Madison, WI). 
Light Cycler 480® SYBR I green master mix was obtained from Roche Applied Science 
(Indianapolis, IN). QCM™ 24-well colorimetric cell migration assay kit was purchased from 
Millipore (Billerica, MA). BCA protein assay reagent was purchased from Thermo Fisher 
Scientific Inc (Rockford, IL). TRI Reagent® and all other chemicals were products of 
commercial grade purchased from Sigma Chemicals and used without further purification.  
Cell Culture 
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LS-180 and T47D cells were maintained in T-75 flasks at 37
°
C in a humidified 
atmosphere of 5% CO2 and 90% relative humidity with DMEM medium supplemented with 10% 
FBS (heat inactivated), 1% non-essential amino acids, 20 mM HEPES, 29 mM sodium 
bicarbonate and 100 µg/mL of penicillin and streptomycin each. PC-3 cells were maintained in 
RPMI 1640, supplemented with 10% FBS (non-heat inactivated), 15 mM HEPES, 24 mM 
sodium bicarbonate and 100 µg/mL of each penicillin and streptomycin. The medium was 
replaced every alternate day. After reaching 80-90% confluency, cells were passaged using 
TrypLE™ Express and seeded at a density of one million cells in 25 cm2 flasks, 250,000 
cells/well in 12-well plates or 10,000 cells/well in 96-well plates. Drug solution stocks were 
prepared in dimethyl sulfoxide (DMSO) and sterile filtered using 0.22 µm filters. Prior to 
initiation of a treatment; stocks were diluted in appropriate volume of the medium and final 
concentration of DMSO did not exceed 0.5% (v/v). LS-180 cells were used for gene/protein 
expression and functional activity studies. T47D and PC-3 cells were used for efficacy studies 
upon cotreatment. 
Quantitative Gene Expression Studies 
LS-180 cells were treated with drug solutions for 72 hours. Following treatment, RNA 
was extracted from cells using TRI® reagent following manufacturer’s protocol. Cells were 
lysed in phenol and chloroform was added for phase separation. The aqueous phase containing 
RNA was collected and 100% isopropanol was added to precipitate RNA. The pellet was washed 
with 75% ethanol and dissolved in DNase⁄RNase-free water. RNA was quantified with Nanodrop 
(Thermo Fisher Scientific, Wilmington, DE). Two microgram of RNA was reverse transcribed 
with oligodT as template using M-MLV reverse transcriptase. The conditions for reverse 
transcription were initial denaturation at 70
°
C for 5 min, reverse transcription at 42
°
C for 1 hour 
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and final extension at 72
°
C for 5 min. For quantitative gene expression analysis, 80 µg of cDNA 
was amplified using SYBR-green master mix on ABI Prism 5700 Sequence Detection System 
(Applied Biosystems). Primers were designed with Primer-Blast tool from PubMed and are 
summarized in Table 5. The reactions were carried out with initial denaturation at 70
°
C for 5 
min, followed by 45 cycles of denaturation at 95
°
C for 10 sec, annealing at 55
°
C for 10 sec and 
extension at 72
°
C for 10 sec. PCR specificity was confirmed by melting curve analysis. Relative 
amount of RNA levels was normalized to the internal standard GAPDH (glyceraldehyde 3-
phosphate dehydrogenase) in each sample. Any difference in RNA levels in treated vs control 
samples was quantified using modified ddCT method [277]. 
Immunoblot Analysis 
After treatment with respective drug solutions, cells were washed with PBS (3.2 mM 
Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl and 135 mM NaCl) and lysed in PBS with 1% Triton 
X-100 and protease inhibitor cocktail maintained at pH 7.4, for 15-20 min on ice. Upon 
homogenization, cells were centrifuged at 12,000 rpm for 10 min and the protein lysate was 
collected. The amount of protein in the lysate was determined using BCA protein assay reagent. 
An equivalent amount of protein (25 μg) in all samples was separated with poly acrylamide gel 
electrophoresis (PAGE). The protein was then transferred onto a polyvinylidene difluoride 
(PVDF) membrane and blocked overnight at 4
°
C with 2% non-fat dry milk and 0.25% BSA 
prepared in 0.05 M tris buffered saline. The blot was then exposed to primary P-gp antibody 
(Abcam, MA) at 37
°
C for 4 hours. After subsequent washes the blot was then exposed to 
secondary antibody-goat anti rabbit HRP conjugate (Santa Cruz Biotechnology, Inc., CA). 
Finally the blot was visualized for the protein using chemiluminescent substrate (Pierce 
Biotechnology, Rockford, IL) in chemiImager 8900 (AlphaInnotech, San Leandro, CA). 
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Table 5. Primers used in quantitative gene expression analysis. Sequence is given from 5'->3'. 
 
Gene Forward primer Reverse primer 
GAPDH ATCCCTCCAAAATCAAGTGG GTTGTCATGGATGACCTTGG 
MDR1 CTTATGCTCTGGCCTTCTGG TGCTTCAATGCTTGGAGATG 
MRP2 AAATATTTTGCCTGGGAACC TGTGACCACAGATACCAGGA 
CYP3A4 ACCGTGACCCAAAGTACTGG GTTTCTGGGTCCACTTCCAA 
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Uptake Study 
Uptake studies with [
3
H] lopinavir were conducted to confirm the functional activity of 
the transcribed genes. This study was performed on LS-180 cells plated in 12-well plates. After 
treatment, the drug solutions were aspirated and cells were washed twice with 2 mL of DPBS (30 
mM NaCl, 2.5 mM KCl, 7.5 mM Na2HPO4, 1.5 mM KH2PO4, 1 mM CaCl2, 0.5 mM MgSO4, 5 
mM glucose and 20 mM HEPES) at pH 7.4 for 10 min. Uptake was initiated by adding 0.5 mL 
of [
3
H] lopinavir (0.5 µCi/mL) into the wells. After 30 min of incubation, solution was removed 
and uptake was terminated with ice-cold stop solution (200 mM KCl and 2 mM HEPES). Cells 
were lysed overnight at 25
°
C using lysis solution (0.1% (v/v) Triton-X in 0.3 N NaOH). Cell 
lysate was then quantified for radioactivity with a scintillation counter (BeckmanCounter, 
Fullerton, CA). The amount of radioactivity was normalized to protein count and analyzed 
following a previously published method [252].  
Vivid™ CYP3A4 Assay 
This assay was performed on cells plated in 96-wells. Cells treated with 100 µL of drug 
solutions were subsequently lysed with 100 µL of lysis solution. Forty microliters of cell lysate 
was then added to 60 µL of master mix containing Vivid™ Red Substrate. The metabolite 
formed is highly fluorescent and dependent upon cellular CYP3A4 levels. After 30 min 
incubation, the fluorescent readings were monitored at an excitation wavelength of 530 nm and 
an emission wavelength of 585 nm by a microtiter plate reader (SpectraFluor Plus, Maennedorf, 
Switzerland). The readings were then normalized to protein count as described earlier. 
Cell Proliferative Assay  
This study was performed on T47D and PC-3 cells to determine the IC50 value (half-
maximal inhibitory concentration of tumor cells growth) of chemotherapeutic drugs 
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(doxorubicin, paclitaxel, tamoxifen and vinblstine) alone, and in the presence of ritonavir. T47D 
/PC-3cells were seeded in 96-well plates and cultured for 24 hours, before the initiation of 
treatment. Later, medium was aspirated and cells were treated with various concentrations of 
drug alone and in presence of ritonavir for 72 hours. Following treatment, the drug solutions 
were aspirated and 100 µL of serum free media and 20 µL of MTS and PMS reagents were 
added to the wells. After incubating for 3 hours, the quantity of formazan product was measured 
at 490 nm with a plate reader. The amount of formazan formed from dehydrogenase enzymes is 
directly proportional to the number of viable cells. Data was fitted to a transformed nonlinear 
regression curve analysis program (GraphPad Prism Version 4.0; GraphPad Software, San 
Diego, CA) to calculate IC50 value. 
Migration Assay 
This assay was performed in modified Boyden’s insert, where cells from an upper 
compartment were allowed to migrate into a lower compartment across the microporous 
membrane in the presence of a chemoattractant. Briefly, T47D and PC-3 cells pretreated with 
drugs were serum starved for 16 hours. Later, 300 µL of cell suspension (1 million/ml) in serum 
free media was seeded in the upper compartment and 500 µL of 10% serum media was added to 
the lower compartment. This gradient in serum concentration acts as a driving force for cells to 
migrate. The cells that had migrated into lower compartment were then incubated with a cell 
stain solution, subsequently extracted using an extraction reagent and quantified by measuring 
the absorbance at 560 nm.  
Caspase-3/7 Assay 
This assay was used to determine the apoptotic induction of chemotherapeutic drugs 
alone and in presence of ritonavir. The assay consists of a pro-fluorescent substrate which when 
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cleaved by caspases-3/7 produces fluorescent rhodamine. The amount of fluorescence produced 
is proportional to the extent of apoptosis in cells. This assay was performed in 96-well plates. 
After treating the cells, drug solutions were aspirated and 100 µL of serum free media and equal 
volume of caspase buffer with substrate were added. The contents were gently mixed in a plate 
shaker for 1 min and incubated for 2 hours at room temperature. Later, the fluorescent readings 
were monitored at an excitation wavelength of 485 nm and an emission wavelength of 527 nm 
with a microtiter plate reader.  
Statistical Analysis 
Results were expressed as mean ± standard deviation (SD). One way analysis of variance 
(ANOVA) or student’s t test (Graph Pad InStat Version 4.0) was performed to confirm statistical 
significance of the experimental values. A P-value of less than 0.05 was considered to be 
statistically significant. Post-hoc analysis was performed using Scheffe test.  
Results 
RNA Expression Analysis 
LS-180 cells were treated with vinblastine alone and in presence of different 
concentrations of ritonavir. The concentration of vinblastine was determined from previously 
published results [265]. Ritonavir concentrations ranging from 1/8th -1/2nd of vinblastine dose 
were selected, to determine the optimal booster dose. Vinblastine (0.1 µM) alone showed 7 fold 
induction in MDR1, which was significantly lowered in the presence of ritonavir (25 nM, 30 nM 
and 35 nM). The minimal concentration of ritonavir (25 nM) equivalent to 1/4th of vinblastine 
dose significantly lowered MDR1 to the basal level (Figure 29). Levene’s statistic to test the 
homogeneity of variance for this data is as follows: F (6,21) = 2.24, p = 0.08. This concentration 
was selected as optimal booster dose for all further experiments. Vinblastine exhibited 8 fold 
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induction in MRP2 levels which significantly diminished in the presence of ritonavir. 
Vinblastine is a well-known inducer of CYP3A4. Vinblastine alone produced 40 fold induction 
in CYP3A4 mRNA levels which was completely abolished in presence of ritonavir (Figure 30).  
Protein Expression Analysis 
LS-180 cells were treated with vinblastine alone and in the presence of optimal ritonavir 
dose (25nM) for 72 hours. The relative fold induction of MDR1 protein expression was 
determined. Vinblastine showed induction in MDR1 protein level which was neutralized when 
cells were treated with vinblastine and ritonavir (Figure 31).  
Uptake Study 
Lopinavir is a well-known substrate for both MDR1 and MRP2 efflux pumps [244]. To 
evaluate the functional activity of the efflux pumps upon treatment, uptake of [
3
H] lopinavir was 
quantified on LS-180 cells. In vinblastine treated cells, the uptake of [
3
H] lopinavir was 
significantly lower compared to control suggesting enhanced activity of efflux pumps. However, 
in cells treated with vinblastine and ritonavir, the uptake was comparable to control, showing 
reduced activity of efflux pumps upon cotreatment (Figure 32).  
Vivid™ CYP3A4 Assay 
To study the functional activity of CYP3A4 gene, vivid assay was performed following 
drug treatment. The amount of metabolite formed from the substrate is dependent on levels of 
CYP3A4 activity in the cells. Compared to control cells, vinblastine treated cells showed 80% 
increase in metabolite formation which confirms high CYP3A4 activity. However, the cells 
cotreated with vinblastine and ritonavir, such CYP3A4 activity was significantly diminished, 
comparable to control value (Figure 33).  
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Figure 29. Relative fold induction of MDR1 mRNA in LS-180 cells treated with vinblastine (0.1 
µM) alone and in presence of different concentrations of ritonavir for 72 hours. Values represent 
mean ± SD. * represents statistical significance from control at P-value of <0.05. 
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Figure 30. Relative fold induction of (A) MRP2 and (B) CYP3A4 mRNA in LS-180 cells treated 
with vinblastine (0.1 µM) alone and optimized concentration of ritonavir (25 nM) for 72 hours. 
Values represent mean ± SD. * represents statistical significance from control at P-value of 
<0.05. 
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Figure 31. Immunoblot analysis showing the protein expression of MDR1 post treatment with 
vinblastine (0.1 µM) alone and optimized concentration of ritonavir (25 nM) on LS-180 cells for 
72 hours. β-actin was used as an internal control. 
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Figure 32. Uptake of [
3
H] lopinavir post treatment with vinblastine alone (0.1 µM) and 
optimized concentration of ritonavir (25 nM) on LS-180 cells for 72 hours. Values represent 
mean ± SD. * represents statistical significance from control at P-value of <0.05. 
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Figure 33. Percentage CYP3A4 activity post treatment with vinblastine alone (0.1 µM) and 
optimized concentration of ritonavir (25 nM) on LS-180 cells for 72 hours. Values represent 
mean ± SD. * represents statistical significance from control at P-value of <0.05. 
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Cell Proliferation Assay 
MTS assay was performed to determine inhibitory effect of chemotherapeutic agents 
(doxorubicin, paclitaxel, tamoxifen, and vinblastine) alone and in the presence of ritonavir in 
T47D cells. IC50 values of doxorubicin and paclitaxel (478 ± 13 nM and 3.3 ± 1.2 nM) were 
reduced by almost four fold in the presence of ritonavir to 167 ± 14 nM and 0.9 ± 0.4 nM, 
respectively (Figure 34). Similarly, presence of ritonavir lowered IC50 of tamoxifen (3.5 ± 1.1 
μM) by almost three fold (1.1 ± 0.6 μM). IC50 of vinblastine was observed to be 10.81 ± 1.38 
nM. This IC50 value was diminished by seven fold in the presence of ritonavir to 1.44 ± 0.45 nM 
(Figure 35). These results show that ritonavir enhanced the ability of all chemotherapeutics to 
inhibit cell growth. 
Migration Assay 
T47D cells pretreated with drug solutions were serum starved for 16 hours. The relative 
numbers of cells that had migrated towards 10% serum media were estimated by a 
spectrophotometer. The numbers of cells that have migrated was reduced by 10 - 40% in cells 
treated with chemotherapeutics alone. This reduction was further enhanced to almost 1.5 - 2 fold 
in cells cotreated with ritonavir (Figure 36 and Figure 37).  
Caspase-3/7 Assay 
This assay was performed to determine levels of apoptosis in T47D cells in the presence 
of anticancer agents alone and with ritonavir.  The chemotherapeutics alone raised apoptosis by 
approximately 3 - 4.5 fold and this value was further enhanced by almost two fold in the 
presence of ritonavir (Figure 38 and Figure 39).  
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Figure 34. Dose-dependent percentage viability of T47D cells treated with different 
concentrations of (A) doxorubicin (1.5 µM - 1.5 nM) and (B) paclitaxel (4 µM - 0.03 nM) alone 
and in presence of ritonavir for 72 hours. Values represent mean ± SD. 
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Figure 35. Dose-dependent percentage viability of T47D cells treated with different 
concentrations of (A) tamoxifen (50 µM - 12 nM) and (B) vinblastine (4 µM - 0.03 nM) alone 
and in presence of ritonavir for 72 hours. Values represent mean ± SD. 
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Figure 36. Relative number of T47D cells migrated towards 10% serum media post treatment 
with (A) doxorubicin and (B) paclitaxel alone and in presence of optimized concentration of 
ritonavir for 72 hours. Values represent mean ± SD. * represents statistical significance from 
control at P-value of <0.05. 
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Figure 37. Relative number of T47D cells migrated towards 10% serum media post treatment 
with (A) tamoxifen and (B) vinblastine alone and in presence of optimized concentration of 
ritonavir for 72 hours. Values represent mean ± SD. * represents statistical significance from 
control at P-value of <0.05. 
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Figure 38. Relative fold apoptosis in T47D cells post treatment with (A) doxorubicin and (B) 
paclitaxel alone and in presence of optimized concentration of ritonavir for 72 hours. Values 
represent mean ± SD. * represents statistical significance from control at P-value of <0.05. 
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Figure 39. Relative fold apoptosis in T47D cells post treatment with (A) tamoxifen and (B) 
vinblastine alone and in presence of optimized concentration of ritonavir for 72 hours. Values 
represent mean ± SD. * represents statistical significance from control at P-value of <0.05. 
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The relative levels of cell proliferation, migration and apoptosis in T47D and PC-3 cells 
treated with different chemotherapeutics alone or in presence of ritonavir were summarized in 
Table 6 and Table 7, respectively. 
Discussion 
Development of MDR in cancer therapy necessitates progressive increase in dosing of 
anticancer drugs which in turn may lead to systemic toxicity and adverse side effects. Various 
mechanisms of drug resistance, including reduced cellular drug accumulation, higher 
detoxification, hypoxic conditions leading to neovascularization, altered enzymatic activities, 
downregulation of target and enhanced DNA repair can be considered [149]. The primary 
objective of this study was to develop strategy for overcoming acquired drug resistance and 
enhance antitumor activity. LS-180 cells were employed as an in vitro cell culture model to study 
drug resistance. These cells have been shown to be an excellent model to predict long term drug-
drug interactions based on inductions of efflux transporters and metabolizing enzymes [269]. 
Vinblastine, substrate of both efflux transporters and metabolizing enzymes, was chosen 
as a model anticancer drug. Prolonged exposure to vinblastine is known to induce efflux 
transporters and metabolizing enzymes [265]. Overexpression of MDR1 is considered to be a 
major contributor to drug resistance. In order to neutralize the vinblastine mediated inductions of 
efflux transporters and metabolizing enzymes, ritonavir, which is a known substrate and inhibitor 
was selected. Dose dependent studies were performed to optimize ritonavir dose and to evaluate 
the induction potential of MDR1 gene upon cotreatment. Presence of ritonavir at various 
concentrations (25nM, 30nM and 35nM) demonstrated a significant lowering of MDR1 
overexpression caused by vinblastine. The lowest concentration i.e. 25nM which was adequate to 
completely overcome this overexpression of MDR1 was selected for all further studies. Upon 
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treatment with vinblastine alone and in the presence of ritonavir for 72 hours on LS-180 cells, 
gene expression analysis of MRP2, and CYP3A4 was studied with real time PCR. Vinblastine 
induced overexpression of MRP2 (8 fold) and CYP3A4 (40 fold) was neutralized in the presence 
of ritonavir and the gene expression levels almost reached to the endogenous levels of their 
respective control genes. Results from these experiments clearly suggest that ritonavir can inhibit 
the ability of vinblastine to induce expression of MDR1, MRP2, and CYP3A4 at the 
transcriptional level.  
To evaluate whether induction of efflux transporters and metabolizing enzyme at the 
transcriptional level correlates to the protein expression and activity, immunoblot and functional 
activity studies were performed, respectively. Immunoblot analysis further confirmed the 
induction of MDR1 by vinblastine alone. This induction was diminished when cells were 
cotreated with vinblastine and ritonavir. Reduced intracellular accumulation of [
3
H] lopinavir in 
vinblastine treated cells confirmed the functional activity of transcribed efflux transporters. On 
the other hand, no change in [
3
H] lopinavir uptake in the presence of vinblastine and ritonavir 
suggest that ritonavir can completely block the functional activity of efflux transporters. 
CYP3A4 activity was assessed by using Vivid™ assay. An increase in CYP3A4 activity for 
vinblastine treated cells was found to correlate well with the mRNA levels qualitatively but not 
quantitatively. Functional activity was elevated by about 1.7 times while mRNA was induced by 
almost 40 fold. Induced expression of CYP3A4 significantly increased the formation of 
metabolite confirming elevated CYP3A4 activity. Cotreatment of vinblastine with ritonavir 
significantly neutralized such increased activity.  
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Table 6. Ratio of cell proliferation IC50 reduction, migration inhibition and apoptosis increase of 
chemotherapeutics in the presence of ritonavir to chemotherapeutics alone in T47D cells. 
 
Drug Ratio of enhanced efficacy in presence of ritonavir 
Cell Proliferation (IC50) ↓ Migration  ↓ Apoptosis ↑ 
Doxorubicin 2.9 2.1 1.5 
Paclitaxel 3.7 2.1 1.5 
Tamoxifen 3.2 1.4 1.4 
Vinblastine 7.7 1.5 1.8 
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Table 7. Ratio of cell proliferation IC50 reduction, migration inhibition and apoptosis increase of 
chemotherapeutics in the presence of ritonavir to chemotherapeutics alone in PC-3 cells 
Drug Ratio of enhanced efficacy in presence of ritonavir 
Cell Proliferation (IC50) ↓ Migration  ↓ Apoptosis ↑ 
Doxorubicin 3.9 3.0 2.8 
Paclitaxel 4.3 3.6 2.0 
Tamoxifen 3.0 2.2 2.5 
Vinblastine 3.2 2.5 3.2 
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With the encouraging results from gene and protein expression analysis, three other 
chemotherapeutics (doxorubicin, paclitaxel and tamoxifen) were tested for different efficacy 
studies on T47D and PC-3 cells. Although gene and protein expression studies were conducted 
on LS-180 cells, efficacy studies were performed on T47D and PC-3 cells due to their aggressive 
phenotypic nature. Cell proliferative assay was performed in T47D breast cancer cells to evaluate 
the efficacy of anticancer drug and its cotreatment with ritonavir. IC50 value of all four drugs 
(doxorubicin, paclitaxel, tamoxifen and vinblastine) was lowered in the presence of ritonavir. 
This observation clearly shows that ritonavir enhances the antitumor efficacy, preventing the 
proliferation of cancer cells. Recent studies have shown that PIs also possess antiproliferative 
activity. Ritonavir can reduce proliferation of cancerous cells through inhibition of nuclear factor 
κB (NFκB) translocation and transcriptional activation [278-280].  
Cell migration is another important cellular process involved in angiogenesis, wound 
healing and immune responses. Migration assay was performed to better correlate in vitro 
migratory potential of cancer cells to their in vivo invasive properties. This assay was performed 
to better understand tissue repair and regeneration during cancer progression. All the four drugs, 
except for tamoxifen, inhibited cell migration compared to control. Interestingly, cells cotreated 
with ritonavir significantly impaired cell migration by almost 1.5 fold. Thus cell proliferation 
and migration assays further confirmed that cellular accumulation of vinblastine increased over 
time in the presence of ritonavir. Apoptosis is a self-defense mechanism for causing cell death to 
maintain development, homeostasis or aging. A cascade of cleavage events by caspases may lead 
to apoptosis. The levels of apoptosis were further enhanced in presence of ritonavir. This 
significant increase in apoptotic cells may be due to enhanced cellular accumulation and also due 
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to ritonavir, which can also promote apoptosis via inhibition of various signal transducers [281, 
282].   
Conclusions 
In summary, cotreatment with ritonavir neutralizes the induced gene expression of many 
drug resistant proteins and may overcome MDR. This promising data from our in vitro studies 
can form the basis for further development of a clinically applicable oral formulation of 
vinblastine or any other anticancer drug combined with ritonavir. The process of traditional drug 
development could be fastened since ritonavir is clinically approved for human use [283]. Its 
repositioning in cancer chemotherapy may provide an excellent platform to reverse and 
overcome drug resistance besides providing enhanced antitumor efficacy. 
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CHAPTER 5 
HYPOXIA-INDUCIBLE FACTOR 1 (HIF-1): A POTENTIAL TARGET FOR 
INTERVENTION IN OCULAR NEOVASCULAR DISEASES 
Introduction 
A constant oxygen supply is essential for proper tissue development, homeostasis and 
function of all eukaryotic organisms. Cells require oxygen as an electron acceptor during 
oxidative phosphorylation for efficient ATP production. Oxidative phosphorylation produces 
higher energy (~18 fold) than glycolysis [284, 285]. Oxygen serves as a major element in 
regulating membrane transport, intracellular signaling, expression of many genes, and cell 
survival [286, 287]. Hypoxia (~1% O2) occurs when tissue oxygenation demand exceeds the 
vascular supply. Response to reduced oxygen levels is mediated by the transcriptional regulator 
hypoxia-inducible factor 1 (HIF-1). HIF-1 was first discovered by its ability to induce expression 
of erythropoietin (EPO) in kidney and liver. Such production of EPO is inversely related to tissue 
oxygen concentration. In response to hypoxia, EPO is stimulated which in turn promotes red 
blood cell production and oxygen carrying capacity. This information led to the identification of 
a hypoxia response element (HRE; 5’-RCGTG-3’) in the 3'-enhancer region of EPO [288, 289].  
Structure and Regulation of HIF-1 
A functional HIF-1 system is expressed in all metazoan species including the simplest 
animal Trichoplax adhaerens [290]. The HIF1A gene was mapped on 14q21-q24 human 
chromosome. HIF-1 is a heterodimeric complex consisting of an oxygen-dependent subunit 
(HIF-1α) and a constitutively expressed nuclear subunit (HIF-1β) [291]. HIF-1β is also known as 
the aryl hydrocarbon receptor nuclear translocator (ARNT). It was first identified as structural 
binding component of aryl hydrocarbon receptor (AHR), which induces the transcription of 
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Cyp1a1 metabolizing enzyme [292]. Both subunits are members of basic helix-loop-helix-PER-
ARNT-SIM (bHLH-PAS) protein family. In human, HIF1A, EPAS1 and HIF3A genes encode 
three different isoforms of HIF-α (HIF-1α, HIF-2α and HIF-3α), respectively [293].  
Structurally, HIF-1α exhibits bHLH and PAS domains at the N-terminal. The bHLH 
domain and N-terminal of PAS (PAS-A) (amino acids/aa 1-166) facilitate DNA dimerization 
while complete bHLH and PAS domains (aa 1-390) facilitate DNA binding [294, 295]. HIF-1α 
also exhibits an oxygen-dependent degradation (ODD) domain, two transactivating domains 
(TADs) and two nuclear localizing signals (NLS). The ODD domain (aa 401-575) located within 
central region plays a predominant role in regulating stability of HIF-1α with respect to oxygen 
concentration [296]. Two TADs (N-TAD; aa 531-575 and C-TAD; 786-826) help in recruiting 
various coactivators required for transcription of target genes. Bridged between them is an 
inhibitory domain (ID; aa 576-785) capable of repressing their transcriptional activity under 
normoxic conditions (~20% O2) [297, 298]. N-NLS (aa 17-30) and C-NLS (aa 718-721) promote 
nuclear translocation of HIF-1α. However, studies have demonstrated that nuclear import is 
highly dependent on C-NLS [299]. HIF-1α is ubiquitously expressed in all human tissues, while 
the other related protein HIF-2α is primarily expressed in lung, endothelium and carotid artery 
[300-302]. HIF-2α shares 48% structural identity with HIF-1α. A third protein, HIF-3α, is also 
expressed in many tissues including adult thymus, lung, brain, heart, and kidney. This protein 
lacks C-TAD. However, the N-terminus of this protein shares 57% and 53% structural homology 
with HIF-1α and HIF-2α, respectively [303, 304]. A splice variant of HIF-3α is the inhibitory 
PAS domain (IPAS) protein, primarily expressed in Purkinje cells and corneal epithelium. This 
variant acts like a negative regulator of HIF-1 by binding to amino terminal region of HIF-1α, 
preventing transactivation. Further, this protein is also induced under hypoxia in heart and lung, 
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suggesting a negative feedback mechanism for HIF-1 activity [305, 306]. The domain 
organization of both the subunits (HIF-1α and HIF-1β) is depicted in Figure 40.  
Functional activity of HIF-1 is regulated by levels of oxygen-dependent HIF-1α subunit. 
Although transcription of HIF-1α mRNA occurs at normoxic conditions, the protein is rapidly 
degraded via the ubiquitin proteasome pathway [307, 308]. HIF-1α protein has a very short half-
life (t1/2~5 min) and its stability is highly regulated by posttranscriptional modifications including 
hydroxylation, ubiquitination, acetylation, phosphorylation and nitrosation [309, 310]. 
Prolyl Hydroxylation  
Hydroxylation of proline residues led to the identification of oxygen sensing mechanism 
of HIF-1α [311, 312]. It was considered a major breakthrough in delineating the signal 
transduction of HIF-1. Mutagenic studies substituting proline stabilized HIF-1α even under 
normal oxygen tension, demonstrate its importance in regulating transcriptional responses. Two 
proline residues (Pro/P 402 and 564) located within ODD domain are rapidly hydroxylated by 2-
oxoglutarate (2-OG) dependent dioxygenases [313-315]. These dioxygenases recognize a 
conserved amino acid sequence ‘LXXLAP’, where X represents any amino acid. Human 
dioxygenases have been coined as prolyl hydroxylases (PHDs) or HIF- prolyl hydroxylases 
(HPHs) [316]. PHDs require oxygen for hydroxylation as well as ferrous ion (Fe
2+
)
 
and ascorbate 
as cofactors [317]. During hydroxylation an oxygen molecule is split so that one oxygen atom is 
transferred on to proline while the other reacts with 2-OG to produce succinate and CO2 [313, 
318]. Absolute requirement for Fe
2+
 ion stems from the observation that iron chelators or 
transition metal ions can suppress hydroxylation either by reducing the availability of Fe
2+
 or 
substituting Fe
2+
 at the active binding site [319, 320]. Ascorbate plays a very important role in 
regulating the activity of PHDs and maintaining the Fe
2+ 
state of iron [318].  
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Figure 40. Structure of HIF-1 subunits depicting various domains. 
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Molecular cloning studies have identified three isoforms of PHDs (PHD 1, 2 and 3) 
[321]. All the three isoforms can hydroxylate HIF-1α, with the highest activity exhibited by 
PHD2. The relative in vitro hydroxylation activity can be demonstrated as PHD2 >> PHD3 > 
PHD1 [316, 322]. Subcellular localization of these isoforms varies. PHD1 is exclusively 
localized in the nucleus; while PHD2 is localized in the cytoplasm and PHD3 is found in both 
compartments. However, PHD2 is able to shuttle between cytoplasmic and nuclear components 
facilitating HIF-1α degradation in both compartments. Further studies have suggested that PHD2 
and PHD3 mRNA expression is hypoxia-inducible, while PHD1 mRNA expression is not altered 
by hypoxia [323]. 
Polyubiquitination 
 Post hydroxylation, von Hippel-Lindau protein (pVHL) binds HIF-1α. X-ray 
crystallographic studies have demonstrated that hydroxyproline fits accurately into a pocket in 
pVHL hydrophobic core and this binding is highly specific [324, 325]. Moreover, pVHL 
associates with elongin C and this interaction is stabilized by elongin B. Cullin-2 and Rbx1 
proteins are also recruited to form the VCB-Cul2 E3 ligase complex which facilitates 
polyubiquitination and degradation by the 26S proteasome [326, 327]. Although pVHL-E3 ligase 
complex is predominantly expressed in the cytoplasm, cytoplasmic-nuclear trafficking of the 
complex facilitates HIF-1α degradation in both compartments [328, 329]. pVHL thus plays a 
predominant role in the degradation of HIF-1α. Loss of activity or mutation of pVHL has been 
implicated in the development of many disease processes due to induction of hypoxia regulated 
genes [330-332].  
Lysine Acetylation  
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Jeong et al., have identified a key lysine residue (Lys/K 532) that plays a crucial role in 
determining proteasomal degradation of HIF-1α. An acetyl group of acetyl-coA is transferred 
onto K532, located within ODD domain, by acetyltransferase ARD1. This modification further 
promotes interaction of HIF-1α with pVHL, in concert with proline hydroxylation. ARD1 is 
present in all the human tissues and its activity is not dependent on oxygen levels. However, the 
transcriptional and translational levels of ARD1 are reduced under hypoxia, causing decreased 
acetylation [333]. Replacing lysine with arginine enhances stability of HIF-1α while increasing 
acetylation promoted its degradation [334, 335].  
Asparagine Hydroxylation 
A third hydroxylation site on asparagine 803 (Asn/N 803) was identified on C-TAD of 
HIF-1α. This asparagyl residue is conserved on HIF-2α isoform (N851) [336, 337]. Unlike other 
posttranslational modifications already discussed, asparagine hydroxylation may not affect the 
stabilization of HIF. Rather, it promotes HIF activity via modulation of TADs. Under normoxic 
conditions, N803 is hydroxylated by a factor inhibiting HIF-1 (FIH-1), an oxygen-dependent 2-
OG dioxygenase requiring Fe
2+
 and ascorbate as cofactors [338-340]. It is considered as a second 
oxygen sensor and is localized in cytoplasm. Transcription of FIH-1 is not dependent on oxygen 
concentration [323]. Hydroxylation on N803 prevents interaction of HIF-1α with its coactivators 
CREB binding protein (CBP)/p300 due to steric inhibition. This coactivator recruitment is 
essential for transactivation of HIF-1α [341, 342].  
Phosphorylation 
Phosphorylation of HIF-1α by mitogen-activated protein kinase (MAPK) pathway 
appears to play a crucial role in regulating its activity and function. HIF-1α is highly 
phosphorylated in vitro by p42/p44 and p38 kinases [343-345]. Such activation promotes 
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transcriptional activity of HIF-1. It is hypothesized that HIF-1β exhibits preferential binding to 
the phosphorylated HIF-1α protein [346]. Inhibitors of p42/44 protein kinases diminished 
hypoxia induced transcriptions of target genes, while their stimulation accelerates their 
translational activity [347]. Threonine (Thr/T) at residues 796 and 844 appear to be the potential 
phosphorylation sites in HIF-1α and HIF-2α, respectively [348]. 
Transactivation and Target Genes  
 In normoxic conditions, de novo synthesized cytoplasmic HIF-1α is rapidly hydroxylated 
(P402 and P564) and acetylated (L532). Later, HIF-1α is captured by pVHL and degraded by 
26S proteasome [311, 325, 327]. However, in hypoxic conditions hydroxylation is inhibited. It 
becomes stabilized and then translocates into nucleus via NLS. The protein heterodimerizes with 
constitutively expressed HIF-1β, binds to the pentacore DNA binding sequence, recruits 
coactivators and activates transcription of various target genes (Figure 41) [349-351]. To date, 
more than hundred target genes of HIF-1 have been identified. The target genes play a key role 
in regulating angiogenesis, cell survival and proliferation, chemotherapy and radiation resistance, 
invasion and metastasis, genetic instability, immortalization, immune evasion, metabolism and 
stem cell maintenance [56-63]. Some important target genes have been listed in Table 8.  
Angiogenesis is a complex signaling process involving multiple gene products [352]. 
Many of these genes are upregulated due to hypoxic insult [353-357]. Hypoxia is an important 
regulatory factor directing angiogenic switch, with HIF-1 playing a predominant role in “flipping 
the switch” via direct transcriptional upregulation of vascular endothelial cell growth factor 
(VEGF). VEGF is a potent endothelial-specific mitogen. It interacts with its receptor (VEGFR) 
localized on endothelial cells and stimulates endothelial cell proliferation [354, 358-360].  
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Figure 41. Schematic representation of oxygen-dependent regulation of HIF-1. 
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Table 8. Target genes of HIF-1 pathway. 
 
 
FUnc t ion Oxygen Regnla ted Gen e 
Endocrine g land derived VEGF (EG-VEGF) 
Angiogelle-sis 
T ransfonning growth factor- JB (TGF - JB) 
Vascular endothelial gro'w1h fa c tor (VEGF) 
VEGF receptor (VEGFRIlF1t- l) 
Apopto sis N ip3 
Insulin-like growth factor (lGF) 2 
IGF-billding protein (IGFBP) - 1 
Cell prol iferatio n and survival IG FBP -2 
IGFBP- 3 
Transfonll.ing growth factor- a (TGF-a ) 
Dedifferentia t ion Inhibitor o f differentiation protein-2 (ID2) 
Breast cancer resistance- protein (BCRP) 
Dnlg resistance 
P - glycoprotein (P-gpIMDRI ) 
Energy metabolisJ.n Leptill 
Erythropoies i s Erythropo ietin ( EPO) 
Genet ic. insta bility M n tSalpha (MSH2 and MSH 6 complex) 
Aldolas e -A 
Al<lol ase-C 
E nolase- l 
Glucos e transporter- l (GLUT- I ) 
G L UT-3 
Glucose nle tabolisJ.n 
H exokinase- l 
H exokinase-2 
Lactate dehydrogenase A (LDHA) 
Phos phofruc to k in ase L ( PFKL) 
Phosphoglycerate kinase 1 (PGKl ) 
His tone nlo difiers JMJD2 B 
C eruloplaslnl.n 
Iron Dle ta b o lism Transferrin 
Transferrin receptor 
Collagen proly l hydroxylase 
Matrix nletabol isnl Matrix Inetalloproteinases (MMPs) 
Plasullnogen ac.t ivator inhibitor - 1 (PAl- I ) 
a " Jh integ rin 
Migratio nlInv a s ion 
CheDlokine receptor (CXCR4) 
N udeotide Illetabolisul Adenylate kinase-3 
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Apart from VEGF induction, many complex mechanisms are also involved in HIF-1 
mediated angiogenic control. The expression of α1B-adrenergic receptor, adrenomedulin (ADM), 
angiopoietin 2, endothelin-1 (ET1), heme oxygenease-1 (HO-1), nitric oxide synthase, placental 
growth factor (PGF), platelet derived growth factor-B (PDGF-B) and stromal derived growth 
factor-1 (SDF-1) is regulated by hypoxia [361-369]. Also, expression of collagen prolyl 
hydroxylase, matrix metalloproteinases (MMPs) and plasminogen activator receptors and 
inhibitors (PAIs) under hypoxic control regulates matrix metabolism and vessel maturation 
(Figure 42) [370-372].  
Role of HIF-1 in Ocular Diseases 
 Retina, a light sensitive tissue, forms the inner lining of posterior ocular segment and is 
metabolically one of the most active tissues in human body [373]. Continuous oxygen supply to 
retina facilitates high energy demand for sensitive and efficient transduction of images to 
readable neuronal signals [374, 375]. This neuronal function is executed by five different cell 
types including photoreceptors, bipolar cells, amacrine cells, horizontal cells and ganglion cells. 
Photoreceptors (cones and rods) play a vital role in phototransduction process. Cones mediate 
vision in bright light while rods mediate in dim light [376, 377]. Number of rods outweighs the 
number of cones by ~20 fold. Under dark conditions, a single rod cell requires 10
8 
ATP/sec for 
ion homeostasis and signal transduction machinery. However under light exposure due to 
reduction in ion influx, energy requirement falls by 75% [378]. The energy requirement is met 
by oxidative phosphorylation process occurring in mitochondria, located within inner segment of 
photoreceptors [379]. Thus, oxygen concentration tightly controls retinal function. In human a 
constant supply of oxygen is regulated via choroidal and retinal circulation. Since human retina 
is thick, these two separate and distinct systems act to facilitate diffusion.  
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Figure 42. Schematic representation of angiogenic regulation by HIF-1. 
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Choroidal vasculature nourishes the outer retina including retinal pigment epithelium 
(RPE) and photoreceptors while retinal vasculature perfuses the inner retinal layers. Choroidal 
circulation is highly vascularized. It is under low autoregulation and requires strong sympathetic 
control. Retinal circulation is relatively sparse, controlled by autoregulation and lacks 
sympathetic control. Arteriovenous oxygen gradient is also different between the two 
vasculatures [380, 381]. Further, the choroidal vessels are fenestrated while the retinal vessels 
lack fenestrations and express tight junctions [382]. Both vasculatures play an important role in 
regulating retinal physiology. Lack of oxygen supply can lead to vision threatening pathologies 
such as diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration and 
glaucoma. Despite the fact that initiating events are different, hypoxia with subsequent 
neovascularization is a characteristic phenomenon noticed with all these vascular diseases. 
Diabetic Retinopathy  
Diabetic retinopathy (DR) is a frequent secondary microvascular complication in patients 
with diabetes mellitus. It is one of the four major causes of visual impairment often leading to 
blindness [383, 384]. Almost 25-50% of diabetic patients exhibit retinopathy symptoms within 
the first 10-15 years and this number approaches nearly 100% within 30 years of diabetic onset 
[385, 386]. DR is characterized by bi-phasic progression with an initial non-proliferative (vaso-
obliterative) phase followed by a proliferative (vaso-proliferative) phase. During initial stages, a 
persistent rise in blood glucose levels leads to a loss of intramural pericyte function. As a result 
small saccular capillary outpouchings, known as microaneurysms appear [387]. Intraretinal 
microvascular abnormalities, hemorrhages, edematous thickening of basement membrane, soft 
exudates and cotton wool spots are also observed [388-391]. Changes in vasculature and 
perturbations in oxygen tension lead to development of hypoxia, elevating the expression of 
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angiogenic factors and subsequent neovascularization (proliferative phase) (Figure 43) [392]. 
The newly formed blood vessels are often fragile and permeable. Such vessels grow through the 
surface of retina into the vitreous and subsequent bleeding may lead to obstructed vision. 
Further, contraction of associated fibrovascular component may result in retinal detachment, 
vision loss and blindness [393-396].  
The role of HIF-1 in the proliferative stage of DR has been clearly established. Mean 
oxygen tension is significantly lower in diabetics relative to non-diabetic patients in both lens 
(8.4 ±  0.7 mm Hg vs 10.7 ± 0.8 mm Hg) and vitreous cavity (5.7 ± 0.7 mm Hg vs 8.5 ± 0.6 mm 
Hg) [397]. Expression levels of HIF-1α and VEGF are elevated in diabetic preretinal membranes 
compared to non-diabetic idiopathic epiretinal membranes [398, 399]. Moreover, the production 
of VEGF and intercellular adhesion molecule (ICAM)-1 are diminished in a diabetic mice model 
lacking Hif-1α expression. It leads to much reduced vascular leakage and neovascularization in 
Hif-1α knockout mice relative to wild type mice [400]. These findings clearly suggest that 
alteration in HIF-1α pathway may be an attractive strategy for the treatment of DR.   
Retinopathy of Prematurity 
Retinopathy of prematurity (ROP), formerly known as retrolental fibroplasias, is the 
leading cause of visual impairment and blindness in children [401]. It was first described in early 
1940s. This condition is associated with low gestational period, low birth weight and hyperoxia  
[402]. Human retinal vasculature begins to develop during 16
th
 week of gestation and concludes 
at 40
th
 week. Hence, premature infant’s exhibit incompletely developed retinal vasculature and 
peripheral avascular zone. Oxygen supplementation (hyperoxia) is often needed in premature 
infants to overcome respiratory insufficiency. Such acute rise in oxygen tension can stimulate 
apoptosis of vascular endothelia cells and may cause vaso-obliteration via generation of reactive 
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oxygen species (ROS) (Phase I). Further, high perinatal levels of prostaglandins (PGD2 and 
PGE2) and nitric oxide (NO) accelerates oxidative metabolism. Reduced levels of antioxidants 
may induce complexity in disease pathology [403-406]. In a subsequent phase, the infant’s vaso-
obliterated retina undergoes hypoxic/ischemic stress. It triggers a series of events such as 
stabilization of HIF-1α and production of various proangiogenic factors resulting in 
neovascularization (Phase II) (Figure 43). In contrast to normal developmental vasculature, this 
pathological vasculature displays excessive, uncontrolled and misdirected growth towards 
vitreous and lens. It can cause fibrous scarring, retinal detachment and blindness [407-410].  
Given the regulatory role of oxygen, it is evident that HIF plays a predominant role in the 
development and progression of ROP. In a mouse oxygen-induced retinopathy (OIR) model, the 
expression levels of HIF-1α and HIF-2α proteins peak after two hours of hypoxic exposure. 
However, HIF-1α is stabilized in neuronal cells and inner retinal layers whereas HIF-2α was 
upregulated in Muller glia and astrocytes [411]. Indeed, inhibition of Hif-1α and Vegf by gene 
therapy in mice ischemic retinopathy model inhibited neovascular tufts and nuclei compared to 
control hypoxia group [412]. Hence, altering the HIF-1α pathway may be beneficial than 
targeting other downstream factors.  
Age-Related Macular Degeneration 
Age-related macular degeneration (AMD) is the leading cause of blindness in patients 
over the age of 65. World Health Organization (WHO) global eye disease survey has revealed 
that more than 50 million people are affected with AMD and atleast one-third of them are blind 
or severely visually impaired [413]. Development of AMD is multifactorial including aging, 
smoking, genetic factors, obesity, hypertension and hypercholesterolemia [414-418]. The disease 
is characterized by degeneration of central retina leading to disturbed fine and color vision. 
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AMD is classified into two clinical forms, non-exudative/dry AMD and exudative/wet AMD 
[419]. The dry phase accounts for 85 to 90% of the total cases. It is characterized by the presence 
of acellular polymorphous debris, termed as drusen, between the basal lamina of RPE and inner 
collagenous layers of Bruch’s membrane (Figure 43). As AMD progresses geographical atrophy 
of photoreceptors and central retina are noticed [420, 421]. Although wet AMD represents 10 to 
15% of total cases, it accounts for approximately 90% of vision loss. In certain cases, dry AMD 
progresses to wet AMD characterized by choroidal neovascularization (CNV). These abnormal 
blood vessels penetrate Bruch’s membrane; grow into RPE and neural retina. This may lead to 
blurred vision, retinal detachment, fibrosis and complete vision loss [422, 423].  
Cell and molecular biology studies have demonstrated that hypoxia, chronic oxidative 
stress and inflammation play key role in AMD [424-426]. Hypoxia may result from higher 
oxygen consumption, resulting from increased metabolic activity of the inflamed retina or due to 
poor circulation in central macula, resulting from vessel stenosis and microthrombosis [427-
429]. Also, thickening of Bruch’s membrane and drusen formation further stabilizes HIF [430]. 
ROS also causes elevation in HIF protein expression and results in increased transcriptional 
activity of hypoxia regulated genes [431, 432]. Such hypoxic milieu contributes to progression of 
exudative AMD and development of CNV. Infact, HIF-1α and HIF-2α expression were 
identified in endothelial cells and macrophages of choroidal neovascular membranes [433, 434].  
Glaucoma 
 Glaucoma represents a multifactorial optic neuropathic disease [435]. It is classified into 
open and closed-angle depending on the anterior chamber angle. Open-angle glaucoma exhibits 
unobstructed and normal iridocorneal angle while the closed-angle glaucoma exhibits occlusion 
of the angle by the peripheral iris [436, 437]. Glaucoma is characterized by increased intraocular 
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pressure, degeneration of retinal ganglion cells and axons. However, the exact role of hypoxia in 
the development of glaucoma is still unknown. Clinical observations have demonstrated retinal 
vascular abnormalities and impaired blood flow at the optic nerve head which may result in 
stabilization of hypoxic factors leading to retinal ganglion cell death [438, 439]. The expression 
of HIF-1α in control and glaucomatous human donor eyes was studied. Indeed, higher expression 
of the protein was noticed in retina and optic nerve head of glaucomatous eyes [440]. These 
findings clearly suggest the importance of hypoxia signaling mechanism in the pathogenesis of 
glaucoma. 
Existing Anti-VEGF Therapeutics 
 Overproduction of VEGF plays an important role in pathogenesis of DR, ROP, AMD, 
neovascular glaucoma, central and branch retinal vein occlusion [441-444]. The human VEGFA 
gene localized in chromosome 6p21.3 exhibits eight exons and four principal isoforms. The 
shorter isoform, VEGF121, is an acidic polypeptide and lacks heparin binding domain. The larger 
isoforms, VEGF189 and VEGF206, are highly basic and exhibit high affinity binding to heparin. 
The shorter isoform is freely diffusible while the larger isoforms are completely sequestered in 
the extracellular matrix. VEGF165 exhibits intermediate properties, existing in both diffusible and 
bound forms [445]. The primary sources of VEGF in retina are RPE cells, Muller cells and 
ganglion cells. VEGF binds to two types of protein kinase activating receptors, VEGFR1 and 
VEGFR2. These high affinity receptors have been localized on retinal endothelial cells and 
pericytes [446-449]. Currently, anti-VEGF therapeutics are indicated in the treatment of ocular 
neovascular diseases. These include Pegaptanib sodium (Macugen; Eyetech 
Pharmaceuticals/Pfizer, NY), Ranibizumab (Leucentis; Genentech, CA), Bevacizumab (Avastin; 
Genentech, CA) and Aflibercept (VEGF Trap-Eye; Regeneron, NY).  
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Figure 43. (A) Stages of diabetic retinopathy (DR). (B) Development of retinopathy of 
prematurity (ROP). (C) Schematic representation of dry and wet age-related macular 
degeneration (AMD). Reproduced with permission from references [402, 426].  
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Pegaptanib (50 kDa) is the first anti-VEGF agent approved by US Food and Drug 
Administration (FDA) in 2001 for the treatment of exudative AMD. It is a 28-base ribonucleic 
acid aptamer, covalently linked to two branched polyethylene glycol (PEG- 20 kDa) moieties. It 
binds to extracellular VEGF165 with high affinity and prevents the interaction of VEGF with its 
receptor. Since pegaptanib binds specifically to only one isoform, it exhibits limited efficacy. 
Approval of this drug molecule began a new era in anti-VEGF therapy. Bevacizumab (149 kDa) 
is a humanized recombinant full-length monoclonal antibody. It binds to all VEGF isoforms. 
Although not approved for specific intraocular use, bevacizumab has been indicated as an off-
label therapeutic in the treatment of ocular diseases. Ranibizumab (48 kDa) is the Fab fragment 
of the former, approved by US FDA in 2010 for treatment of macular edema and vein occlusion. 
Both these molecules bind all forms of VEGF. Compared to bevacizumab, ranibizumab 
demonstrates 5-20 fold greater potency due to higher affinity and lack of immunogenicity. 
Aflibercept (115 kDa) was approved by US FDA in 2011 for treatment of AMD. It is a 
recombinant fusion protein consisting of the VEGF binding domains of human VEGFR1 and 
VEGFR2 fused to the Fc domain of human immunoglobulin-G1. It acts as a decoy receptor 
binding free VEGF [450-453].  
Although large molecule therapeutics appear to be promising, their long term usage must 
be considered with caution. A recent investigation by Kurihara et al., reported the deleterious 
effects following deletion of Vegfa gene in adult mice. Choriocapillaris are completely 
attenuated following three days of RPE-specific Vegf inactivation. Further, cone photoreceptors 
were damaged and cone dysfunction was noticed. These dramatic secondary “off-target” effects 
of Vegf antagonism were not observed when Hif1a, Epas1, and Hif1a/Epas1 were genetically 
ablated. The transcriptional mutants did not exhibit any morphological, functional, or 
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transcriptional differences relative to control adult mice. Further, deletion of transcription factors 
reduced pathological angiogenesis in laser photocoagulation model of CNV. These studies 
clearly reinforce the strategy that molecules aiming at HIF pathway may be an alternative, safer 
and effective mode of treatment than attenuating VEGF levels alone [454, 455].  
Development of HIF-1 Inhibitors for Ocular Diseases 
 Significant research has been conducted in recent years to identify inhibitors of HIF-1 
pathway. Based on their putative mechanism of action, HIF inhibitors may be classified as 
modulating i) HIF-1α mRNA expression, ii) HIF-1α protein translation, iii) HIF-1α protein 
degradation, iv) HIF-1α DNA binding activity and v) HIF-1α transcriptional activity. Examples 
of HIF-1 inhibitors are summarized in Table 9 while few of them are described below.  
HIF-1α mRNA Expression 
It has been hypothesized that transcriptional level of HIF-1α is the rate limiting factor of 
HIF-1 activity under hypoxic conditions [456]. Hence, inhibitors that effect HIF-1α mRNA 
expression can lower the rate of HIF-1 translation. Chen et al., have studied the role of HIF-1α 
inhibition by RNA interference (RNAi) with shRNA in BALB/C mouse model of corneal 
neovascularization. The effect of shRNA treatment was assessed by measuring mean 
neovascularization score. The mean score values were as follows: normal (0), control 
neovascular eyes (3.59 ± 1.1), saline treated (4.05 ± 0.75), vehicle-treated (3.64 ± 1.02) and 
RNAi- treated (1.13 ± 0.96). HIF-1α shRNA reduced neovascularization by more than 3 fold 
compared to control eyes. Further, the expression of angiogenic factors (VEGF and MMPs) and 
inflammatory mediator (IL-1β) was also diminished. In summary, this study confirmed the role 
of HIF-1α transcriptional inhibition in reducing corneal neovascularization and associated 
inflammation [457]. 
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Table 9. Inhibitors of HIF-1 pathway. 
 
T argt" t Pa th w a y I :\It"chanis m of A c tio n S mall :\Iolt"c u lt"s 
HIT-I o mR.. .... A t"]:pl"t"Ss io ll 
Amino flavon e 
Transcriptio n EZN-2968 
RNA interfen>nce 
HIT-l o p l·ott" ili t"xpl· t" ssioll 
Digoxin 
Translation PX-478 
Topote-call 
Erotinib 
Recepto r tyrosine kinases 
Gefitinib 
Genistein 
LY294002 
PBK-AKTpathway 
NeLfinavlr 
W ortmannin 
ERK-AKT pathway R esveratrol 
Everolilnus 
Rapam ycin 
mTOR palhway 
Silib inin 
Tetll5irolimus 
PD980S9 
Ras-MAPK pathw ay 
Sarafenib 
HIF-l o: p l·ott"ill d t"gn'lda tioli 
A pigenin 
Hsp 90 inhibitor Deguelin 
Gelda.nam ycin 
FK228 
HDAC ildJibitor SAHA 
Trichosta tin A 
O tht"1"S 
Cyclin-dependent kinase F1avopiridol 
Cispla tin 
Doxomb icin 
D NA b inding 
Echinom ycin 
Pyrrole - imidazole poly amide 
Microtubu les 2-methoxyestradiol (2ME2) 
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A similar study with RNAi of HIF-1α was performed by Jiang et al., in C57BL/6J mice 
of ischemic retinopathy. The researchers have counted the number of neovascular nuclei on the 
vitreal side of inner limiting membrane. The number of nuclei per cross section were as follows: 
normoxia (0.05 ± 0.29), hypoxia (41 ± 2.8), vehicle-treated (41 ± 2.6) and siRNA-treated (28 ± 
2.8). The number of neovessels significantly decreased in transfected group relative to hypoxic 
group (p<0.01). This report clearly demonstrates the application of HIF-1α RNAi as a novel 
therapeutic for the treatment of neovascular eye diseases [412].  
HIF-1α Protein Translation 
 Although the precise mechanism of HIF-1α protein translation in hypoxic conditions is 
not clear, several translational inhibitors have been identified. These molecules can directly 
inhibit translation or inhibit various signaling pathways (receptor tyrosine kinases, 
PI3K/AKT/mTOR and Ras-MAPK pathway). These signaling pathways play a predominant role 
in upregulating HIF-1α translation and thus inhibition of these growth factors can alter hypoxic 
regulation. Cardiac glycosides can inhibit HIF-1α protein translation and digoxin has been 
identified as a potent inhibitor in a cell-based reporter assay [458]. The effect of digoxin on 
ocular neovascularization was demonstrated by Yoshida et al., in C57BL/6 mice with ischemic 
retinopathy. Intraocular injection of digoxin lowered retinal neovascularization by almost 75% 
compared to saline group. Also, the area of CNV at Bruch’s membrane was significantly lowered 
in presence of digoxin. Apart from inhibiting HIF-1α protein expression, digoxin also inhibited 
the expression of several angiogenic factors including VEGF, PDGF-B, SDF-1, VEGFR2, 
chemokine receptor (CXCR4) and Tie2 receptor in ischemic retina. This observation suggests 
that digoxin may offer advantages over VEGF antagonists in the treatment of neovascular 
diseases due to inhibition of several proangiogenic pathways. This study signifies that digoxin, a 
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potent HIF-1α inhibitor, can possibly provide a better therapeutic intervention [459].
 Genistein, a naturally occurring isoflavonoid, exhibits strong antiangiogenic activity. The 
underlying mechanism is hypothesized as inhibition of HIF-1α translation caused by inhibition 
of tyrosine kinases [460]. Wang et al., examined the effects of genistein on retinal 
neovascularization in C57BL/6 OIR mouse model. Number of vascular nuclei anterior to inner 
limiting membrane was quantified and data obtained was represented as: normoxia (0.76 ± 0.81), 
hypoxia (23.9 ± 4.4), genistein (50 mg/kg) (20.9 ± 4.7), genistein (100 mg/kg) (17.2 ± 4.0) and 
genistein (200 mg/kg) (14.2 ± 3.2). The nuclei numbers were diminished by 87, 72 and 59% 
respectively, as the dose of genistein was raised. Further, dose-dependent reduction in HIF-1α 
and VEGF levels were also observed. This report suggests possible pharmacological application 
of genistein in ocular neovascularization [461].  
HIF-1α Degradation   
 The molecular chaperone, heat shock protein 90 (Hsp90) is required for activity of 
various signaling proteins [462]. The interaction of Hsp90 with HIF-1α is required for proper 
conformational stability. Inhibitors of Hsp90 can promote degradation of HIF-1α via oxygen-
independent proteasomal degradation [463]. Geldanamycin and its analogs (17-N-allylamino-17-
demethoxygeldanamycin (17-AAG) and 17-dimethylaminoethylamino-17-
demethoxygeldanamycin (17-DMAG/Deguelin)) may interfere with Hsp90/HIF-1α interaction 
by competing with the ATP binding site [464]. Kim et al. evaluated the potential of deguelin in 
the treatment of vaso-proliferative retinopathies. In an OIR mouse model, deguelin treated mice 
exhibited lower neovascularization as assessed by fluorescein angiography (Figure 44). Further, 
the number of vascular lumens between posterior lens and anterior inner limiting membrane 
were estimated. Compared to control group the deguelin injected group showed lower number of 
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vascular lumens (19 ± 3.4 vs 4 ± 2.1). Moreover, deguelin treatment did not alter normal retinal 
morphology as evident by normal retinal thickness and lack of any inflammation in vitreous, 
retina or choroid. This data clearly implies that modulation of HIF pathway reduces retinal 
neovascularization without any retinal toxicity [465]. 
HIF-1α DNA Binding and Transcriptional Activity 
 Binding of active heterodimeric HIF-1 to the consensus -RCGTG- enhancer element of 
target genes is another crucial step necessary for transcription of hypoxia-inducible target genes. 
Also, the interaction of coactivator p300 with HIF-1α is another potential mechanism required 
for transcriptional activity of HIF-1. These molecular pathways can also be targeted in the 
treatment of various neovascular diseases [466-468].  
Conclusions and Future Perspectives 
 In summary, high levels of energy is required for proper retinal function. Any 
perturbations in oxygenation may lead to progression of several retinal degenerative diseases 
including DR, ROP and AMD. Mechanistic studies of cellular and molecular components of 
hypoxia signaling have opened a new era in the treatment of retinopathies. Given the role of 
HIF-1 in the etiology of these diseases, it is evident that manipulation of this pathway at various 
stages can lead to more effective treatment of oxygen-dependent ocular diseases. As discussed in 
this chapter, many inhibitors have been identified and evaluated both in in vitro cell culture 
models and animal models. However, further work validating the pharmacological intervention 
of these inhibitors in retinal diseases and their translation from bench to bedside is necessary. 
Nonetheless, there is significant optimism that modulation of HIF pathway can provide new 
treatments for ocular neovascular diseases.  
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Figure 44. Estimation of retinal neovascularization in (A) control and (B) deguelin treated 
oxygen-induced retinopathy mouse model. Reproduced with permission from reference [465]. 
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CHAPTER 6 
MOLECULAR EXPRESSION AND FUNCTIONAL ACTIVITY OF EFFLUX AND INFLUX 
TRANSPORTERS IN HYPOXIA INDUCED RETINAL PIGMENT EPITHELIAL CELLS 
Rationale 
Retina, a light sensitive tissue, forms the inner lining of posterior segment of the eye and 
is metabolically one of the most active tissues. It is highly sensitive to oxygen tension. 
Mammalian cells require oxygen as an electron acceptor during oxidative phosphorylation for 
ATP production to maintain normal metabolic functions. Oxygen serves as a major contributor 
for regulating membrane transport, intracellular signaling, expression of many genes, and 
initiation of apoptosis [286, 287, 469, 470]. Exposure to low oxygen tension even for short time 
periods may bring about alterations in the maintenance of oxygen homeostasis [471]. Hypoxia is 
a condition in which oxygen is found to be below the normal level. Many regulatory systems in 
the human body are activated by hypoxia and consequently cells under this hypoxic stress elicit 
various adaptive responses. 
A master regulator of hypoxic response is hypoxia-inducible factor (HIF). It is a 
heterodimer consisting of oxygen-dependent HIF-α subunit and independent HIF-β subunit [291, 
472]. Under normal oxygen levels, HIF-α subunit is hydroxylated by prolyl hydroxylases 
(PHD1-3) and rapidly degraded by E3 ubiquitin-proteasome system [312, 321, 473]. Under 
hypoxic conditions, hydroxylation is inhibited due to inactive PHDs leading to translocation of 
HIF-α to the nucleus. HIF-α heterodimerizes with HIF-β, recruits various co-activators and binds 
to the pentanucleotide hypoxic response element sequence (RCGTG) to modulate the expression 
of various genes. To date several HIF responsive genes have been identified, which play a key 
role in regulating many cellular processes. Few important genes include vascular endothelial 
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growth factor (VEGF), erythropoietin (EPO), glucose transporter-1 (GLUT-1), angiopoietin 2, 
endothelin-1 (ET1), heme oxygenease-1 (HO-1), nitric oxide synthase, placental growth factor 
(PGF), platelet derived growth factor-B (PDGF-B) and stromal derived growth factor-1 (SDF-1) 
[294, 474-476].  
There is a general consensus that hypoxic conditions contribute to many retinal diseases 
such as von Hippel-Lindau (VHL) disease, diabetic retinopathy (DR), retinopathy of prematurity 
(ROP), macular edema, glaucoma, age-related macular degeneration (AMD) and retinitis 
pigmentosa [388, 402, 440, 477-480]. In response to hypoxia, retinal cells release various growth 
factors which produce paracrine effects, resulting in angiogenesis, fibro vascular tissue 
formation, retinal ablation and ultimately loss of vision. Inspite of recent advances in therapeutic 
intervention for these diseases, currently available agents demonstrate only modest effects. It 
could be attributed to cascade of reactions underlying hypoxia signaling. Since drug disposition 
is predominantly regulated by membrane transporters, evaluating the molecular response of 
efflux and influx transporters to reduced oxygen levels is of considerable interest. Efflux 
transporters such as P-glycoprotein (P-gp/MDR1), multidrug resistance protein 2 (MRP2), breast 
cancer resistant protein (BCRP) are the leading membrane bound protein families in both 
prokaryotes and eukaryotes. These proteins are also referred as ATP binding cassette (ABC) 
transporters since these efflux pumps derive energy from ATP hydrolysis. Expression and 
functional activity of various efflux transporters was characterized on human and rabbit retinal 
cells [481, 482]. These efflux pumps are mainly responsible for extruding molecules out of 
cytoplasm. In order to facilitate enhanced cellular absorption and evasion of efflux transporters, 
several strategies were examined [483-485]. One of such approaches include utilization of influx 
transporters such as neutral and cationic amino acid transporter (B
 (0, +)
), folate receptor-alpha 
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(FR-α) and sodium dependent multivitamin transporter (SMVT). B (0, +) is an amino acid 
transporter which recognizes neutral as well as cationic amino acids for membrane translocation. 
FR-α is a membrane receptor anchored to the plasma membrane by glycosylphosphatidylinositol 
(GPI), with greater affinity for folic acid and reduced forms such as methyltetrahydrofolate [486, 
487]. SMVT is an important transmembrane protein responsible for translocation of vitamins and 
other essential cofactors such as biotin, pantothenic acid and lipoic acid [488]. The role of these 
influx transporters in ocular drug delivery has also been explored. Therefore, in this study, we 
have examined the differential expressions of efflux transporters (MDR1, MRP2 and BCRP) and 
influx transporters (B
 (0, +)
, FR-α and SMVT) in human retinal pigment epithelial (RPE) (D407 
and ARPE-19) cells under hypoxic and normoxic conditions.  
Materials and Methods 
Materials 
Human retinal pigment epithelial (D407) cells were obtained as a generous gift from Dr. 
Richard Hunt (University of South Carolina, Columbia, SC). ARPE-19 cells were procured from 
American Type Culture Collection (Manassas, VA). Dulbecco’s modified eagle’s medium 
(DMEM), DMEM: Nutrient Mixture F-12 (DMEM/F12), trypsin replacement 
(TrypLE
™
 Express), non-essential amino acids, and TRIzol® were obtained from Invitrogen 
(Carlsbad, CA). Fetal bovine serum (FBS) was purchased from Atlanta Biologicals 
(Lawrenceville, GA). Culture flasks (75 cm
2
 and 25 cm
2
growth area), 12-well plates (3.8 
cm
2
 growth area per well) and 96-well plates (0.32 cm
2
 growth area per well) were procured 
from Corning Costar Corp. (Cambridge, MA). [
14
C] Arginine (specific activity: 346 mCi/mMol), 
[
3
H] abacavir (specific activity: 40 Ci/mMol) and [
3
H] biotin (specific activity: 53.4 Ci/mMol) 
were procured from PerkinElmer (Waltham, MA). [
3
H] Digoxin (specific activity: 0.1 Ci/mMol), 
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[
3
H] folic acid (specific activity: 25.6 Ci/mMol) and [
3
H] lopinavir (specific activity: 0.5 
Ci/mMol) were purchased from Moravek Biochemicals (Brea, CA). OligodT, dNTP, M-MLV 
reverse transcriptase and CellTiter 96® aqueous non-radioactive cell proliferation assay were 
obtained from Promega Corporation (Madison, WI). Light Cycler 480® SYBR I green master 
mix was obtained from Roche Applied Science (Indianapolis, IN). Human VEGF ELISA kit was 
purchased from Thermo Fisher Scientific Inc. (Rockford, IL). Unless otherwise mentioned, all 
other chemicals were purchased from Sigma Chemicals (St. Louis, MO) and used without further 
purification.  
Cell Culture 
D407 cells (passage numbers 65-70) were employed in this study [489]. Cells were 
maintained in DMEM medium supplemented with 10% FBS (heat inactivated), 1% non-essential 
amino acids, 20 mM HEPES, 29 mM sodium bicarbonate and 100 U/mL of penicillin and 100 
µg/mL of streptomycin. ARPE-19 cells (passage numbers 20-25) were cultured in D-MEM/F-12 
supplemented with 10% FBS (heat inactivated), 15 mM HEPES, 29 mM sodium bicarbonate, 
100 U/mL penicillin, 100 μg/mL streptomycin [490]. Cells were cultured in T-75 flasks at 37°C 
in a humidified atmosphere of 5% CO2 and 90% relative humidity. The medium was replaced 
every alternate day and passaged using TrypLE
™
 Express after reaching 80% confluency. Cells 
were seeded at a density of 1 million cells in T-25 flasks and 250,000 cells/well in 12-well 
plates. After reaching 80% confluency, cells were subjected to hypoxic conditions for a specific 
period of time in a bactron anaerobic chamber with a gas mix consisting of 1% O2, 5% CO2 and 
94% N2, following a previously published method [489, 491].  
Extraction of RNA 
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Cells cultured under hypoxic conditions were processed in the anaerobic chamber itself to 
avoid any exposure to normoxic conditions. Cells were lysed in TRIzol® reagent and the lysate 
was transferred into an eppendorf tube. To this lysate, chloroform was added to facilitate phase 
separation. The aqueous layer was separated and isopropanol was added to precipitate RNA. The 
RNA pellet obtained was washed twice with 75% ethanol and dissolved in DNase/RNase free 
water. The concentration of RNA was determined by detecting UV absorbance at 260 nm with 
Nanodrop (Thermo Fisher Scientific, Wilmington, DE). RNA (4 µg) was reverse transcribed into 
complementary DNA (cDNA) with OligodT as a template and M-MLV reverse transcriptase. 
The conditions for reverse transcription were denaturation for 5 min at 70
°
C, reverse 
transcription for 1 hour at 42
°
C and final extension for 5 min at 72
°
C. 
Quantitative Real-Time Polymerase Chain Reaction (qPCR) Studies 
Primers were custom designed with Primer-Blast tool from Pubmed and listed in Table 
10. All the primers were designed such that 100-150 bp long amplicons could be generated to 
increase the efficiency of amplification. For quantitative gene expression analysis, 80 µg of 
cDNA was amplified using 10 µM of forward and reverse primers and Light Cycler 480® SYBR
 
I green master mix using ABI Prism 5700 Sequence Detection System (Applied Biosystems, 
CA). The reactions were carried out with initial denaturation at 70
°
C for 5 min, followed by 45 
cycles of denaturation at 95
°
C for 10 sec, annealing at 55
°
C for 10 sec and extension at 72
°
C for 
10 sec. The specificity of PCR products was confirmed by melting curve analysis. Relative 
amount of RNA levels was normalized to the internal standard GAPDH (glyceraldehyde 3-
phosphate dehydrogenase) in each sample. GAPDH was selected as an internal control from 
previously published results [492]. Initial experiments were carried out to ensure that the target 
and control genes were amplified with equal efficiencies. 
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Table 10. Primers used in quantitative gene expression analysis. Sequence is given from 5'->3'. 
Gene Forward primer Reverse primer 
GAPDH ATCCCTCCAAAATCAAGTGG GTTGTCATGGATGACCTTGG 
MDR1 CTTATGCTCTGGCCTTCTGG TGCTTCAATGCTTGGAGATG 
MRP2 AAATATTTTGCCTGGGAACC TGTGACCACAGATACCAGGA 
BCRP AGCTGCAAGGAAAGATCCAA TGCCCATCACAACATCATCT 
B 
(0, +)
 AGCCGAGGGAGTGAACCATG GGACCAGTTACCACGGTCCT 
FR-α AGGACAGACATGGCTCAGCG TGTGGTGCTTGGCGTTCATG 
SMVT TACCAGTTCTGCCAGCCACAGTG CAGGGACACCAAAACCTCCCTCT 
HIF-1α GTACCCTAACTAGCCGAGGAAGAA GTGAATGTGGCCTGTGCAGT 
VEGF CTTGCCTTGCTGCTCTAC TGGCTTGAAGATGTACTCG 
GLUT-1 CGGGCCAAGAGTGTGCTAAA TGACGATACCGGAGCCAATG 
PEPT1 CAAGAAGTTCAAGCCACAGG GAAATGCCTTACTCCGATGC 
PEPT2 CCTTCAGCAGCCTCTGTTAT AGGACTGTGTGTACCACTTG 
OCT1 GTGGGATAATCACCCCCTTC TCTGGAAGAAGTAGCGTCAC 
OCT2 TTGGCTCTATGAGTATCGGC AGGACTGTAGTTAGGAGGCA 
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Enzyme-Linked Immunosorbent Assay (ELISA)  
A sandwich ELISA was performed to determine the amount of VEGF secreted in cell 
culture medium post exposure to normoxic and hypoxic conditions, following manufacturer’s 
instructions. Briefly, an anti-human VEGF165 antibody was precoated to the 96-well microplate. 
The samples/standards (50 µL) were added to the wells and incubated for 2 hours. After 
removing unbound antigen, biotinylated secondary detecting antibody (100 µL) was added and 
further incubated for 1 hour. Excess detecting antibody was removed and streptavidin - 
horseradish peroxidase (HRP) was added which subsequently reacts with TMB (3,3′,5,5′-
tetramethylbenzidine) substrate to produce a colorimetric signal. This signal was estimated by 
detecting the absorbance at 450 nm using a plate spectrophotometer (SpectraFluor Plus, 
Maennedorf, Switzerland). 
Immunoblot Analysis 
Following growth under normoxic and hypoxic conditions, cells were washed with PBS 
(3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl and 135 mM NaCl) and lysed in PBS with 
1% Triton X-100 and protease inhibitor cocktail maintained at pH 7.4, for 15-20 min on ice. 
Upon homogenization, cells were centrifuged at 12,000 rpm for 10 min and the protein lysate 
was collected. The amount of protein in the lysate was determined using Bio-Rad protein 
estimation kit (Bio-Rad, Hercules, CA) using bovine serum albumin (BSA) as the standard. An 
equal amount of protein (20 μg) in all samples was separated using poly acrylamide gel 
electrophoresis (PAGE). The separated protein bands were transferred onto a polyvinylidene 
difluoride (PVDF) membrane and blocked overnight at 4
°
C with 2% non-fat dry milk and 0.25% 
BSA prepared in 0.05 M tris buffered saline. The blot was exposed to primary antibody at 25
°
C 
for 4 hours. After subsequent washes the blot was again exposed to secondary antibody-HRP 
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conjugate for 1 hour. The blot was visualized for the protein of interest using chemiluminescent 
substrate in chemiImager 8900 (AlphaInnotech, San Leandro, CA). 
Uptake Studies 
Uptake studies were performed on confluent cell monolayers cultured in 12-well plates. 
Uptake experiments for hypoxic conditions were performed in the anaerobic chamber itself to 
prevent cell exposure to normal oxygen levels during the study. After culturing in normoxic or 
hypoxic conditions, the medium was removed and cells were washed three times with 1 mL of 
dulbecco’s phosphate buffered saline (DPBS) (130 mM NaCl, 0.03 mM KCl, 7.5 mM Na2HPO4, 
1.5 mM KH2PO4, 1 mM CaCl2, 0.5 mM MgSO4, 20 mM HEPES and 5 mM glucose) maintained 
at pH 7.4. Test solution (500 µL) was added and cells were incubated for 30 min at 37
°
C. Uptake 
was arrested with ice cold PBS and 1 mL of lysis solution (0.1% (v/v) Triton-X in 0.3 N NaOH) 
was added. Cells were lysed overnight and the lysate was then quantified for radioactivity with 
scintillation cocktail (Fisher Scientific, Fair Lawn, NJ) in a scintillation counter 
BeckmanCounter, Fullerton, CA). Uptake in each well was normalized to the respective protein 
content, as determined by Bio-Rad protein estimation kit (Bio-Rad, Hercules, CA). [
3
H] Digoxin, 
[
3
H] lopinavir and [
3
H] abacavir were used as model substrates for MDR1, MRP2 and BCRP 
mediated transport respectively. [
14
C] Arginine, [
3
H] folic acid and [
3
H] biotin were used as 
model influx transporter substrates for B 
(0, +)
, FR-α and SMVT respectively. 
Cell Proliferative Assay 
A cell proliferative assay (MTS assay) was performed to determine the effect of hypoxia 
on RPE cells. Post exposure to normoxic or hypoxic conditions, medium was aspirated and 100 
µL of serum free media and 20 µL of MTS and PMS reagent were added. Following incubation 
for 3 hours, the quantity of formazan formed from MTS is measured at 490 nm using a plate 
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spectrophotometer. The amount of formazan formed is directly proportional to the number of 
viable cells.  
Data and Statistical Analysis  
Relative expression of each gene was quantified following delta-delta (ΔΔCt) method 
according to Eq.s 1, 2 and 3 
                                        Eq.1 
Treated represents hypoxic samples and control represents normoxic samples 
                       Eq.2 
Target gene represents either MDR1, MRP2, BCRP, B
 (0, +)
, FR-α, SMVT, HIF-1α, VEGF or 
GLUT-1 and reference gene represents GAPDH. Relative fold expression is calculated according 
to Eq.3 
                                             Eq.3 
Cellular accumulation of radioactive substrates was calculated with Eq.4 
                                         Eq.4 
DPM represents disintegrations per min and C represents concentration.  
All the experiments were performed in quadruplicates. The results are expressed as mean 
± standard deviation (SD). One way analysis of variance (ANOVA) or student’s t test (Graph 
Pad InStat Version 4.0) was performed to confirm statistical significance of the experimental 
values. A P-value of less than 0.05 was considered to be statistically significant. 
Results 
Quantitative Gene Expression Analysis 
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Among the different cell culture models of retinal pigment epithelial cells, D407 and 
ARPE-19 cells were selected for their expression of efflux and influx transporters [481, 493-
495]. Further, both these cells induce VEGF expression under hypoxic conditions [496, 497]. 
Both D407 and ARPE-19 cells represent RPE with respect to epithelial morphology, transporter 
expression and polarization [490, 498]. D407 cells were cultured for 3, 6, 12, 24, 48 and 72 
hours under both normoxic and hypoxic conditions to determine the optimum time for induction 
of membrane transporters. RNA was extracted and cDNA was synthesized. Real-time PCR 
analysis was performed to determine the quantitative gene expression levels of efflux 
transporters (MDR1, MRP2 and BCRP), influx transporters (B
 (0, +)
, FR-α, and SMVT), hypoxic 
regulator (HIF-1α) and hypoxic markers (VEGF and GLUT-1).  
Expression of Efflux Transporters: MDR1 expression did not change significantly 
following exposure to hypoxic conditions for 3 and 6 hours. The expression was elevated to 
almost 2.5 fold within 12 hours of hypoxic exposure which was maintained for over 72 hours. 
The expression of MRP2 remained the same within 3 hours of hypoxic exposure. Once again 
expression level was significantly induced from 6 to 24 hours, with highest induction noticed at 
24 hours and then an attenuation of MRP2 mRNA levels was observed within 48 and 72 hours. 
Exposure to hypoxia for 3 and 6 hours did not alter the expression levels of BCRP. A significant 
rise in BCRP expression was evident when cells were exposed to hypoxia for 12 (2.5 fold) and 
24 hours (3.1 fold). A sudden drop in RNA expression compared to control levels was observed 
as time progressed from 48 to 72 hours (Figure 45).  
Expression of Influx Transporters: The expression levels of influx transporters- B
 (0, +)
, 
FR-α, and SMVT did not rise significantly following hypoxic exposure over 3 and 6 hours. The 
expression level of B
 (0, +)
 was induced by 2 fold upon hypoxic exposure for 12 and 24 hours and 
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then dropped to basal levels upon prolonged exposure to 72 hours. FR-α showed incremental 
induction as hypoxic exposure was prolonged. A maximum of 3 fold induction was observed in 
48 to 72 hours. The expression level of SMVT elevated to 2.5 fold after 12 hours and reached to 
a peak of 4 fold with 24 hours of hypoxic exposure. Interestingly, prolonged exposure to hypoxia 
dramatically reduced SMVT expression to basal levels (Figure 46). Among all the time points 
studied, hypoxic exposure to 24 hours demonstrated elevated RNA expression levels of efflux 
and influx transporters, HIF-1α, VEGF and GLUT-1 in D407 cells. Therefore, 24 hour exposure 
duration was selected for all subsequent studies.  
With these promising results, ARPE-19 cells were exposed to hypoxia for 24 hours. A 
similar trend in RNA expression levels of efflux and influx transporters, HIF-1α, VEGF and 
GLUT-1 was also noticed in ARPE-19 (Figure 47).  
ELISA 
The exposed cell culture medium was collected and assayed to determine the amount of 
VEGF secreted, using sandwich ELISA method. This assay can detect different concentrations of 
VEGF varying from 31.25 - 2000 pg/mL (R
2
 = 0.99). From this standard graph, the 
concentration of VEGF in D407 normoxic conditions was calculated to be 272.83 ± 25.69 
pg/mL. However, exposure to hypoxia for 24 hours increased the concentration of VEGF to 
583.83 ± 14.84 pg/mL (2 fold increase). Similarly, the concentration of VEGF in ARPE-19 cells 
increased to 329.33 ± 14.14 pg/mL (3.5 fold increase) in hypoxic conditions compared to 93.66 
± 11.83 pg/mL in normoxic conditions (Figure 48). The induction observed at the RNA level for 
VEGF was well correlated with the values obtained from ELISA. 
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Figure 45. Relative fold RNA expression of various efflux transporters (A) MDR1, (B) MRP2 
and (C) BCRP in D407 cells exposed to hypoxic conditions for various time points (3, 6, 12, 24, 
48 and 72 hours). Values represent mean ± SD. * represents statistical significance from control 
at P-value of <0.05. 
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Figure 46. Relative fold RNA expression of various influx transporters (A) B
 (0, +)
, (B) FR-α and 
(C) SMVT in D407 cells exposed to hypoxic conditions for various time points (3, 6, 12, 24, 48 
and 72 hours). Values represent mean ± SD. * represents statistical significance from control at 
P-value of <0.05. 
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Figure 47. Relative fold RNA expression of efflux transporters (MDR1, MRP2 and BCRP), 
influx transporters (B
 (0, +)
, FR-α and SMVT) and hypoxic markers (HIF-1α, VEGF and GLUT-1) 
post hypoxic exposure for 24 hours in (A) D407 and (B) ARPE-19 cells. Values represent mean 
± SD. * represents statistical significance from control at P-value of <0.05. 
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Figure 48. Sandwich ELISA measuring (A) absorbance at 450 nm post exposure to different 
concentrations of VEGF standards (31.25 - 2000 pg/mL), (B) concentration of VEGF in D407 
cell culture supernatant post exposure to normoxic and hypoxic conditions (24 hours) and (C) 
concentration of VEGF in ARPE-19 cell culture supernatant post exposure to normoxic and 
hypoxic conditions (24 hours). Values represent mean ± SD. * represents statistical significance 
from control at P-value of <0.05. 
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Immunoblot Analysis 
Immunoblot analysis was performed to evaluate if the induction in gene expression levels 
correlate with protein expression on exposure to hypoxia. Since BCRP and SMVT were highly 
upregulated as evident from qPCR analysis, these two transporters were examined for their 
protein expression. RPE cells were cultured for 24 hours in both normoxic and hypoxic 
conditions. Total protein was extracted, separated using PAGE and amount of specific protein 
was determined using antibody staining. The protein level of β-actin was measured as a loading 
control during the experiment. Both the proteins BCRP and SMVT demonstrated significant 
induction in hypoxic relative to normoxic conditions in both D407 and ARPE-19 cells (Figure 
49). The induction observed at the protein level for representative efflux and influx transporters 
correlated well with the mRNA change observed in qPCR analysis. 
Uptake Studies 
Uptake of Efflux Transporter Substrates: [
3
H] Digoxin, [
3
H] lopinavir and [
3
H] abacavir 
were used as model substrates to study MDR1, MRP2 and BCRP mediated efflux, respectively.  
A significant decrease in cellular accumulation of these substrates in hypoxic conditions was 
evident in D407 cells. Uptake of [
3
H] digoxin and [
3
H] lopinavir was lower by 30% and 25%, 
respectively. Notably, a 65% reduction in uptake of [
3
H] abacavir was noticed. In ARPE-19 
cells, uptake of [
3
H] digoxin, [
3
H] lopinavir and [
3
H] abacavir was reduced by 25%, 30% and 
55%, respectively. This data confirms increased activity of efflux transporters under hypoxic 
conditions in both the cells (Figure 50).  
Uptake of Influx Transporter Substrates: [
14
C] Arginine, [
3
H] folic acid and [
3
H] biotin 
were employed as model influx substrates to study the functional activity of B
 (0, +)
, FR-α, and 
SMVT respectively. [
14
C] Arginine demonstrated 85% rise in cellular accumulation under 
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hypoxic conditions in D407 cells. [
3
H] Folic acid and [
3
H] biotin also exhibited an elevation in 
cellular uptake in hypoxic conditions by 40% and 50%, respectively. Uptake of all the three 
influx transporter substrates raised by 65%, 60% and 40%, respectively in ARPE-19 cells 
exposed to hypoxia for 24 hours. This study demonstrates the enhanced activity of influx 
transporters under hypoxic conditions (Figure 51). 
Cell Proliferation Assay 
 MTS assay was performed to examine the cytotoxicity of cells post exposure to hypoxic 
conditions (24 hours). RPE cells (D407 and ARPE-19) did not exhibit any significant cell death 
(Figure 52). 
Discussion 
Deficiencies in oxygenation (hypoxia) stimulate the expression of proangiogenic factors 
leading to the development of neovascularization in retinal diseases [375]. In the past decade, 
significant research has been conducted to comprehend the pathogenesis and genetics of oxygen-
dependent retinal diseases. Most of the therapies aimed at inhibiting this pathway demonstrated 
partial success owing to the underlying complex multifactorial signaling process. Significant 
attention has not been paid to transporter expression during retinal hypoxic complications, 
regardless of their potential value in drug absorption. Therefore, the aim of this study was to 
examine the changes in molecular expression and functional activity of efflux and influx 
transporters under hypoxic conditions in retinal pigment epithelial cells (D407 and ARPE-19 
cells). These observations would be helpful for predicting drug accumulation in ocular tissues 
under hypoxic conditions.  
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Figure 49. Immunoblot analysis showing the protein expression of BCRP and SMVT in (A) 
D407 and (B) ARPE-19 cells post exposure to normoxic and hypoxic conditions (24 hours). β-
actin was used as an internal control. 
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Figure 50. Uptake of efflux transporter substrates [
3
H] digoxin, [
3
H] lopinavir and [
3
H] abacavir 
in (A) D407 and (B) ARPE-19 cells post exposure to normoxic and hypoxic conditions (24 
hours). Values represent mean ± SD. * represents statistical significance from control at P-value 
of <0.05. 
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Figure 51. Uptake of influx transporter substrates [
14
C] arginine, [
3
H] folic acid and [
3
H] biotin 
in (A) D407 and (B) ARPE-19 cells post exposure to normoxic and hypoxic conditions (24 
hours). Values represent mean ± SD. * represents statistical significance from control at P-value 
of <0.05. 
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Figure 52. Cell proliferation assay of D407 and ARPE-19 cells post exposure to normoxic and 
hypoxic conditions (24 hours). Values represent mean ± SD. 
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Real time-PCR studies revealed that RNA levels of efflux transporters were strongly 
induced in hypoxic cells. Exposure of D407 cells induced the expression of MDR1 gene levels 
after 12 hours and continued induction upto 72 hours. These results are consistent with earlier 
studies which demonstrated that the basal expression of MDR1 is indeed regulated by HIF-1α 
[67]. The expression of MRP2 in hypoxic cells was upregulated after incubation from 6 to 24 
hours, with the differences being statistically significant. However, such induction of MRP2 
expression was diminished after continuous exposure to hypoxia for 48 and 72 hours. Also, a 
similar trend was observed for BCRP expression in D407 cells. These results suggest that the 
induction of both MRP2 and BCRP genes at hypoxic state was transient. Elevation in BCRP 
levels was also suggested to be upregulated by HIF- α, thus conferring a survival advantage 
under hypoxic conditions [66, 499, 500]. Cheng et al. have identified a region within BCRP 
promoter site in close proximity to the reported HIF-1α response element, which is responsible 
for regulation of BCRP via HIF-1α [501]. BCRP has also been reported to play a major role in 
heme and folate homeostasis, which may help in cell survival under hypoxic conditions. Thus, 
malignant or diseased cells may utilize the over expressing efflux transporters to survive against 
hypoxic stress [132, 133].  
Besides efflux transporters, the expression level of influx transporters including B
 (0, +)
, 
FR-α, and SMVT were also examined in these studies. Elevated expression of B (0, +), FR-α, and 
SMVT after hypoxic exposure suggest that these transporters are also susceptible to oxygen 
tension. It appears that cells exposed to hypoxic stress may require high intake of amino acids, 
vitamins and other nutrients as compared to normal cells. This requirement is generally met by 
acquisition of genetic mutations that functionally alter receptor-initiated signaling pathways in 
malignant or diseased cells. Consequently such pathways aid in activating the uptake and 
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metabolism of amino acids, vitamins and other nutrients necessary for promotion of cell survival 
and growth. Enhanced expression of nutrient transporters occurs as a result of adaptive response 
to hypoxic insult [502, 503]. Apart from B
 (0, +)
, FR-α, and SMVT, other influx transporters 
including peptide transporters (PEPT1 and PEPT2) and organic cation transporters (OCT1 and 
OCT2) are also identified on RPE cells and their importance in ocular drug disposition has been 
documented in literature [504]. Hence, a preliminary study was conducted to evaluate the 
differential expression of PEPT1, PEPT2, OCT1 and OCT2 in hypoxic conditions. Surprisingly, 
RNA expression of PEPT1 and PEPT2 did not alter significantly while the expression of OCT1 
and OCT2 was downregulated in RPE cells following 24 hours of hypoxic exposure (Figure 53). 
OCTs play an important role in the transport of ionic drug molecules across ocular 
barriers. Consistent with our results, Kadam RS and colleagues have demonstrated that hypoxia 
downregulates OCT mRNA expression in rat choroid-retina. Also, the apparent permeability of 
MPP
+ 
(OCT substrate) across hypoxic calf’s sclera-chorid-RPE and cornea was diminished by 
61% and 49%, respectively. This study suggests that both the expression and functional activity 
of OCTs were significantly reduced in ocular tissues under chronic hypoxic conditions [505]. 
Literature also reports that the expression of organic cation/carnitine transporter 1 (OCTN1) is 
reduced under hypoxic conditions. Also, decreased carnitine (OCTN1 substrate) uptake is 
evident in placental explants and BeWo cells under hypoxia. The study suggests that hypoxia 
plays an important role in the regulation of OCTN expression, probably via regulation of 
transcriptional factor - PPARα and its DNA-binding partner - RXRα [506].  
A sandwich ELISA assay confirmed the increased secretion of VEGF during hypoxic 
conditions. This assay further validates the hypoxic conditions used in our studies. Results from 
immunoblot analysis further indicated that the RNA expression of these transporters is being 
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well translated to protein expression. Results from gene expression studies were further 
confirmed by performing uptake studies to delineate the functional activity of various 
transporters in hypoxic conditions. Lower uptake of [
3
H] digoxin, [
3
H] lopinavir and [
3
H] 
abacavir was observed as a result of elevated efflux by MDR1, MRP2 and BCRP, respectively in 
RPE cells. This decrease in intracellular accumulation of radiolabeled substrates suggested that 
hypoxia may inhibit the uptake of various active molecules that are substrates of efflux 
transporters. An interesting observation was that uptake of [
3
H] abacavir was reduced to a greater 
degree in cells exposed to hypoxia for 24 hours suggesting that BCRP is more susceptible to 
hypoxic stress compared to MDR1 and MRP2. 
We also examined the functional activity of influx transport systems-B
 (0, +)
, FR-α and 
SMVT by measuring uptake of [
14
C] arginine, [
3
H] folic acid and [
3
H] biotin, respectively. 
Enhanced uptake of these substrates suggest that rise in cellular accumulation may be due to 
induction of B
 (0, +)
, FR-α and SMVT respectively, further confirming the results from gene 
expression studies. [
14
C] Arginine accumulation was higher compared to [
3
H] folic acid and [
3
H] 
biotin in both the RPE cells, suggesting that B 
(0, +)
 transporter is functionally more active under 
hypoxic conditions relative to FR-α and SMVT. However, data from gene expression analysis 
revealed that SMVT is highly induced compared to B 
(0, +)
 and FR-α. The discrepancy can be 
attributed to posttranscriptional modifications of the respective protein. MTS assay was carried 
out to check cell proliferation under normoxic and hypoxic conditions. Results from this assay 
revealed that hypoxic insult for 24 hours did not induce RPE cell death. This result is consistent 
with earlier report in which another human RPE cell line (R-50) did not exhibit any cytotoxic 
effects even after 48 hours of hypoxic exposure [507].  
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Figure 53. Relative fold RNA expression of peptide transporters (PEPT1 and PEPT2) and 
organic cation transporters (OCT1 and OCT2) post hypoxic exposure for 24 hours in (A) D407 
and (B) ARPE-19 cells. Values represent mean ± SD. * represents statistical significance from 
control at P-value of <0.05. 
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Conclusions 
In conclusion, this study demonstrates for the first time that hypoxic conditions alter 
expression levels of efflux and influx transporters in human RPE cells. These molecular and 
functional alterations in the expression of membrane transporters/receptors may facilitate cell 
survival and growth under hypoxic conditions. Also, hypoxic conditions in retinal diseases may 
alter cellular accumulation of various molecules targeted to ocular tissues. Better knowledge of 
physiological and pathological conditions of hypoxia induced disorders offers a promising 
approach for effective ocular drug delivery. 
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CHAPTER 7 
RITONAVIR INHIBITS HIF-1α MEDIATED VEGF EXPRESSION IN RETINAL PIGMENT 
EPITHELIAL CELLS 
Rationale 
Retina is the most metabolically active tissue and consumes more oxygen than any other 
tissue in the human body [508]. Retinal hypoxia (oxygen deficiency) leading to angiogenesis is a 
major pathological condition underlying a number of sight threatening diseases including 
diabetic retinopathy (DR), retinopathy of prematurity (ROP), age-related macular degeneration 
(AMD), and neovascular glaucoma [375]. In response to hypoxia, retinal pigment epithelial 
(RPE) cells release various growth factors resulting in angiogenesis, fibro vascular tissue 
formation, retinal ablation and ultimately loss of vision. This response is mediated via the 
transcriptional regulator hypoxia-inducible factor (HIF). It is a heterodimeric complex consisting 
of hypoxically stabilized subunit (HIF-1α) and stable nuclear subunit (HIF-1β/ARNT). In 
normoxic conditions, HIF-1α protein is rapidly hydroxylated on proline residues by 2-
oxoglutarate dependent oxygenases. Post hydroxylation, von Hippel-Lindau tumor suppressor 
protein (pVHL) marks HIF-1α for E3 ubiquitin ligase mediated proteosomal degradation. Under 
hypoxic conditions, hydroxylation is inhibited leading to nuclear translocation of HIF-1α and 
subsequent dimerization with HIF-1β. This transcriptionally active complex recruits several 
coactivators and modulates the gene expression of various target genes by binding to hypoxia 
response element (HRE) [474, 475, 509].  
To date, more than hundred HIF target genes have been identified, many of which play a 
critical role in mediating angiogenesis, vascular tone, glucose and iron metabolism, cellular 
differentiation, invasion/metastasis, apoptosis and maintenance of stem cells [510-512]. Few 
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important target genes include vascular endothelial growth factor (VEGF), angiopoietin 2, 
platelet-derived growth factor-B (PDGF-B), placental growth factor (PGF) and erythropoietin 
(EPO) [374]. Many investigations have demonstrated that VEGF is a common denominator 
promoting ocular angiogenesis. It is a predominant mitogen promoting vascular endothelial cell 
proliferation and migration [352, 374]. Currently available anti-VEGF therapeutics for the 
treatment of ocular neovascular diseases includes pegaptanib (Macugen), bevacizumab 
(Avastin®) and ranibizumab (Lucentis®). Pegaptanib is a 28-base RNA aptamer, bevacizumab 
is a humanized monoclonal antibody while ranibizumab is an antibody binding fragment of the 
former. All these molecules bind to secreted VEGF and prevent its interaction with VEGF 
receptors [280, 513, 514]. These molecules are administered repeatedly at very high doses. 
Intravitreal injections of these antagonists resulted in serious complications such as 
endophthalmitis, vitreous hemorrhage and retinal detachment. Further, systemic side effects also 
warrant their utility in the treatment of ocular diseases [515, 516]. Hence, therapeutic molecules 
that aim at inhibiting the signaling mechanisms underlying neovascularization (HIF-pathway) 
appear to have promising antiangiogenic roles with fewer side effects. 
Resurgent interest is directed towards identifying new implications of existing drugs, 
rather than discovering new molecules. This process of drug repositioning can limit the 
associated cost and expedite the time required from bench to bedside transition of therapeutic 
molecules. Ritonavir, a HIV protease inhibitor exhibits antineoplastic effects independent from 
its ability to inhibit HIV protease [279-281]. Also, research has demonstrated that ritonavir can 
inhibit angiogenesis in Kaposi sarcoma, head and neck carcinoma [282, 517]. However, the 
inhibitory potency of ritonavir on HIF pathway and de novo synthesized VEGF in retinal tissues 
have not been so far investigated. Hence, the primary objective of this study was to investigate 
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the expression of HIF-1α and VEGF in human RPE cells (ARPE-19 and D407) treated with 
ritonavir under hypoxic and normoxic conditions. These results may assist in understanding the 
molecular mechanism of VEGF inhibition by ritonavir. Further, inhibition of VEGF via HIF 
pathway may serve the possibility of using ritonavir in the treatment of various ocular angiogenic 
diseases.  
Materials and Methods 
Materials 
ARPE-19 and RF/6A cells were procured from American Type Culture Collection 
(Manassas, VA). D407 cells were obtained as a generous gift from Dr. Richard Hunt (University 
of South Carolina). Ritonavir was obtained from Sigma Chemicals (St. Louis, MO). Dulbecco’s 
modified eagle’s medium (DMEM), DMEM: Nutrient Mixture F-12 (DMEM/F12), RPMI1640, 
trypsin replacement (TrypLE™ Express), non-essential amino acids, and TRIzol®, and custom 
designed primers were purchased from Invitrogen (Carlsbad, CA). Fetal bovine serum (FBS) was 
obtained from Atlanta Biologicals (Lawrenceville, GA). Culture flasks (75 cm
2
 and 25 cm
2
 
growth area) and 96-well plates (0.3 cm
2
 growth area per well) were procured from Corning 
Incorporated (Cambridge, MA). The reagents for cDNA synthesis (OligodT, dNTP, M-MLV 
reverse transcriptase) and CellTiter 96® aqueous non-radioactive cell proliferation assay were 
supplied by Promega Corporation (Madison, WI). Light Cycler 480® SYBR I green master mix 
was obtained from Roche Applied Science (Indianapolis, IN). BCA protein assay reagent and 
human VEGF ELISA kit were purchased from Thermo Fisher Scientific Inc (Rockford, IL). 
Unless otherwise mentioned, all other chemicals were purchased from Sigma Chemicals and 
used without further purification.  
Cell Culture 
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ARPE-19 cells (passage numbers 25-30) were cultured in D-MEM/F-12 supplemented 
with 10% FBS (heat inactivated), 15 mM HEPES, 29 mM sodium bicarbonate, 100 U/mL 
penicillin and 100 μg/mL streptomycin. D407 cells (passage numbers 65-70) were maintained in 
DMEM medium supplemented with 10% FBS (heat inactivated), 1% non-essential amino acids, 
20 mM HEPES, 29 mM sodium bicarbonate and 100 U/mL of penicillin and 100 µg/ml of 
streptomycin. RF/6A cells (passage numbers 5-10) were cultured using RPMI1640 supplemented 
with 10% FBS, 100 U/mL of penicillin and 100 µg/mL of streptomycin. All the cells were 
maintained in a humidified atmosphere of 5% CO2 and 90% relative humidity at 37
°
C in T-75 
flasks. The medium was replaced every alternate day and cells were passaged using TrypLE™ 
Express after reaching ~80% confluency. Cells were seeded at a density of 1 million cells in T-
25 flasks. After reaching ~80% confluency, cells were subjected to hypoxic conditions in a 
bactron anaerobic chamber with a special gas mix (1% O2, 5% CO2 and 94% N2) for specified 
time periods following a previously published method [489]. Cells cultured under hypoxic 
conditions were processed in the chamber itself to avoid any exposure to normoxic conditions. 
Extraction of RNA 
RNA was extracted using the standard phenol-chloroform-isopropanol method. Briefly, 
cells were lysed in TRIzol® reagent and the lysate was transferred into an eppendorf tube. To 
facilitate phase separation, chloroform was added to lysate. The aqueous layer containing RNA 
was separated and isopropanol was added to precipitate RNA. RNA pellet was washed twice 
with 75% ethanol and dissolved in DNase/RNase free water. The concentration of RNA was 
estimated by detecting UV absorbance at 260 nm with Nanodrop (Thermo Fisher Scientific, 
Wilmington, DE). Reverse transcription of RNA (4 µg) into complementary DNA (cDNA) was 
carried out with OligodT as a template and M-MLV reverse transcriptase. The conditions for 
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reverse transcription include denaturation for 5 min at 70
°
C, reverse transcription for 1 hour at 
42
°
C and final extension for 5 min at 72
°
C. 
Quantitative Real-Time Polymerase Chain Reaction (qPCR) Studies 
For quantitative gene expression analysis, 80 µg of cDNA was amplified for specific 
genes with corresponding forward and reverse primers (10 µM) and SYBR green master mix 
using ABI Prism 5700 Sequence Detection System (Applied Biosystems, CA). Primers were 
designed with Primer-Blast tool from Pubmed. β-actin was selected as an internal standard in all 
the samples The sequences of the primers are as follows: β-actin forward 5’- 
GCATTGCTTTCGTGTAAATTATGT-3’ reverse 5’- ACCAAAAGCCTTCATACATCTCA-3’;  
HIF-1α forward 5’-GTACCCTAACTAGCCGAGGAAGAA -3’ reverse 5’-
GTGAATGTGGCCTGTGCAGT-3’; VEGFA forward 5’- CTTGCCTTGCTGCTCTAC-3’ 
reverse 5’-TGGCTTGAAGATGTACTCG-3’. The reactions were carried out with initial 
denaturation at 70
°
C for 5 min, followed by 45 cycles of denaturation at 95
°
C for 10 sec, 
annealing at 55
°
C for 10 sec and extension at 72
°
C for 10 sec. Melting curve analysis was used to 
check the specificity of PCR products. The relative fold mRNA expression in treated vs control 
samples was quantified by comparative threshold method as mentioned in data analysis section.  
Immunoblot Analysis 
Following exposure to normoxic and hypoxic conditions, cells were washed with PBS 
(3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl and 135 mM NaCl). Protein was extracted 
using radio immunoprecipitation assay (RIPA) buffer and protease inhibitor cocktail at pH 7.4. 
The amount of protein in the lysate was quantified using BCA protein assay kit. An equal 
amount of protein (20 μg) in all samples was separated using poly acrylamide gel electrophoresis 
(PAGE). The separated protein bands were transferred onto a polyvinylidene difluoride (PVDF) 
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membrane and blocked for 2 hours with 5% non-fat dry milk prepared in 0.05 M tris buffered 
saline. The blot was exposed overnight at 4
°
C to primary antibody. After subsequent washes, the 
blot was exposed to secondary antibody conjugated with horseradish peroxidase (HRP) for 2 
hours. Finally, the blot was visualized for the protein of interest using chemiluminescent 
substrate in ChemiImager 8900 (Alpha Innotech, San Leandro, CA). 
Enzyme-Linked Immunosorbent Assay (ELISA)  
The amount of VEGF secreted into the culture medium post exposure to normoxic or 
hypoxic conditions was estimated by performing a sandwich ELISA, following manufacturer’s 
instructions. An anti-human VEGF165 antibody was precoated to the 96-well microplate. The 
samples/standards (50 µL) were added to the antibody coated wells and incubated for 2 hours. 
Unbound antigen was washed, followed by addition of biotinylated secondary detecting antibody 
(100 µL) and subsequent incubation for 1 hour. Excess detecting antibody was removed and 
streptavidin-HRP was added. It reacts with TMB (3,3′,5,5′-tetramethylbenzidine) substrate to 
produce a colorimetric signal. This signal was detected by measuring the absorbance at 450 nm 
using a plate spectrophotometer (SpectraFluor Plus, Maennedorf, Switzerland). 
Cell Proliferation Assay  
Relative proliferation of choroid-retinal endothelial cells (RF/6A) was determined using 
spent culture medium of ARPE-19 and D407 cells exposed to hypoxic or normoxic conditions, 
following a previously published method  [518]. Briefly, RF/6A cells were seeded in a 96-well 
plate at a density of 5000 cells/well. Following 24 hours of seeding, cells were serum-starved 
overnight. Later, cells were treated for 24 hours with medium collected from either normoxic or 
hypoxic conditions. Subsequently, solutions were aspirated and 100 µL of serum free medium 
was added. Twenty microliters of MTS and PMS reagent was then added to wells. After 
164 
 
incubating for 4 hours, the quantity of formazan formed from MTS was measured at 490 nm 
using a plate reader.  
Cytotoxicity Assay  
A cytotoxicity assay was performed to determine the possible toxic effect of ritonavir on 
ARPE-19 and D407 cells. Briefly, RPE cells were seeded in a 96-well plate at a density of 10000 
cells/well. Following 24 hours of seeding, cells were exposed to either normoxic or hypoxic 
conditions in the absence or presence of three different concentrations of ritonavir for 12 hours. 
The solutions were aspirated and cytotoxicity was determined using MTS and PMS reagents as 
described above.  
Data and Statistical Analysis 
Relative expression of each gene was quantified by delta-delta (ΔΔCt) analysis following 
previously published method [277]. All the experiments were performed in biological duplicates 
and experimental quadruplicates. Results were expressed as mean ± standard deviation (SD). 
Statistical significance between experimental values was checked by performing one way 
analysis of variance (ANOVA) or student’s t test (Graph Pad InStat Version 4.0). A P-value of 
less than 0.05 was considered to be statistically significant and represented by *. 
Results 
Quantitative Gene Expression Analysis 
Two RPE cell culture models (ARPE-19 and D407) were selected. Cells were exposed to 
normoxic and hypoxic conditions for 3, 6 and 12 hours. The expression of HIF-1α did not 
change significantly following exposure of ARPE-19 cells for 3 hours of hypoxic conditions. 
However, 6 and 12 hours of hypoxic exposure induced the expression of HIF-1α to almost 2 and 
3 fold respectively. The expression of VEGF was significantly elevated by 2.5 to 6 fold upon 
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hypoxic exposure from 3 to 12 hours. Three hours of hypoxic exposure did not alter the 
expression levels of both HIF-1α and VEGF in D407 cells. A significant rise in their expression 
was evident when cells were exposed to 6 and 12 hours of hypoxia. Among the three time points 
studied, hypoxic exposure to 12 hours demonstrated significant elevation of HIF-1α and VEGF 
mRNA expression levels in both cell lines (Figure 54). Hence, this time point was selected for 
all subsequent studies.  
To evaluate if ritonavir can inhibit HIF-1α and subsequent VEGF expression, cells were 
exposed to normoxic and hypoxic conditions in the presence or absence of ritonavir for 12 hours 
and expression levels were monitored. Three different concentrations of ritonavir (5, 10 and 20 
μM) were selected. Ritonavir did not alter mRNA expression of HIF-1α in both ARPE-19 and 
D407 cells under hypoxic conditions. Surprisingly, the presence of ritonavir strongly inhibited 
hypoxia-induced expression of VEGF in a concentration-dependent manner in ARPE-19 cells. A 
similar trend was noticed even in D407 cells; ritonavir dramatically reduced the expression of 
VEGF to basal levels (Figure 55). 
Protein Expression Analysis 
Immunoblot analysis was performed to determine HIF-1α protein expression levels. 
ARPE-19 and D407 cells were cultured for 12 hours in normoxic or hypoxic conditions in the 
absence or presence of ritonavir. In ARPE-19 cells, the normoxic expression of HIF-1α was 
negligible. The expression of HIF-1α was stabilized following 12 hours of hypoxic conditions. 
However, the presence of ritonavir (10 μM) in hypoxic conditions significantly inhibited HIF-1α 
protein expression. Similar results were also obtained in D407 cells. Exposure to hypoxia alone 
stabilized the expression of HIF-1α, while presence of ritonavir in hypoxic conditions inhibited 
HIF-1α protein translation (Figure 56).  
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Figure 54. Relative fold RNA expression of HIF-1α and VEGF in (A) ARPE-19 and (B) D407 
cells post exposure to 3, 6 and 12 hours of hypoxia. Values represent mean ± SD. * represents 
statistical significance from control at P-value of <0.05. 
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Figure 55. Relative fold mRNA expression of HIF-1α and VEGF in (A) ARPE-19 and (B) D407 
cells post exposure to hypoxia (12 hours) in the absence or presence of three different 
concentrations of ritonavir (5, 10 and 20 μM). Values represent mean ± SD. * represents 
statistical significance from control at P-value of <0.05.  
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Figure 56. Immunoblot analysis showing the protein expression of HIF-1α in (A) ARPE-19 and 
(B) D407 cells post exposure to hypoxia (12 hours) in the absence or presence of ritonavir (10 
μM). β-actin was used as an internal control. 
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Although ritonavir did not alter HIF-1α mRNA expression, the protein expression was 
significantly diminished. This study suggests that ritonavir inhibits HIF-1α synthesis only at the 
translational level. Many signaling mechanisms including receptor tyrosine kinases, 
PI3K/AKT/mTOR and Ras-MAPK pathways play a predominant role in HIF-1α translation. 
Hence, an immunoblot analysis was performed to delineate the mechanism of HIF-1α inhibition 
by ritonavir. Our study demonstrates that ritonavir decreased the level of AKT phosphorylation 
(at Ser
473
) in both ARPE-19 and D407 cells (Figure 57). Although the levels of total AKT 
remained the same, a decrease in phosphorylation resulted in inhibition of HIF-1α protein 
translation.  
Estimation of VEGF by ELISA 
ARPE-19 and D407 cells were exposed to 12 hours in normoxic or hypoxic conditions, 
either in the absence or presence of ritonavir (5, 10 and 20 μM). The exposed culture media were 
collected and analyzed for concentration of VEGF secreted, using sandwich ELISA method. This 
method was able to detect different VEGF concentrations varying from 31.25 - 2000 pg/mL with 
an estimated R
2
 value (Pearson coefficient) of 0.99. Concentration of VEGF in ARPE-19 cells 
exposed to normoxic conditions was estimated to be ~94 pg/mL. Three fold rise in VEGF 
concentration (~330 pg/mL) was noticed in cells exposed to hypoxia. Interestingly, when cells 
were exposed to hypoxia in the presence of ritonavir, there was a concentration-dependent 
decrease in the amount VEGF secreted. A similar trend was also observed in D407 cells. Post 
exposure to hypoxic conditions, concentration of VEGF increased from ~273 pg/mL to ~584 
pg/mL. However, hypoxia induced VEGF secretion was inhibited by the presence of ritonavir in 
culture medium (Figure 58). Two concentrations of ritonavir (10 and 20 μM) completely 
diminished overexpression of VEGF in hypoxic conditions. 
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Figure 57. Immunoblot analysis showing the protein expression of pAKT in (A) ARPE-19 and 
(B) D407 cells post exposure to hypoxia (12 hours) in the absence or presence of ritonavir (10 
μM). β-actin was used as an internal control. 
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Figure 58. Sandwich ELISA assay measuring concentration of VEGF in (A) ARPE-19 and (B) 
D407 cell culture supernatant post exposure to hypoxia (12 hours) in the absence or presence of 
ritonavir (5, 10 and 20 μM). Values represent mean ± SD. * represents statistical significance 
from control at P-value of <0.05. 
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Estimation of RF/6A Cell Proliferation 
RPE cells were cultured for 12 hours in normoxic or hypoxic conditions, with or without 
ritonavir (5, 10 and 20 μM). The exposed culture media were collected, sterile filtered using 0.22 
μm syringe filters and tested for their ability to induce endothelial (RF/6A) cell proliferation. 
Following serum starvation, RF/6A cells were incubated with media from ARPE-19 and D407 
cultures for 24 hours. Proliferation of endothelial cells was enhanced by 2.2 fold when treated 
with ARPE-19 hypoxic medium. However, ritonavir (10 and 20 μM) significantly inhibited this 
VEGF-induced proliferation. Similarly, hypoxic culture medium of D407 cells also induced the 
proliferation of RF/6A cells by 2 fold. Compared to the hypoxic group, cell proliferation was 
reduced in the presence of two concentrations of ritonavir tested (10 and 20 μM) (Figure 59). 
Cytotoxicity assay 
MTS assay was performed to examine the possible cytotoxicity of various concentrations 
of ritonavir. All the three concentrations used were found to be non-cytotoxic to the RPE cells 
either under normoxia or hypoxia (Figure 60). This study suggests that any alterations in mRNA 
or protein expression levels are not attributed to drug toxicity. 
Discussion 
Ocular angiogenesis or formation of new blood vessels is a leading cause of ischemic 
retinopathies. It results from complex interplay between multiple gene products. Hypoxia or 
reduced oxygenation resulting in activation of HIF-1 was identified as a key transcriptional 
regulator of angiogenesis [519]. In response to hypoxic conditions, HIF-1 induces transcription 
of many angiogenic stimulators in RPE cells [520]. Current therapies aimed at treating ocular 
neovascular diseases include the utilization of large molecule therapeutics targeting VEGF. 
Although promising, long term usage of such therapeutics is not free of side effects. 
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Figure 59. RF/6A cell proliferation with (A) ARPE-19 and (B) D407 spent cell culture media 
post exposure to hypoxia (12 hours) in the absence or presence of ritonavir (5, 10 and 20 μM). 
Values represent mean ± SD. * represents statistical significance from control at P-value of 
<0.05. 
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Figure 60. Cytotoxicity assay on ARPE-19 and D407 cells post exposure to (A) normoxia or (B) 
hypoxia (12 hours) in the absence or presence of ritonavir (5, 10 and 20 μM).  
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Kurihara et al., have demonstrated the off-target effects resulting from specific knock-out 
of Vegfa gene in adult mice. The knock-out mice exhibited degeneration of choriocapillaris, 
dysfunction of cone photoreceptors and ultimately vision loss. However, the transcriptional 
(HIF) mutants did not elicit any dramatic secondary off-target effects [454, 455]. These studies 
clearly reinforce that therapeutics aiming at HIF pathway may be an alternative, safer and 
effective mode of treatment than attenuating VEGF levels alone in the treatment of ocular 
neovascular diseases. Hence, there is an immediate necessity to identify modulators of HIF 
pathway for better treatment of angiogenic diseases. 
Significant research has been conducted in the past few years to identify inhibitors of the 
HIF pathway in RPE cells, which may provide better treatment for ischemic retinopathies [457, 
521-525]. Although RNAi and many other small molecule inhibitors have been identified, their 
clinical translation is slow. Hence, interest is directed towards identifying new implications of 
existing drugs, rather than discovering new molecules. This process of drug repositioning may 
expedite the clinical transition of therapeutic molecules. Ritonavir, a HIV protease inhibitor 
exhibits antiangiogenic, antiproliferative and antitumorigenic effects. Hence, ritonavir was 
evaluated for inhibition of HIF-1α and VEGF in RPE cells, since this inhibition can provide 
therapeutic interventions for diseases caused by pathological neovascularization. 
Since RPE cells are an important source of angiogenic factors in retina, we selected two 
in vitro RPE models (ARPE-19 and D407) [526]. These cells have structural and functional 
characteristics similar to RPE cells and have been selected for studying the effects of hypoxia in 
RPE physiology. Hypoxic exposure for 12 hours exhibited a significant rise in expression levels 
of HIF-1α and VEGF in both ARPE-19 and D407 cells. When RPE cells were cultured in 
presence of three different concentrations of ritonavir, the mRNA expression of HIF-1α 
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remained unaltered. Interestingly, the expression of VEGF was inhibited in a concentration-
dependent manner in the presence of ritonavir. Based on their putative mechanism of action, HIF 
inhibitors may be classified as modulating RNA expression, protein translation, protein 
degradation, DNA binding activity or transcriptional activity [527]. Although ritonavir did not 
alter HIF-1α mRNA expression, immunohistochemical results suggest that it significantly 
inhibited HIF-1α protein translation. Our results corroborated with Pore et al., who demonstrated 
that nelfinavir, another HIV protease inhibitor, interfered with HIF-1α protein translation in 
carcinoma cells [528]. An active PI3K/AKT pathway is required for hypoxia induced expression 
of HIF-1α protein translation [529, 530]. Hence, a preliminary study was performed to analyze 
the levels of AKT in RPE cells post treatment with ritonavir. Our study indicates that ritonavir 
inhibits HIF-1α protein translation via inhibition of AKT phosphorylation. 
A major angiogenic stimulator in both physiological and pathological ocular conditions is 
VEGF. Although it exists as multiple isoforms due to alternative splicing, VEGF165 plays a vital 
role in augmenting vascular leakage and breakdown of blood retinal barrier [531]. Our study has 
demonstrated that hypoxic RPE cells exhibited high levels of VEGF secretion. However this 
hypoxia induced expression diminished significantly following treatment with ritonavir. This 
could possibly result from decreased HIF-1α translation and subsequent VEGF transcription. The 
secreted VEGF modulates angiogenesis by inducing endothelial cell proliferation [532]. To 
address antiangiogenic activity of ritonavir, exposed RPE culture medium was used to assess the 
proliferation of choroid-retina endothelial (RF/6A) cells. While proliferation of these cells 
increased significantly upon exposure to hypoxic medium, ritonavir inhibited such proliferation 
signifying its antiangiogenic properties. Cytotoxicity studies revealed that alterations in HIF-1α 
and VEGF expressions are not attributed to ritonavir toxicity.  
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Conclusions 
Our studies have demonstrated that ritonavir inhibits the expression of HIF-1α mediated 
VEGF expression in RPE cells probably via inhibition of PI3K/AKT pathway (Figure 61). This 
inhibition may reduce retinal neovascularization. These findings shed new light on the possibility 
of incorporating ritonavir in the treatment regimen of ocular angiogenic diseases. Although many 
inhibitors of HIF-1α are in clinical trials, additional benefit of using ritonavir is that it has been 
given to HIV patients with relatively low toxicity. The process of traditional drug development 
could be fast tracked since ritonavir is clinically approved for human use. However, further 
preclinical and clinical experiments are necessary to determine the repositioning of ritonavir in 
the treatment of ocular neovascular diseases. 
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Figure 61. Schematic representation of inhibition of HIF-1α protein translation by ritonavir. 
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SUMMARY AND RECOMMENDATIONS 
Summary 
Cancer remains one of the major leading causes of death worldwide. Acquisition of 
multidrug resistance (MDR) remains a major impediment to successful chemotherapy. As the 
name implies, MDR is not limited only to one drug but often associated to structurally and 
functionally unrelated chemotherapeutics. Extensive research and investigations have identified 
several mechanisms underlying the development of MDR. This process of drug resistance is 
considered to be multifactorial including decreased drug accumulation, increased efflux, 
increased biotransformation, drug compartmentalization, modification of drug targets and defects 
in cellular pathways. Although the pathways can act independently, they are more often 
intertwined. Of the various mechanisms involved, upregulation of efflux transporters and 
metabolizing enzymes constitute a major resistance phenotype.  
Interaction of gemifloxacin with efflux transporters is studied in polarized canine kidney 
cells overexpressing efflux transporters. Dose-dependent inhibition studies were performed with 
[
14
C] erythromycin on MDCKII-MDR1 and MDCKII-MRP2 cells. Results from our study 
suggest that gemifloxacin inhibited both MDR1 and MRP2 mediated efflux with IC50 values of 
123 ± 2 µM and 16 ± 2 µM, respectively. Transport studies were conducted to determine 
bidirectional permeability and to assess efflux ratio of gemifloxacin. The efflux ratio of [
14
C] 
erythromycin lowered from 3.56 to 1.63 on MDCKII-MDR1 cells and 4.93 to 1.26 on MDCKII-
MRP2 cells. This significant reduction in efflux ratio further confirmed the inhibitory potential 
of gemifloxacin towards MDR1 and MRP2. ATP determination assay was performed to examine 
ATP involvement in cellular translocation of gemifloxacin. No significant change in the ATP 
activity was observed suggesting that efflux by gemifloxacin is not affected by ATP activity. 
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Similarly, results obtained from cytotoxicity assay indicated that gemifloxacin tested at various 
concentrations do not elicit any cytotoxic effects in MDCKII-MDR1 and MRP2 cells. 
Human colon adenocarcinoma cells (LS-180) were treated for 72 hours with vinblastine 
alone and in presence of ritonavir. RNA expression levels of efflux transporters (MDR1 and 
MRP2) and metabolizing enzyme (CYP3A4) were measured by quantitative real time PCR. The 
expression of MDR1, MRP2 and CYP3A4 was induced in response to vinblastine. This 
overexpression was completely neutralized when cells were cotreated with ritonavir. Uptake of 
[
3
H] lopinavir and Vivid™ assay were performed to evaluate the functional activity of efflux 
transporters and metabolizing enzymes respectively. A reduction in lopinavir uptake and 
increased formation of vivid substrate further confirmed the functional activity of transcribed 
genes upon cotreatment. Cell proliferation, migration and apoptosis assays were performed on 
human breast cancer cells (T47D) and prostate cancer cells (PC-3) to better delineate the efficacy 
upon cotreatment of anticancer drug (doxorubicin, paclitaxel, tamoxifen or vinblastine) with 
ritonavir. Reduced cell proliferation and migration and increased apoptosis of cancer cells were 
indicative of enhanced activity of chemotherapeutics in the presence of ritonavir. In summary, 
combination therapy of anticancer drug with ritonavir may overcome drug resistance, by 
neutralizing overexpression of efflux transporters and metabolizing enzymes. Further, this 
combination may also increase the efficacy in a synergistic way due to antitumorigenic and 
antiangiogenic properties of ritonavir. Therefore, we anticipate that drug regimens containing 
ritonavir would enhance patient exposure to chemotherapeutics, thereby preventing or 
overcoming resistance and potentially improving chemotherapeutic efficacy. 
A decrease in tissue oxygen levels (aka hypoxia) mediates a number of vascular retinal 
diseases. Despite introduction of novel therapeutics, treatment of retinal disorders remains 
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challenging, possibly due to complex nature of hypoxia signaling. Human retinal pigment 
epithelial (RPE) cells were cultured under normoxic and hypoxic conditions. Quantitative real 
time PCR analysis showed elevated expression of efflux transporters (MDR1, MRP2 and BCRP) 
and influx transporters (FR-α, B (0, +), SMVT) in a time-dependent manner. The expression of 
peptide transporters did not alter significantly in hypoxia while the expression of organic cation 
transporters was downregulated significantly. Immunoblot analysis further confirmed elevated 
expression of BCRP and SMVT. A decrease in the uptake of efflux transporter substrates 
(digoxin, lopinavir and abacavir) and enhanced uptake of influx transporter substrates (arginine, 
folic acid and biotin) in hypoxia relative to normoxia further confirmed elevated expression of 
the transporters, respectively. Our study demonstrates for the first time that hypoxic conditions 
may alter expression of efflux and influx transporters in RPE cells. These findings suggest that 
hypoxia may further alter disposition of ophthalmic drugs. 
Retinal hypoxia mediated activation of the hypoxia-inducible factor (HIF pathway) 
leading to angiogenesis is a major signaling mechanism underlying a number of sight-threatening 
diseases. Inhibiting this signaling mechanism with an already approved therapeutic molecule 
may have promising antiangiogenic role with fewer side effects. Hence, we examined the 
expression of HIF-1a and VEGF in RPE cells treated with ritonavir under hypoxic and normoxic 
conditions. Presence of ritonavir in the culture medium strongly inhibited VEGF expression in a 
concentration-dependent manner under hypoxic conditions. Immunoblot analysis demonstrated a 
substantially reduced protein expression of HIF-1α in the presence of ritonavir. Further, hypoxic 
exposure induced VEGF secretion was also inhibited by ritonavir, as demonstrated using ELISA. 
Finally, ritonavir significantly diminished the proliferation of choroid-retinal endothelial 
(RF/6A) cells demonstrating potential antiangiogenic activity. Our study demonstrates for the 
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first time that ritonavir can inhibit HIF-1α and VEGF in RPE cells. Such inhibition may form a 
platform for application of ritonavir in the treatment of various ocular diseases. 
Recommendations 
The goal of my dissertation project was to identify a novel multidrug resistance 
modulator that can be used in both cancer and ocular diseases. A few recommendations can be 
suggested to continue with this project.  
(1) Both the chemotherapeutic and ritonavir can be encapsulated in nanoparticles (NPs) 
for efficient drug delivery into the tumor tissues following systemic administration. 
(2) Since ritonavir inhibits efflux and metabolism of the coadministered drug, it should be 
given at the same time the chemotherapeutic is administered. If co-formulation is not feasible, a 
cocktail of drug NPs and ritonavir NPs can be injected simultaneously. 
(3) Ritonavir could be formulated into nanomicelles for promising delivery in ocular 
neovascular diseases. Also, nanomicelles can be targeted using specific targeting ligands 
attached to the micelle surface. Studies from this dissertation have shown the differential 
expression of various influx transporters in hypoxic conditions. Selection of an influx transporter 
highly expressed in hypoxia compared to normoxia enables targeted drug delivery into diseased 
tissues. 
(4) Further, ritonavir can also be used as a preventive drug in the treatment of age-related 
eye diseases (ARED). Ritonavir inhibits HIF-pathway which is only activated in diseased 
conditions. Hence, using it as a preventive measure may reduce the risk of neovascularization in 
ARED. 
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